Note: Descriptions are shown in the official language in which they were submitted.
CA 02316994 2000-06-30
WO 99/63938 I PCT/US99/12775
COMPOSITION & METHOD FOR PREVENT10N & TREATMENT
OF CARDIOPULMONARY & RENAL FAILURE OR DAMAGE
ASSOCIATEDWITH ISCHEMIA, ENDOTOXIN RI:LEASE,~ARDS OR
BROUGHT ABOUT BY ADMIrIISTRATION OF CERTA1N DRUGS
BACKGROUND OF TIIE INVENTION
Field of the Invention
This invention relates to a composition, formulations and method for
prevention and therapy of
cardiac, cardiopulmonary and renal damage or failure seen in certain diseases
or conditions associated
with ischcmia and/or cndotoxin release, acute respiratory distress syndrome
CARDS), or brought about
by administration of certain drugs such as cancer chemotherapeutic agents,
glycerol, radiocontrast media,
and adenosine which is administered, for example, in stress tests and the
treatment of supraventricular
tachycardia (SVT).
Description of the Background
Adenosine, a natural nucleoside, may constitute an important natural mediator
of many of
diseases, including asthma, and the like. The inhalation of adenosine by
asthmatics, but not by normal
subjects, causes broncho-constriction. Theophyllinc, a xanthine, may be useful
in reversing this
asthmatic effect. Other experimental data suggest the possibility that
adenosine receptors may also be
involved in allergic and inflammatory responses. It has been postulated that
the modulation of signal
transduction at the surface of inflammatory cells influences acute
inflammation. Adenosine is said to
inhrbit the production of super-oxide by stimulated neutrophils. Moreover, the
treatment of experimental
allergic uveitis produced a marked reduction in inflammation. Adenosine may
attenuate this behavior by
reducing the hyperactivity of the central dopaminergic system.
Adenosine plays a unique role in the body as a regulator of cellular
metabolism. It can raise the
cellular level of AMP, ADP and ATP which arc the energy intermediates of the
cell. Adenosine can
stimulate or down regulate the activity of adenylatc cyclase and hence
regulate cAMP levels. CAMP, in
turn, plays a role in neurotransmitter release, cellular division and hormone
release. Adenosine's major
role appears to be to act as a protective injury autocoid. In any condition in
which ischemia, low oxygen
tension or trauma occurs adenosine appears to play a role. Defects in
synthesis, release, action and/or
degradation of adenosine have been postulated to contribute to the over
activity of the brain excitatory
amino acid neurotransmitters, and hence various pathological states. Recent
evidence suggests that
adenosine may also play a protective role in stroke, CNS trauma, epilepsy,
ischemic heart disease,
coronary by-pass, radiation exposure and inflammation.
Overall, adenosine appears to regulate cellular metabolism through ATP, to act
as a carrier for
methionine, to decrease cellular oxygen demand and to protect cells from
ischemic injury. Adenosine is a
tissue hormone or inter-cellular messenger that is released when cells arc
subject to ischemia, hypoxia,
cellular stress, and increased workload, and or when the demand for ATP
exceeds its supply. Adenosine
is a purine and its formation is directly linked to ATP catabolism. It appears
to modulate an array of
physiological processes including vascular tone, hormone action, neural
function, platelet aggregation
and lymphocyte differentiation. It also may play a role in DNh formation, ATP
biosynthesis and general
intermediary metabolism. It is suggested that it regulates the formation of
cAMP in the brain and in a
variety of periphernl tissues. Adenosine is also said to participate in the
auto-regulation of blood flow in
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
2
the heart, brain, skeletal muscle, adipose tissue and kidney. In the kidney,
for example, it may act as a
vasoconstrictor, but as a vasodilator in each of the other vascular beds.
Adenosine is said to antagonize
the catabolic effects of honmones and promote the action of the anabolic
hormone insulin. In addition,
adenosine may also act to attenuate the release of neurotransmitters in both
the central and peripheral
nervous systems, inhibit the secretion of insulin and prevent platelet
aggregation. Adenosine has been
said to modulate the function of T lymphocytes by a mechanism which involves
the regulation of protein
synthesis. Adenosine regulates cAMP formation through two receptors A~ and Az.
Via A, receptors,
adenosine reduces adenylate cyclase activity, while it stimulates adenylate
cyclase at Az receptors. The
adenosine A~ receptors are more sensitive to adenosine than the Az receptors.
The CNS effects of
adenosine are generally believed to be A,-receptor mediated, where as the
peripheral effects such as
hypotension, bradycardia, are said to be Az receptor mediated.
Adenosine is said to modulate adenylate cyclase activity as well as nerve cell
firing and the
release of neurotransmitters such as aspartate, glutamate, GABA and serotonin.
It has sedative and anti-
convulsive properties and is said to inhibit both spontaneous and evoked nerve
firing. Its action is
antagonized by caffeine and theophylline. Adenosine's action is mediated
through cell surface receptors
called A,, Aza, Azb and A3, and it acts as a purinergic inhibitory neuro or
cellular transmitter. Adenosine
also has been implicated in anxiety, analgesia, sleep and depression, in
modifying CNS alertness, acting
as neuro-modulator, which actions are terminated by cellular uptake or
deamination. It also has been said
to potentiate the effects of histamine, reduce neuronal excitability, and to
exert the majority of its central
effects pre-synaptically by inhibition of calcium-dependent neurotransmitter
release.
It has been also suggested than the production and release of adenosine is
closely linked to
energy balance. During ischemia, adenosine levels accumulate and ATP is
rapidly depleted. It appears to
be released at the site of trauma or when the cellular oxygen supply is
reduced by hypoxia or ischemia
and, thus, dampens cellular activity and increases blood flow via vascular
dilation. A localized increase
of adenosine at traumatic foci plays an important homeostatic role by down-
regulating physiological
function and, thereby, conserving ATP. In almost every organ ischemia induces
an elevation of
adenosine levels, which results in a slowing of that organ's function, a
process which is postulated to be
mediated by adenosine receptors. In recognition of this, adenosine has been
termed a "retaliatory
metabolite" and an endogenous neuro-protective agent. Adenosine, therefore,
appears to play overall a
homeostatic role throughout the body or, in a sense, to generate recovery time
for traumatized tissue.
Adenosine has been implicated in the regulation of coronary blood flow and
said to have
negative chromotropic and inotrophic effects on heart contractibility. These
effects may be mediated
directly via adenosine receptors, or indirectly by either inhibition of the
release of other
neurotransmitters or by antagonism of the myocardial action of noradrenalin.
Adenosine injections have
been used for the treatment of supraventricular tachycardia (SVT). During
hypoxia, ischemia or reactive
hyperaemia, adenosine appears to be freely released and, through its action
reduce cellular hypoxic stress
by slowing cellular metabolism. Thus, it appears to act as an anti-injury
autocoid. It is believed that both
morbidity and mortality from acute coronary artery occlusion may be reduced if
local myocardial
adenosine concentration is augmented. Adenosine is said to increase collateral
coronary circulation and
even inhibit the generation of superoxide anions by granulocytes, thus
reducing vascular endothelial
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
3
damage. Another effect of adenosine appears to be to block granulocyte
activation, and thereby reduce
capillary plugging and the °no-reflow" phenomenon which contributes to
post-stroke neuro-degeneration.
Adenosine and a majority of adenosine mononucleotides have been said to also
possess
radioprotective activity. This protective activity is thought to occur through
A1 receptors. Internal kidney
vasoconstriction, however, has been observed upon the administration of
radiocontrast agents for
imaging purposes. Adenosine, calcium and ischemia have been postulated to have
a role in this
radiocontrast agent-induced infra-renal vasoconstriction. Ischemia or oxygen
derivation in many
instances are said to produce kidney damage. Certain cancer chemotherapeutic
agents, such as cisplatin
and rnethotrexate, as well as glycerol and the administration of metal ions
such as thallium ('Th), lead
(Pb) and cadmium (Cd) have also been associated with kidney damage, which may
become extensive
upon the release of endotoxins, and even culminate in sepsis. Known adenosine
receptor antagonists
have been said to attenuate the thus produced renal damage. Adenosine, thus,
may have a role as a
natural mediator of infra-renal vasocontriction. In particular, the kidney has
a significant number of
adenosine receptors, adenosine's effect on the kidneys could be mediated
primarily through the
stimulation of adenosine receptors.
One of the characteristics of hyper-responsive subjects in particular is the
over-expression of the
adenosine A, receptor. When activated by adenosine, whose levels are induced,
for example, by ischemia
or by certain agents such as glycerol, endotoxin, chemotherapeutic agents such
as cisplatin and
methotrexate, and by radiocontrast media, the adenosine A, receptor may cause
life threatening, even
fatal, renal damage. Adenosine receptor antagonists, such as theophylline, 8-
cyclopentyl-1, 3-
dipropylxanthine (DPCPX), are known to counter adenosine-mediated
bronchoconstriction in asthmatics.
Theophylline has been also employed to prevent a reduction in the glomerular
filtration rate observed
upon administration of a radiocontrast medium. The therapeutic potential,
however, of currently
available adenosine A, receptor-specific antagonists is drastically limited by
their toxicity. Theophylline,
for example, frequently results in significant toxicity because of its narrow
therapeutic dose range. The
availability of an alternative strategy to prevent and treat the adenosine
associated renal dysfunction,
damage and failure observed in patients with hypoxia or ischemia, and upon the
administration of certain
drugs, particularly in hyperresponsive individuals, would clearly be of
extreme prophylactic and
therapeutic value.
Adenosine A,-mediated diseases and conditions, such as asthma, allergic
rhinitis, and Acute
Respiratory Distress Syndrome CARDS), including in pregnant mothers, and RDS
in premature born
infants, among others, are common diseases in industrialized countries, and in
the United States alone
account for extremely high health care costs. These diseases or conditions
have recently been increasing
at an alarming rate, both in terms of prevalence, morbidity and mortality. In
spite of this, their underlying
causes still remain poorly understood. Acute Respiratory Distress Syndrome
CARDS) is also known in
the medical literature as stiff lung, shock lung, pump lung and congestive
atelectasis, and its incidence is
1 out of 100,000 people. ARDS is believed to be caused by a failure of the
respiratory system
characterized by fluid accumulation within the lung which, in tum, causes the
lung to stiffen. The
condition is triggered by a variety of processes that injure the lungs. In
general ARDS occurs as a
medical emergency. It may be caused by a variety of conditions that directly
or indirectly cause the blood
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
4
vessels to "leak" fluid into the lungs. In ARDS, the ability of the lungs to
expand is severely decreased
and damage to the air sacs and lining (endothelium) of the lung is extensive.
The concentration of
oxygen in the blood remains very low in spite of high concentrations of
supplemental oxygen which are
generally administered to a patient. Among the systemic causes of lung injury
are trauma, head injury,
shock, sepsis, multiple blood transfusions and medications. Pulmonary causes
include pulmonary
embolism, severe pneumonia, smoke inhalation, radiation, high altitude, near
drowning, and more.
ARDS symptoms usually develop within 24 to 48 hours of the occurrence of an
injury or illness. It is
believed that cigarette smoking may be a risk factor.
Among the most common symptoms of ARDS are labored, rapid breathing, nasal
flaring,
cyanosis blue skin, lips and nails caused by lack of oxygen to the tissues,
breathing difficulty, anxiety,
stress and tension. Additional symptoms that may be associated with this
disease are joint stiffness and
pain and temporarily absent breathing. The diagnosis of ARDS is commonly done
by testing for
symptomatic signs. A simple chest auscultation or examination with a
stethoscope, for example, will
reveal abnormal breath sounds which are symptomatic of the condition.
Confirmatory tests used in the
diagnosis of ARDS include chest X-rays and the measurement of arterial blood
gas. In some cases ARDS
appears to be associated with other, diseases, such as patients with acute
myelogenous leukemia, who
developed acute tumor lysis syndrome (ATLS) after treatment with cytosine
arabinoside. In general,
however, ARDS appears to be associated with traumatic injury, severe blood
infections such as sepsis, or
other systemic illness, the administration of high dose radiation therapy and
chemotherapy, and
inflammatory responses which lead to multiple organ failure, and in many cases
death. In premature
babies ("primies"), the lungs are not quite developed and, therefore, the
fetus is in an anoxic state during
development. In addition, lung surfactant is generally yet not present in
sufficient amounts at this early
stage of life. However, premies often hyper-express the adenosine A, receptor
and/or underexpress the
adenosine A~, receptor and are, therefore, susceptible to diseases and
conditions such as
bronchoconstriction, lung inflammation, and ARDS, among others. Respiratory
distress syndrome (RDS)
occurring in the preterm infant is an extremely serious problem. A primary
cause of RDS in such
preterm infants is the immature developmental stage of the infant, resulting
in lack of surfactant, a
material critical for normal respiration. Preterm infants exhibiting RDS are
ventiliated, and administered
oxygen and surfactant preparations. Infants with RDS, when they survive,
frequently develop
bronchopulmonary dysplasia (BPD), also called chronic lung disease of early
infancy. This too is often
fatal.
The death rate from ARDS exceeds 50%. Although many survivors recover normal
lung
function, some individuals may suffer permanent lung damage, which ranges from
mild to severe.
Moreover, ARDS patients are often afflicted with complications, such as
multiple organ system failures.
Up to the present time, no measures to prevent or treat ARDS are known.
Recently, however, it was
reported that an increase in the ratio of certain fatty acid by-products of
phosphatydic acid metabolism is
predictive of the likelihood that a patient will develop ARDS and that,
furthermore, the predictive value
of the index correlates with the severity of the illness. Remedial treatment
is limited to compensating for
the severe dysfunction of the respiratory system and treating the underlying
cause of the lung injury. One
of the fastest developing symptoms in ARDS is hypoxia, which is generally
treated by administration of
hyperbaric oxygen, often at high concentrations, many times 100% oxygen
concentrations are needed.
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
This is done in many circumstances by necessity by means of intubation or by
passing a tube through the
nose or the mouth of the patient into the trachea (airway). In addition,
mechanical ventilation or a
respirator, a machine used to aid the breathing, is usually necessary for
further supporting the respiratory
system. This treatment may need to be continued until a gradual weaning from
the mechanism is
tolerated. Although no therapeutic treatment of ARDS itself exists at the
present time, other medications
may be administered to treat infection, reduce inflammation and eliminate
fluid within the lungs. The
minimal daily chores become tremendously difficult to perform under the
circumstances, and often the
sole recommendation doctors can offer to ARDS patients is that they join
support groups to share
common experiences and problems with other ARDS victims. As already indicated,
respiratory distress
syndrome also occurs in premies and infants. Thus, in view of the potential
for predicting whether or not
a patient may develop ARDS, it becomes even more important to make available a
novel strategy to
treat Acute Respiratory Disorder Syndrome CARDS), because now it has become
possible to apply it to
the prevention of ARDS as well, be it in adults, in children, or in
prematurely born babies ("primies").
Adenosine, in addition, slows the conduction time through the heart's A-V
node, may interrupt
the reentry pathways through the A-V node, and may restore normal sinus rhythm
in patients with
paroxymal supraventricular tachycardia (PSVT), more commonly described as
supraventricular
tachycardia (SVT), including that associated with Wolff Parkinson-White
Syndrome. The systemic
administration of adenosine was found useful for treating SVT, and as a
pharmacologic means to
evaluate cardiovascular health via an adenosine stress test commonly
administered by hospitals and by
doctors in private practice. Adenosine administered by inhalation is known to
cause bronchoconstriction
in asthmatics, possibly due to mast cell degranulation and histamine release,
effects which have not been
observed in normal subjects. Adenosine infusion has caused respiratory
compromise in patients with
obstructive pulmonary disease. As a consequence of the untoward side effects
observed in many patients,
caution is recommended in the prescription of adenosine to patients with a
variety of conditions,
including obstructive lung disease, emphysema, bronchitis, etc, and complete
avoidance of its
administration to patients with or prone to bronchoconstriction or
bronchospasm, such as asthma. In
addition, the administration of adenosine must be discontinued in any patient
who develops severe
respiratory difficulties.
Allergic rhinitis afflicts one in five Americans, accounting for an estimated
$4 billion in health
care costs each year: $2 billion for the seasonal variant and more than $2
billion for the perennial variant.
If associated airway diseases are considered, the cost may approach $10
billion. But even this enormous
figure may underestimate the disorder's true toll. Because many people
mislabel their symptoms as
persistent colds or sinus problems, allergic rhinitis is probably
underdiagnosed. If other associated
airway diseases are considered, the cost may approach $10 billion. But even
this enormous figure may
underestimate the disorder's true toll. Because many people mislabel their
symptoms as persistent colds
or sinus problems, allergic rhinitis is. probably underdiagnosed . Rhinitis
can occur at any age. Typically,
IgE combines with allergens in the nose to produce chemical mediators,
induction of cellular processes,
and neurogenic stimulation, causing an underlying inflammation. Symptoms
include nasal congestion
and discharge, sneezing, and itching. Sufferers also may have itchy, watery,
swollen eyes. Over time,
allergic rhinitis may predispose sufferers to the development of sinusitis,
otitis media with effusion, and
nasal polyposis. In addition, rhinitis can exacerbate asthma. Allergic
rhinitis also can be associated with
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
6
mood and cognitive disturbances, fatigue and irritability. Many medications
may produce adverse
reactions-such as sedation with some over-the-counter anti-histamines-that
could further impair a
patient's quality of life. An understanding of the pathophysiology of the nose
will often dictate
appropriate therapy. Cholinergic pathways, when stimulated, produce typical
secretions that can be
identified by their glandular constituents so as to implicate neurologic
stimulation. Secretions typical of
increased vascular permeability are found in allergic reactions as well as
upper respiratory infections.
Degranulation of mast cells results in the release of preformed mediators that
interact with various cells,
blood vessels, and mucous glands to produce the typical rhinitis symptoms.
Most early- and late-phase
reactions occur in the nose after allergen exposure. The late-phase reaction
is seen in chronic allergic
rhinitis, with hypersecretion and congestion as the most prominent symptoms.
Priming can occur; it is
characterized by a lowered threshold to stimulus after repeated allergen
exposure. This repeated exposure
causes a hypersensitivity reaction to one or many allergens. Sufferers may
also become hyperreactive to
nonspecific triggers such as cold air or strong odors. Rhinitis may be
seasonal or perennial, allergic or
nonallergic. Nonallergic rhinitis can be induced by infections, such as
viruses, or associated with nasal
polyps, as occurs in patients with aspirin idiosyncrasy. Medical conditions
such as pregnancy or
hypothyroidism can cause rhinitis, as can exposure to occupational factors or
medications. The so-called
NARES syndrome is a nonallergic type of rhinitis associated with eosinophils
in the nasal secretions. It
typically occurs in middle-aged individuals and is accompanied by some loss of
sense of smell. Ideally,
attempts should be made to minimize contact with the suspected allergen. If
dust mite sensitivity is
suspected, using allergen-proof covers for the mattress and pillows can
improve symptoms. Washing
sheets in hot water and removing carpets and drapes are other helpful
strategies for reducing dust mite
exposure. Saline alone can improve nasal stuffiness, sneezing, and congestion
saline sprays usually cause
no side effects and may be tried first in pregnant patients. Saline sprays are
generally used to relieve
mucosal invitation or dryness associated with various nasal conditions,
minimize mucosal atrophy, and
dislodge encrusted or thickened mucus. Also, if used immediately before
intranasal corticosteroid
dosing, saline sprays may help prevent drug-induced local irritative side
effects. Antihistamines often
serve as a foundation of symptomatic therapy. Terfenadine and astemizole, two
nonsedating
antihistamines, have been associated with a ventricular arrhythmia known as
Torsades de Points, usually
in interaction with other medications such as ketoconazole and erythromycin,
or secondary to an
underlying cardiac problem. To date loratadine, another nonsedating
antihistamine, and cetirizine have
not been associated with an adverse impact on the QT interval, or with adverse
cardiovascular events.
The most common side effect of cetirizine is drowsiness (14% vs. 6% on
placebo).When used in
recommended doses by patients without known risk factors, the non-sedating
anti-histamines generally
pose minimal risk for an adverse cardiac event. These drugs, e.g. Claritin,
can be effective in relieving
sneezing, runny nose, and nasal, ocular and palatal itching. Although not
approved for this indication,
some of the non-sedating agents may be useful in patients with asthma. Studies
indicate that terfenadine,
loratadine and astemizole exhibit modest bronchodilating effects, reduce
bronchial hyperreactivity to
histamine, and protect against exercise- and antigen-induced bronchospasm,
although some of these
benefits may require higher-than-currently-recommended doses. The sedating-
type antihistamines may
help people to sleep at night, but they cause sleepiness and compromise
performance if taken during the
day. Antihistamines are typically combined with a decongestant to help relieve
nasal congestion.
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
7
Sympathomimetic medications are used as vasoconstrictors and decongestants.
The three common
systemic decongestants are pseudoephedrine, phenylpropanolamine and
phenylephrine. These agents
may cause hypertension, palpitations and tachycardia, as well as restlessness,
insomnia and headache.
The interaction of phenylpropanolamine with caffeine-in doses of two to three
cups of coffee-may
significantly raise blood pressure. In addition, medications such as
pseudoephedrine can cause
hyperactivity in children. Topical decongestants should be used only for a
limited period of time, as they
are associated with a rebound nasal dilatation with overuse. Anticholinergic
agents have a role in
patients with significant rhinorrhea or for specific entities such as
"gustatory rhinitis," which
is usually associated with ingestion of spicy foods. They also have been
studied for their beneficial
effects on the common cold. Cromolyn has a good safety record and is
especially effective if used
prophylactically. Administered via nasal spray, cromolyn can be effective in
reducing sneezing,
rhinorrhea, and nasal pruritus. It can block both early- and late-phase
hypersensitivity responses.
Although side effects are unusual, sometimes the spray will produce sneezing,
transient headache, and
even nasal burning. Topical corticosteroids such as Vancenase are very
effective agents in the treatment
of rhinitis, especially for symptoms of congestion, sneezing, and runny nose.
Depending on the
preparation, the corticosteroid nose sprays may cause irritation, stinging,
burning, or sneezing. Local
bleeding and septal perforation can also occur, especially if the aerosol is
not aimed in the proper
direction. Topical steroids generally are more effective than cromolyn sodium,
and are particularly
effective in the treatment of NARES. These agents can be highly effective in
reducing the symptoms of
rhinitis, but side effects limit their usefulness except for temporary therapy
in patients with severe
symptoms. These agents are particularly useful in shrinking nasal polyps when
local therapy has been
unsuccessful. Immunotherapy, while expensive and inconvenient, often can
provide substantial benefits,
especially for patients who experience side effects from other medications.
The therapy is associated
with production of so-called blocking antibodies, and with an alteration of
cellular histamine release.
Eventually, these changes result in decreased IgE, along with many other
favorable physiologic changes.
Because of the rising prevalence of IgE-mediated diseases, it is important to
note the possible role of
IgE-mediated hypersensitivity in atopic patients who suffer from recurrent
middle ear infections. For
allergic rhinitis sufferers, a runny nose is more than a nuisance. The
disorder can impair quality of life
and set the stage for more serious ailments including psychological problems.
But it may be controlled.
Presently available treatments may 'help to minimize symptoms, such as
propranolol, verapamil, and
adenosine. These have Food and Drug Administration-approved labeling for acute
termination of
supraventricular tachycardia (SVT).
Verapamil has been the most commonly used agent in the general population but
it has several
shortcomings, such as its potential to cause or exacerbate systemic
hypotension, congestive heart failure,
bradyarrhythmias, and ventricular fibrillation. In addition, verapamil readily
crosses the placenta and has
been shown to cause fetal bradycardia, heart block, depression of
contractility, and hypotension.
Adenosine has several advantages over verapamil, including rapid onset,
brevity of side effects,
theoretical safety, and probable lack of placental transfer. Adenosine
ultimately may prove to be the
preferred agent for termination of paroxysmal supraventricular tachycardia
also in the gravid woman.
Given the high numbers of deaths involving myocardial disease, the possibility
of identifying individuals
who are at risk is of great importance, because an early detection permits an
early treatment of the
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
8
conditions. Electrocardiographic stress tests are used for this purpose while
an individual exercises, but
they lack high sensitivity and specificity. This is particularly the case with
asymptomatic patients or with
those with atypical toracic chest pain of angina. In this case, in addition to
the excercise stress test,
cardiac perfusion images are also obtained with y rays, such as those emitted
by 201Th or 99mTc. A
good number of coronary patients, however, cannot excercise at a level
acceptable to validate the results
of the test, such as those afflicted with severe arthritis and peripheral
vascular diseases or conditions,
among others. Hypertensive patients taking (i-blockers and calcium channel
antagonists also present a
problem as to the detection of an adequate pulse and an effective stress test
result while exercising. It is
for these groups of patients who may not exercise adequately that
pharmacological stress tests are most
useful. In the United States about a third of patients referred for myocardial
perfusion tests are
administered pharmacological tests. For these, as well as for patients
attended to in general practice, two
kinds of drugs are utilized: coronary vasodilating drugs and positive
inotropic agents.
Only two coronary dilating agents have been approved by the FDA for use in
this test:
dipyrimidol and adenosine, both of which dilate coronary arteries by elevating
the level of adenosine in
blood and increasing 4 or 5-fold the coronary blood flow. Once these changes
are imparted, the patient is
administered intravenously a radioactive agent, such as 201Ta or 99mTc to do y-
ray imaging. Although
in a normal person the distribution of the radiolabel would be uniform, in a
subject with one or more
stenosis or occlusions in the coronary arteries will exhibit areas or
"defects" in the artery (ies) irrigated
by the radioactive label of different intensity (ies), which is attributtable
to ischemia or to myocardial
necrosis. Contrary to those observed with exercise, the hemodynamic and
electrocardiographic changes
observed upon the administration of pharmacological agents like adenosine are
slight. Usually the pulse
will increase from 10% to 20% and the systemic arterial pressure from 5% to
10%, and the
electrocardiographic depressions of the CT segments in the electrocardiogram
(ECG) indicate a specific
and serious sign of coronary artery disease. Thus, for many patients, the
ability to undergo a
pharmacological stress test is of extreme importance. However, many patients
exhibit secondary effects
(side effects) , which in many cases result in severe bronchospasm, myocardial
infarction and death.
Thus, the administration of adenosine in a pharmacologic stress test is
contraindicated in individuals
afflicted with bronchoconstriction, asthma, including occult asthma,
hypotension, and atrioventricular
blockage of the second and third degrees. Many SVT patients and other subjects
who would benefit
from adenosine administration to assess their cardiovascular function,
however, have hyper-responsive
airways and are, thus, prone to bronchoconstriction in response to the
administration of adenosine. This
by itself, prevents them from being administered adenosine in order to avoid
extreme
bronchoconstriction, which may be life threatening.
The availability of a novel, strategy to prevent and/or counter adenosine
receptor-associated
effects of disorders and conditions associated with symptoms such as pulmonary
bronchoconstriction,
impeded respiration, inflammation and allergy (ies), among others, of great
practical importance. Such
technology is clearly applicable to the treatment of heart, lung and kidney
damage or failure, e.g.
associated with hypoxia ailments including Acute Respiratory Disorder Syndrome
CARDS), asthma,
respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
pulmonary
vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD),
allergic rhinitis, and
cancers such as leukemias, lymphomas, carcinomas, and the like, including
colon cancer, breast cancer,
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
9
lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer,
melanoma, hepatic metastases,
etc., as well as all types of cancers which may metastasize or have
metastasized to the lung(s), including
breast and prostate cancer, would clearly find an immediate therapeutic
application. Similarly, a
composition and method which are suitable for administration before, during
and after other treatments
or diagnostic procedures, including radiation, chemotherapy, administration of
radiocontrast agents,
including those containing metal ions, antibody therapy, phototherapy and
cancer, and other types of
surgery, and adenosine such as in stress tests and in the treatment of SVT,
among others, that may be
effectively administered preventatively, prophylactically or therapeutically,
and in conjunction with
other therapies, or by itself for conditions without known therapies or as a
substitute for therapies that
have significant negative side effects is also of immediate clinical
application.
SUMMARY OF THE INVENTION
The present invention relates to a pharmaceutical composition, which has
cardiopulmonary
and/or renal protective activity or which is effective for preventing or
treating diseases and conditions
such as ARDS, and those associated with ischemia or the release of endotoxins
or with the administration
of certain agents, including adenosine, e.g. for treating SVT, etc. Examples
of these are septic and toxic
shock and septicemia. The main component of the composition is a nucleic acid
which comprises an
oligonucleotide (oligo), which when administered to a subject is effective for
alleviating or inhibiting the
adenosine-mediated diseases and conditions described and many others. The
oligos are anti-sense to
target genes and mRNAs corresponding to the target genes, to genomic flanking
regions such as intron
and exon borders, e.g. the 5' end, the 3' end and the juxta-section between
coding and non-coding
regions, or to all segments of mRNA(s) encoding an adenosine A~, AZ" A26 and
A3 receptors having A,,
AZb and/or A3 agonist activity or A~, antagonist activity, (generally to any
agent having adenosine A~,
agonist activity), anti-sense to target genes and mRNAs corresponding to the
target genes, to genomic
flanking regions such as intron and exon borders selected from the group
consisting of the 5' end, the 3'
end or the juxta-section between coding and non-coding regions, or to
analogues to these oligos
consisting of less than about 15% adenosine (A), or mixtures thereof, and a
physiologically acceptable
carrier, and other agents such as diagnostic agents, e.g. radio-contrast
media, other therapeutic agents for
treating diseases or conditions or exogenous compounds which are associated
with lung, heart or renal
damage, e.g., glycerol, endotoxin and chemotherapeutic agents such as
cisplatin and methotrexate, and
formulation ingredients, among others. Examples of adenosine administration
are in the treatment of
SupraVentricular Tachycardia (SVT) and in stress tests in hyper-sensitized
individuals. Side effects
caused by the exogenous administration of adenosine, such as extreme
respiratory difficulty, airway
blockage, bronchoconstriction, allergy and inflammation, among others, are
prevented and countered by
the present agents and in some cases, depending on the dose administered,
totally abolished. Other
diseases or conditions afflict the kidneys and other organs and their
functions by increasing levels of
endotoxin, and the like. Many diseases and conditions are often associated
with the development of
ischemia or hypoxia which, by itself or through the release of other agent(s),
is either associated with or
brings about cardiopulmonary or renal damage and/or failure, and thus may
benefit from the present
invention as applied to protect the heart and kidneys. Thus, the
pharmaceutical composition of the
invention may be used to protect the lungs, heart and kidneys from damage
associated or caused by other
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
diseases or conditions or the administration of therapeutic or diagnostic
agents. In addition, the present
composition may also be applied to the treatment of numerous conditions which,
in its absence, might
produce considerable heart, lung and kidney damage and even failure, by
addition of one or more
therapeutic agents for treating the disease or condition as well as the agent
described in this patent. For
example, a pharmaceutical composition in accordance with the invention might
comprise an anti-cancer
agent and the Lung, heart and kidney protecting agent of the invention, in
amounts effective for treating
cancer and for preventing kidney damage, respectively. In another example, the
present agent in
combination with other therapeutic agents, including anti-cholinergic agents,
and the like, may be used to
treat food poisoning when endotoxins are released by microorganisms such as
the Botulinium family and
others, or to treat snake poisoning such as when endotoxin is released, etc.,
while protecting the subject
from the effects of endotoxins, including septic shock and septicemia.
Similarly, the present composition
may be utilized to protect a subject from renal damage while conducting a
diagnostic procedure
containing an agent which has deleterious pulmonary, cardiac and/or renal
effects, by separately
administering or combining in one composition the agent of the invention and a
diagnostic agent. The
present composition is also suitable for treating harm associated with the
administration of substances
like adenosine, cysplatin, radiocontrast agents and glycerol, routinely used
for diagnostic and therapeutic
purposes.
The agents of this invention may be formulated for administration by various
different routes,
such as topical and systemic, e.g. oral, parenteral, inhalable, and the like,
and are generally administered
in amounts which prevent or reduce adenosine-mediated side effects such as
bronchoconstriction,
allergy(ies), inflammation and airway obstruction, among others. The present
compositions and
formulations, thus, are suitable for the prevention and alleviation of
adenosine-mediated
bronchoconstriction, allergy and/or inflammation, which are associated with
the administration of
adenosine in the treatment of SVT and in stress tests to hyper-sensitized
individuals. These agents may
be administered by themselves or in conjunction with adenosine or similar
acting drugs, and in a
preventative as well as therapeutic course.
The present composition and formulations may thus be applied to the prevention
or alleviation of
adenosine receptor-mediated cardiopulmonary and/or renal damage or failure,
such as occurs in subjects
afflicted with ischemia and as a consequence of the administration or release
in the organism of certain
compounds such as glycerol, endotoxin, cisplatin, or radiocontrast agents used
for imaging purposes, or
other agents which are administered for therapeutic or diagnostic purposes, or
as a consequence of an
accident. The fonmulations of this invention, e.g. topical, oral, parenteral,
inhalable, and the like, also
reduce adenosine-mediated bronchoconstriction and/or help to prevent or treat
ARDS symptoms. The
formulations may be administered to a subject by themselves or in conjunction
with other therapies that
are known in the art. The present composition is effective to alleviate
bronchoconstriction, lung
allergy(ies) and inflammation, cardiopulmonary and renal diseases and
conditions, e.g. renal damage and
faulure, hypoxia, ARDS, COPD, etc., as well as cardiopulmonary effects
(deleterious) associated with
the administration of certain diagnostic and therapeutic agents, and
optionally comprising a surfactant,
and the oligo described here. Generally, the oligos are anti-sense to an
adenosine A" AZ" A26 or A3
receptor and exhibit adenosine A,, AZb or . A3 receptor inhibitory activity or
adenosine AZa agonistic
activity, and analogues thereof wherein A is substituted by a universal base
that binds to thymidine.
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
11
Moreover, any adenosine AZ agonist is encompassed by this invention, not only
anti-sense oligos. These
analogues evidence either reduced adenosine content or reduced adenosine
receptor activating activity.
The above composition is generally administered in an amount which prevents or
reduces adenosine
receptor associated side effects such as bronchoconstriction, allergy(ies),
inflammation and airway
obstruction, lung, heart and kidney damage, among others. The present
compositions and formulations,
thus, are suitable for the prevention and alleviation of adenosine receptor
associated bronchoconstriction,
allergy and/or inflammation and, therefore, in the treatment of Acute
Respiratory Disorder Syndrome
CARDS), asthma, side effects associated with adenosine administration in
SupraVentricular Tachycardia
(SVT) and in stress tests to hyper-sensitized individuals, ischemia, renal
damage or failure induced by
certain drugs, respiratory distress syndrome, pain, cystic fibrosis, pulmonary
hypertension, pulmonary
vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), and
cancers such as
leukemias, lymphomas, carcinomas, and the like, including colon cancer, breast
cancer, lung cancer,
pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic
metastases, etc., as well
as all types of cancers which may metastasize or have metastasized to the
lung(s), including breast and
prostate cancer, among others. These compositions are also suitable for use in
the prevention and
treatment of adenosine-receptor mediated effects brought about by the
administration of exogenous
agents. The present technology is also applicable in conjunction with other
procedures and/other
therapies, including other therapeutic agents such as antibody therapy and
chemotherapy, among others,
radiation, phototherapy, and cancer and other types of surgery, and is
effectively administered
preventatively, prophylactically or therapeutically. The present
pharmaceutical fonmulations may be
administered to a subject in need of such treatment in amounts comprising an
anti-renal damage or
failure effective amount of the oligo of the invention, and optionally other
agents having specific
activities, carriers and other formulation ingredients as known in the art.
BRIEF DESCRIPTION OF THE DRAWIrIGS
Figure 1 illustrates the effects of A, adenosine receptor anti-sense
oligonucleotides and
mismatch control anti-sense oligonucleotides on the dynamic compliance of the
bronchial airway in a
rabbit model. The two stars represent significant difference at p<0.01,
Student's t-test.
Figure 2 illustrates the specificity of A~ adenosine receptor anti-sense
oligonucleotides as
indicated by the A, and AZ adenosine receptor number present in airway tissue
treated with A1 adenosine
receptor anti-sense oligonucleotides.
Figures 3a and 3b illustrate the response of two hyper-responsive monkeys
(ascaris sensitive) to
a challenge with inhaled adenosine. The right hand bar represents the PC40
adenosine after
administration of the Oligo I, whereas the left hand bar represents the PC40
adenosine value prior to
treatment with the Oligo I. The PC40 adenosine, represented in the Y axis, is
the amount of adenosine in
mg that causes a 40% decrease in dynamic compliance in hyper-responsive
airways.
Figure 3a represents the experimental results obtained without and with pre-
treatment of a first
monkeys with a phosphorothioate agent of the invention (anti-sense oligo I;
SEQ. ID NO: 1), prior to
administration of adenosine.
Figure 3b represents the experimental results obtained without and with pre-
treatment of a
CA 02316994 2000-06-30
WO 99/63938 PC'T/US99/12775
12
second monkey with a phosphorothioate agent of this invention (anti-sense
oligo I; SEQ. ID NO:1), prior
to administration of adenosine.
Figure 4 shows the effect on surfactant in an experimental animal. Figure 4a
shows the baseline
level of sufactant in the rabbit. Figure 4b shows the level of surfactant
after administration of adenosine
(Post adenosine challenge). Figure 4c shows the level of surfactant upon
administration of an adenosine
A~ anti-sense oligonucleotide (SEQ.1D NO: 1 ) and then adenosine.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIIVVIENTS
One aspect of this invention arose from a desire by the inventor to improve on
his own prior
technology for the treatment of acute bronchoconstriction, allergy and/or
inflammation associated with
various diseases and conditions and as an improvement on ineffective existing
methods for treating
diseases and conditions such as Acute Respiratory Distress Syndrome CARDS),
allergic rhinitis, asthma,
adenosine administration e.g. in the treatment of SupraVentricular Tachycardia
(SVT) and other
arrhythmias, and in stress tests to adenosine hyper-sensitized individuals,
ischemia, renal damage or
failure induced by certain drugs, infantile respiratory distress syndrome,
pain, cystic fibrosis, pulmonary
hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive
pulmonary disease (COPD),
and cancers such as leukemias, lymphomas, carcinomas, and the like, including
colon cancer, breast
cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney
cancer, melanoma, hepatic
metastases, etc., as well as all types of cancers which may metastasize or
have metastasized to the
lung(s), including breast and prostate cancer. Extremely dangerous, and in
many cases lethal, effects are
encountered when adenosine receptors are activated by adenosine,
administration. The activation of the
adenosine A, receptor, in particular, may cause life threatening, and in some
cases even fatal,
bronchoconstriction in hyper-responsive individuals. The inventor, in
addition, wanted to provide a
treatment which would improve the outcome and life style of patients
undergoing other procedures or
being administered other therapies, including antibody therapy, chemotherapy,
radiation, phototherapy,
and surgery e.g. cancer surgery, and that could be effectively administered
preventatively,
prophylactically or therapeutically.
He succeeded in this endeavor and is providing in this patent novel and
improved compositions,
fonmulations and methods which afford greatly improved results when compared
with previously known
treatments for preventing and alleviating bronchoconstriction, allergy(ies),
inflammation, breathing
difficulties and blockage of airways, cardiopulmonary and renal damage, and
the like. The nucleic acid,
and optional surfactant and other components, of the composition of the
invention may be formulated
alone with a carrier, or with other therapeutic agents and formulation agents
as is known in the art. The
compositions of this invention, thus, may be incorporated into a variety of
formulations for systemic and
topical administration.
The present composition and treatment are applicable to avoiding
cardiopulmonary and renal
damage, such as that seen in association with ischemic or hypoxic conditions
as well as with the
administration of radio-contrast media, and certain other agents, e.g. those
known to cause ischemia
and/or to produce cardiopulmonary and/or renal damage or failure, such as such
as radiocontrast agents,
glycerol and chemotherapeutic agents such as methotrexate and cisplatin. In
addition, the inventor found
that the present technology is suitable for the prevention and treatment of
renal damage and failure such
CA 02316994 2000-06-30
WO 99/63938 PG"T/US99/12775
13
as is produced in food and snake poisoning as well as septicemia and septic or
toxic shock caused by the
release of endotoxins, such as when microorganisms of the type Botulinum, and
the like, are ingested, or
even from unknown sources.
To his surprise, the inventor found that the present agent had a protective
effect with respect to
the heart, lung and kidneys, and that it could be administered
prophylactically as well as therapeutically.
In addition, when specific other agents are included the present composition
may also be applied to the
treatment of diseases and conditions where the other agents have a secondary
deleterious
cardiopulmonary or renal effect, including diseases and conditions associated
with ischemia, the
administration of adenosine, e.g. for the treatment of SVT or in stress tests,
for the treatment of cancer,
e.g. by administration of an anti-cancer drug such as cisplatin and the oligo
of this invention. Thus, the
anti-sense oligonucleotide (oligo) of the invention may be administered as a
variety of formulations,
either by itself, with or without a surfactant, or with other agents. The anti-
sense oligonucleotide of this
invention, thus, may be incorporated into a variety of formulations for
systemic and topical
administration.
The present invention also improves on the state of the art for rescuing
patients afflicted with
ARDS, whether as a consequence of multiple traumatic injury, severe blood
infections such as sepsis, or
other systemic illness, the administration of high dose radiation therapy and
chemotherapy, and
inflammatory responses which lead to multiple organ failure, and in many cases
death. Although a large
number of persons are afflicted with this disease or condition every year, up
to the present time, no
measures to prevent ARDS have been available. ARDS has been and still is
considered to be untreatable,
and the only palliative treatment has been limited to compensating for the
severe dysfunction of the
respiratory system and treating the underlying cause of the lung injury. One
of the fastest developing
symptoms in ARDS is hypoxia, which is generally treated by administration of
hyperbaric oxygen, often
at high concentrations. The inventor extensively investigated the etiology of
Respiratory Distress
Syndrome (RDS) and ARDS and other conditions which appear to trigger ARDS, and
is hereby
proposing the implementation of a prophylactic or preventative and therapeutic
treatment based on the
administration of oligonucleotides, with or without vectors linked to them
designed to treat the acute
impairment of the airways, bronchoconstriction, allergy and/or inflammation
symptoms seen in patients
who develop ARDS. The present composition, formulations and methods are, thus,
applicable to the
prophylaxis of ARDS immediately after a potential diagnosis is made that a
patient is a good candidate
for developing the condition. In addition, and given that ARDS symptoms many
times develop extremely
fast, the present technology is also applicable to the treatment of patients
who are already afflicted with
the respiratory and inflammatory symptoms seen in ARDS. The present
composition and formulations
may be administered by themselves or in conjunction with other ancillary
agents directed to alleviating
ARDS symptoms, such as oxygen-enriched air, surfactants, blood pressure
controlling agents, and the
like. The composition of the invention is provided in a variety of
formulations for systemic and topical
administration, which may utilized as prescribed by a clinician.
The present inventor unexpectedly found that the agents of the invention,
particularly those
which have at least some inhibitory activity over the adenosine A~ receptor,
strongly inhibit, and in some
cases terminate, with 100% efficacy, the acute respiratory and inflammatory -
symptoms of ARDS.
Experimental work, some of which~is provided in the examples of this patent,
has shown a complete
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
14
interference with, and cessation of, bronchoconstriction and other unwanted
side effects associated with
ARDS, which are mediated by adenosine receptors) in each of two animal models
of human bronchial
hyper-responsiveness: a hyper-responsive rabbit model and a hyper-responsive
cynamologous monkey
model, both being widely acknowledged by the scientific community as models
for bronchoconstriction,
allergy and inflammation involving the respiratory airways in humans. The
agents of this invention,
therefore, have been shown to prevent and counter these ARDS-associated
symptoms, associated with
adenosine receptors, possibly with an adenosine A, receptor. The prevention
and suppression of ARDS
symptomatology seen upon administration of the agent of this invention is
clearly applicable to the
prevention of ARDS and to the treatment of patients afflicted by this
condition by itself, either prior to,
simultaneously with, and subsequent to other palliative therapy. The present
invention now is set to save
a large number of previously unnecessarily lost lives, given the high
morbidity and mortality associated
with ARDS.
Respiratory distress syndrome (RDS) occurs in preterm infants ("preemies"),
and is an extremely
serious problem. A primary cause of RDS in such preterm infants is the
immature developmental stage
of the infant, resulting in low levels or lack of surfactant, a material
critical for normal respiration.
Preterm infants or "premies"exhibiting RDS are ventiliated, and administered
oxygen and surfactant
preparations. When they survive, infants with RDS frequently develop
bronchopulmonary dysplasia
(BPD), also called chronic lung disease (CLD) of early infancy. This condition
too is often fatal.
The causes of surfactant depletion in the preterm infant are unknown. However,
it is known that
surfactant secretion is upregulated through adenosine A~, receptors and
inhibited through adenosine
adenosine A, receptors. It has been shown that ATP and A, adenosine receptor
agonists mobilize
intracellular calcium and activate potassium and chloride currents in normal
and cystic fibrosis airway
epithelial cells. Furthermore, the adenosine A, receptor is also known to
participate in the protection of
tissues from the effects of oxygen deprivation or hypoxia. Based on these and
other pieces of
information, the inventor hypothesized that, during normal fetal development,
there is a changing
(increasing) ratio of the adenosine AZ, receptor to the adenosine A, receptor
(A~,:A, ratio), such that the
A, receptor protects fetal lung tissues during fetal anoxia and inhibits
premature surfactant secretion. The
adenosine A, receptor expression decreases as the fetus approaches term.
Conversely, he hypothesized
that the adenosine A2, receptor is less expressed in early fetal stages, and
its expression increases as the
fetus approaches term, ensuring normal levels of surfactant secretion upon
birth. In the pre-term infant,
an existing high adenosine A,:A2, ratio does not have an opportunity to
reverse itself because the infant
is born before adequate adenosine A2, receptor expression occurs and while
there is still significant
adenosine A, expression. This causes decreased surfactant production at birth
and thereafter.
Accordingly, he surmised that the administration of an adenosine A, anti-sense
oligonucleotide would
reduce the level of adenosine A, receptor formed. In addition, he also
surmised that the administration
of any adenosine Az, agonist, whether or not an oligonucleotide, would
specifically stimulate this
receptor. Either therapy or a combination of both would be suitable for
treating RDS, particularly in
"preemies."
Rhinitis is not a disease, it is a term describing a group of symptoms
produced by nasal irntation
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
or inflammation. Allergies, however, including allergic rhinitis, affect an
estimated 40 to 50 million
people in the United States. Some allergies may interfere with day-to-day
activities or lessen the quality
of life. Rhinitis is a term describing the symptoms produced by wasal
irritation or inflammation.
Symptoms of rhinitis include runny nose, itching, sneezing and stuffy nose due
to blockage or
congestion. These symptoms are the nose's natural response to inflammation and
irritation. Arbitrarily,
rhinitis lasting less than six weeks is called acute rhinitis, and persistent
symptoms are called chronic
rhinitis. Acute rhinitis is generally caused by infections or chemical
irritation. Chronic rhinitis may be
caused by allergy or a variety of other factors. The nose normally produces
mucus, which traps
substances like dust, pollen, pollution, and germs such as bacteria and
viruses. Mucus flows from the
front of the nose and drains down the back of the throat. When mucus
production is excessive, it can
flow from the front, as a runny nose, or become noticeable from the back, as
post-nasal drip. Nasal
mucus, normally a thin, clear liquid, can become thick or colored, perhaps due
to dryness, infection or
pollution. When post-nasal drip is excessive, thick, or contains irritating
substances, cough is the natural
response for clearing the throat. Itching and sneezing are also natural
responses to irritation caused by
allergic reactions, chemical exposures including cigarette smoke, or
temperature changes, infections and
other factors. The nasal tissues congest and decongest periodically. In most
people, nasal congestion
switches back and forth from side to side of the nose in a cycle several hours
long. Some people,
especially those with narrow nasal passages, notice this nasal cycle more than
others. Strenuous exercise
or changes in head position can affect nasal congestion. Severe congestion can
result in facial pressure
and pain, as well as dark circles under the eyes. Sinusitis is inflammation or
infection of any of the four
groups of sinus cavities in the skull, which open into the nasal passages.
Sinusitis is not the same as
rhinitis, although the two may be associated and their symptoms may be
similar. The terms sinus trouble
or sinus congestion are sometimes wrongly used to mean congestion of the nasal
passage itself. Most
cases of nasal congestion, though, are not associated with sinusitis. Known to
most people as hay fever,
allergic rhinitis is a very common medical problem affecting more than 15
percent of the population,
both adults and children. Allergic rhinitis takes two different forms seasonal
and perennial. Symptoms of
seasonal allergic rhinitis occur in spring, summer and/or early fall and are
usually caused by allergic
sensitivity to pollens from trees, grasses or weeds, or to airborne mold
spores. Other people experience
symptoms year-round, a condition called perennial allergic rhinitis. It is
generally caused by sensitivity
to house dust, house dust mites, animal dander andlor mold spores. Underlying
or hidden food allergies
are considered a possible cause of perennial nasal symptoms. Some people may
experience both types of
rhinitis, with perennial symptoms worsening during specific pollen seasons.
There are, however, other
causes for rhinitis. When a sensitive person inhales an allergen (allergy-
causing substance) like ragweed
pollen, the body's immune system reacts abnormally with the allergen. The
allergen binds to allergic
antibodies (immunoglobulin E) that are attached to cells that produce
histamine and other chemicals. The
pollen "triggers" these cells in the nasal membranes, causing them
to release histamine and
the other chemicals. Histamine dilates the small blood vessels of the nose and
fluids leak out into the
surrounding tissues, causing runny noses, watery eyes, itching, swelling and
other allergy symptoms.
Antibodies circulate in the blood stream, but localize in the tissues of the
nose and in the skin. This
makes it possible to show the presence of these antibodies by skin testing, or
less commonly, by a special
blood test. A positive skin test mirrors the type of reaction going on in the
nose. Hay fever is a turn-of
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
16
the-century term which has come to describe the symptoms of allergic rhinitis,
especially when it occurs
in the late summer. However, the symptoms are not caused by hay (ragweed is
one of the main culprits)
and are not accompanied by fever. So physicians prefer the term "allergic
rhinitis" because it
is more accurate. Similarly, springtime symptoms are sometimes called rose
fever but it's just
coincidental that roses are in full-bloom during the grass-pollinating season.
Roses and other sweet-
smelling, showy flowers rely on bees, not the wind, for pollination, so not
much of their pollen gets into
the air to cause allergies.
A common question from allergic rhinitis sufferers is whether they may
relocate to a place where
their allergies will go away. Some allergens are tough to escape. Ragweed
which affects 75% of allergic
rhinitis sufferers blankets most of the United States. Less ragweed is found
in a band along the West
Coast, the southern-most tip of Florida and northern Maine, but it is still
present. Even Alaska and
Hawaii have a little ragweed . A move may be of questionable value because a
person may escape one
allergy to ragweed, for example only to develop sensitivity to grasses or
other allergens in the new
location. Some known complications include ear infections, sinusitis,
recurrent sore throats, cough,
headache, fatigue, irritability, altered sleep pattenns and poor school
performance. Occasionally, children
may develop altered facial growth and orthodontic problems. In some cases,
allergy treatment can
eliminate or alleviate most of these problems. Rhinitis may result from many
causes other than allergic
reaction. Not all rhinitis symptoms are the result of allergies. The following
are the three most common
causes of rhinitis with some of their characteristics: Rhinitis or Allergic
Sensitivity is generally caused
by allergic hay fever dust, foods, animals, pollens, molds, perennial and/or
seasonal infectious colds or
flu viruses, bacteria, and others, and generally lasts 3-7 days. Non-allergic
rhinitis may be caused by
irritant smoke, air pollution, exhaust fumes, aerosol sprays, fragrance, paint
fumes, etc.The most
common condition causing rhinitis is the common cold, an example of infectious
rhinitis. Most
infections are relatively short-lived, lasting from three to seven days. Colds
can be caused by any one of
more than 200 viruses. Children, particularly young children in school or day
care centers, may have
from eight to 12 colds each year. Fortunately, the frequency of colds lessens
after immunity has been
produced from exposure to many viruses. Colds usually begin with a sensation
of congestion, rapidly
followed by runny nose and sneezing. Over the next few days, congestion
becomes more prominent, the
nasal mucus may become colored, and there may be a slight fever and cough.
Cold symptoms resolve
within a couple of weeks, although a cough may sometimes persist. Cold
symptoms that last longer may
be due to other causes, such as chronic rhinitis or sinusitis. Allergic
rhinitis very often has no cure. Most
treatments aim at keeping its symptoms under control by avoiding or reducing
exposure to substances
that cause symptoms and by taking medication when needed.
Dryness of the nasal tissues can be a normal effect of aging, or a
characteristic of a nasal
condition associated with a foul smelling nasal discharge. Rhinitis can also
be a feature of endocrine
disease, like hypothyroidism, or can occur during pregnancy. Rhinitis can be
made worse or even
improved during pregnancy. Alcoholic beverages can cause the blood vessels in
the nose to enlarge
temporarily and produce significant nasal congestion. Sometimes several
conditions can coexist in the
same person. In a single individual, ~ allergic rhinitis could be complicated
by vasomotor rhinitis, septal
deviation (curvature of the bone separating the two sides of the nose) or
nasal polyps. Use of spray
decongestants for chronic sinusitis, septal deviation or vasomotor rhinitis
may cause rhinitis
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
17
medicamentosa. Any of these conditions will be made worse by catching a cold.
Nasal symptoms caused
by more than one problem can be diffcult to treat, often requiring the
cooperation of an allergist-
immunologist and an otolaryngologist (ear, nose and throat specialist). Once
allergic rhinitis is
diagnosed, treatment options include avoidance, medication and immunotherapy
(allergy shots), neither
of which offers a complete cure. A single ragweed plant may release one
million pollen grains in just one
day. The pollen from ragweed, grasses and trees is so small and buoyant that
the wind may carry it miles
from its source. Mold spores, which grow outdoors in fields and on dead
leaves, also are everywhere and
may outnumber pollen grains in the air even when the pollen season is at its
worst. While it's difficult to
escape pollen and molds, exposure may be lessened by keeping windows closed,
using air-conditioning
in the summer and a HEPA (High Energy Particulate Air) filter or an
electrostatic precipitator to clean
pollen and mold from the air. Early morning is a good time to limit outdoor
activities because outdoor
air is most heavily saturated with pollen and mold between 5 and 10 a.m , etc.
Other than avoidance
measures, medications such as antihistamines and decongestants are the most
commonly used for
allergic rhinitis. Newer medications, such as cromolyn, inhibit the release of
chemicals that cause
allergic reactions. Nasal corticosteroid sprays reduce the inflammation from
the allergic trigger.
Medications help to alleviate nasal congestion, runny nose, sneezing and
itching. They are available in
many forms, including tablets, nasal sprays, eye drops and liquids. Most of
these medications cause side
effects. Allergen immunotherapy, known as allergy shots may be recommended for
persons who don't
respond well to treatment with medications, experience side-effects from
medications or have allergen
exposure which is unavoidable. Immunotherapy, however, does not cure allergies
but can be very
effective in controlling allergic symptoms. Allergy injections are usually
given at variable intervals over
a period of three to five years. An immunotherapy treatment program may
consist of injections of a
diluted allergy extract, administered frequently in increasing doses until a
maintenance dose is reached.
Then, the injection schedule is changed so that the same dose is given with
longer intervals between
injections. Immunotherapy helps the body build resistance to the effects of
the allergen, reduces the
intensity of symptoms caused by allergen exposure, and sometimes can actually
make skin test reactions
disappear. As resistance develops, symptoms should improve, but the
improvement from immunotherapy
will take several months to occur. Immunotherapy does not help the symptoms
produced by non-allergic
rhinitis.
Antihistamines are the most inexpensive and commonly used treatment for
rhinitis. These
medications counter the effects of histamine, the irritating chemical released
within your body when an
allergic reaction takes place. Although other chemicals are involved,
histamine is primarily responsible
for causing the symptoms. Antihistamines do not cure, but help relieve: nasal
allergy symptoms, such as
sneezing, itching and discharge; eye symptoms, such as itching, burning,
tearing, and clear discharge;
skin conditions, such as hives, eczema, itching and some rashes; and other
allergic conditions as
determined by your physician. There are dozens of different antihistamines and
wide variations in how
patients respond to them. Some are available over-the-counter and others
require a prescription.
Generally, they work well but produce side effects. The body tends to build up
resistance to some
antihistamines over time. This tendency varies from individual to individual.
Persons with nasal dryness
or thick nasal mucus should avoid taking antihistamines without consulting a
physician. Contact your
physician for advice if an antihistamine causes drowsiness or other side
effects. Short-acting
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
18
antihistamines can be taken every four to six hours, while timed-release
antihistamines are taken every
24 hours. The short-acting antihistamines are often most helpful taken 30
minutes before anticipated
allergic exposure (picnic during ragweed season). Timed-release antihistamines
are better suited to
chronic (long-term) use for those who need daily medications. The most common
side effect is sedation
or drowsiness. For this reason, it is important that you do not drive a car or
work with dangerous
machinery the first time you take an antihistamine. You should take the
antihistamine for the first time at
home, several hours before bedtime. When you are sure that the medicine will
not cause sedation, you
then can take it any time as prescribed during the day. In persons who
experience drowsiness, the
sedation effect usually lessens over, time. Some of the newer antihistamines
produce low drowsiness.
Another frequently encountered side effect is excessive dryness of the mouth,
nose, and eyes. Less
common side effects include restlessness, nervousness, over excitability,
insomnia, dizziness, headaches,
euphoria, fainting, visual disturbances, decreased appetite, nausea, vomiting,
abdominal distress,
constipation, diarrhea, increased or decreased urination, high or low blood
pressure, nightmares
(especially in children), sore throat, unusual bleeding or bruising, chest
tightness or palpitations. Alcohol
and tranquilizers increase the sedation side effects of antihistamines and,
therefore, must be avoided
during therapy.
Decongestants help relieve the stuffiness and pressure caused by allergic,
swollen nasal tissue.
They do not contain antihistamines, so do not cause antihistamine side
effects. They do not relieve the
other symptoms of allergic rhinitis, such as runny nose, post-nasal drip and
sneezing. Decongestants are
available as prescription and non-prescription medications and are often seen
in combination with
antihistamines or other medications. It is not uncommon for patients using
decongestants to experience
insomnia if taking the medication in the afternoon or evening. If this occurs,
a dose reduction may be
needed. At times, men with prostate enlargement may encounter urinary problems
while on
decongestants. Patients using medications for the management of emotional or
behavioral problems
should discuss this with their physicians before using decongestants. Pregnant
patients should also check
with their physician before starting decongestants. Non-prescription
decongestant nasal sprays work
within minutes and last for hours, but may not be used for more than a few
days at a time without a
physician's order. Oral decongestants are found in many over-the-counter and
prescription medications,
and may be the treatment of choice for nasal congestion. They don't cause
rhinitis medicamentosa, but
need to be avoided by some patients with high blood pressure. If you have high
blood pressure, you
should check with your physician before using them. Non-prescription saline
nasal sprays help
counteract symptoms of dry nasal passages or thick nasal mucus. Unlike
decongestant nose sprays, a
saline nose spray can be used as often as needed. Sometimes, your physician
may recommend washing
(douching) of the nasal passage. Corticosteroids counteract the inflammation
caused by the body's
release of allergy-causing substances, as well as that caused by other non-
allergic factors. Thus, they
generally work for many causes of rhinitis symptoms and are sometimes useful
for chronic sinusitis.
Corticosteroids are sometimes injected or taken orally, but usually on a short-
term basis for extremely
severe symptoms. Physicians warn that injected or oral steroids may produce
severe side effects when
used for long periods or used repeatedly and, for this reason, they should be
used with extreme caution.
In rhinitis, a corticosteroid is much safer when used by spraying it into the
nose. Side effects are less
common, but may include nasal ulceration, nasal fungal infection, or bleeding.
Cromolyn is a medication
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
19
that blocks the body's release of allergy-causing substances. It does not work
in all patients. The full
dosage is four times daily, and improvement may take several weeks to occur.
Atropine and the related
drug ipratropium bromide are sometimes used to relieve the runny nose of
rhinitis; in fact, most
antihistamines have a slight atropine-like effect. Atropine can be taken
orally and as a nasal spray. It is a
component of some antihistamine decongestant preparations. Antibiotics are for
the treatment of
bacterial infections. They do not affect the course of uncomplicated common
colds, and are of no benefit
for non-infectious rhinitis, including allergic rhinitis. In chronic
sinusitis, antibiotics may help only
temporarily, and surgery may be needed. Eye allergy preparations are used when
the eyes are affected by
the same allergens that trigger rhinitis, causing redness, watery eyes and
itching. Eye preparations are
available as prescription and non-prescription medications.
All of the non-prescription antihistamines (combined with decongestants) are
"first
generation" antihistamines and generally cause drowsiness, slowed
reaction time and dry mouth in
most people. Examples are Actifed (and combination products), Alka Seltzer
Plus Sinus Allergy
Medicine, Allerest (and combination products), A.R.M., BC Cold Powder Multi-
Symptom Formula,
Benadryl (and combination products), Chlor-Trimeton (and combination
products), Comtrex Multi-
Symptom Day/Night, Contac Maximum Strength, Coricidin (and combination
products), Dimetane,
Dimetapp (and combination products), Drixoral (and combination products),
PediaCare Night Rest
Cough-Cold Liquid, Sinarest, Sudafed Plus, Taoist (and combination products),
Triaminic Allergy,
Tylenol Allergy Sinus/Tylenol PM, Vicks NyQuil (and combination products) and
Vicks Pediatric
Formula 44M Cough & Cold, among others. The following medications are second
generation
antihistamines and generally do not cause the extreme degree of side effects
of first generation
antihistamines, such as drowsiness, slowed reaction time and dry mouth.
Examples of prescription
antihistamines are Allegra, Claritin, Hismanal and Zyrtec. The latter may
cause cardiac problems when
combined with certain other medications whereas Hisnlanol has low sedating
side effects. The following
contain first generation antihistamines and generally cause drowsiness, slowed
reaction time and dry
mouth: Atarax, Antivert, Dallergy, Naldecon, Periactin, Rynatan, Temaril,
Trinalin and Vistaril. The
following are examples of non-prescription oral decongestants: Actifed Allergy
Daytime, Allerest,
Drixoral Non-Drowsy Formula, Efidac/24, PediaCare Infants' Decongestant Draps
and Sudafed Tablets.
Examples of prescription oral decongestants are DuraVent, Entex LA, Entex PSE,
Exgest LA, Respaire,
Sinuvent and Guaifed PD. Examples of non-prescription decongestant nasal
sprays are Afrin and related
products, Cheracol, Dristan, Duration 12-Hour, 4-Way Fast Acting and NTZ Long
Acting. Their
prolonged use, however, may cause rebound congestion. Other examples are Neo
Synephrine and related
products, Nostril/Nostrilla, Otrivin, Privine and Vicks Sinex Long-
Acting/Vapor/Vaporub/VapoSteam/Vatronol. An example of non-prescription anti-
allergy nasal spray is
Nasalcrom, and of non-prescription saline nasal sprays are Afrin Saline Mist,
Ayr, Nasal Moisturizer
AF, Ocean and Salinex. An example of a prescription antihistamine nasal spray
is Astelin. Examples of
prescription atropine-like nasal sprays are Atrovent and Prescription nasal
corticosteroid sprays, which
do not contain antihistamines or decongestants. Other therapeutic agents
suitable for the treatment of
allergic rhinitis are Beconase (Pockethaler and Beconase AQ), Flonase,
Nasacort (Nasal Inhaler and
Nasacort AQ), Nasalide, Rhinocort and Vancenase (Pockethaler and Vancenase
DS). Examples of
prescription oral corticosteroids that do not contain antihistamines are
Deltasone, Liquid Pred, Medrol,
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
Pediapred and Prelone.
The present inventor surmised that the administration of the present gents
would be effective for
the treatment of allergic rhinitis whose symptoms are mediated by adenosine
receptors. In addition, the
inventor showed the effectiveness of the present therapy, for example, on the
level of surfactant in the
lung in an animal model in which the adenosine A, receptor is lrnown to be
highly expressed, the allergic
rabbit lung. See, Ail, S. et al., Adenosine-induced bronchoconstriction in
allergic rabbit model, Am. J.
Physiol. 266:L27I-277 (1994); Ali, S. et al., Adenosine-induced
bronchoconstriction and contraction of
airway smooth muscle from allergic rabbits with late-phase airway obstruction:
Evidence for an
inducible adenosine adenosine A, receptor, JPET 268(3):1328-1334 (1994). In
the normal lung, the
adenosine A~ receptor is generally not expressed, whereas the adenosine A~
receptor is expressed. The
experimental set-up and results are shown in Example 37 below.
In the past, anti-sense oligonucleotides received considerable theoretical
consideration as being
potentially useful as pharmacologic agents for the treatment of human disease.
R. Wagner, Nature 372:
333-335 (1994). However, it has been difficult to actually apply them to
alleviating and curing human
diseases. One important consideration in the pharmacologic application of
these molecules has been the
failure of various routes of administration to deliver the compounds to its
target while avoiding invading
the circulation and, therefore,. other untargeted tissues which, thus,
produces a plethora of side effects.
Most in vivo experiments utilizing anti-sense oligonucleotides involved a
direct application of the oligo
to limited regions of the brain. See, C. Wahlestedt, Trends in Pharmacol. Sci.
15: 42-46 (1994); J. Lai et
al., Neuroreport 5: 1049-1052 (1994); K. Standifer et al., Neuron 12: 805-810
(1994); A. Akabayashi et
al., Brain Res. 21: 55-61 (1994). Others applied them into the spinal fluid.
See, e.g. L. Tseng et al.,
European J. Pharmacol. 258: Rl-3 (1994); R. Raffa et al., European J.
Pharmacol. 258: RS-7 (1994); F.
Gillardon et al., European J. Neurosci. 6: 880-884 (1994). Such applications,
clearly, have no clinical
utility due to their invasive nature. Thus, the systemic administration of
anti-sense oligonucleotides poses
significant problems with respect to their pharmacologic application, not the
least of which is the
difficulty in selectively targeting disease-involved tissues.
The systemic administration of anti-sense oligonucleotides also possesses
significant problems
with respect to their pharmacologic application, not the least of which is the
difficulty in selectively
targeting disease-involved tissues. The respiratory system, and in particular
the lung, as the ultimate port
of entry into the organism, however, is an excellent route of administration
for anti-sense
oligonucleotides. This is so not only for the treatment of lung disease, but
also when utilizing the lung as
a means for delivery, particularly because of its non-invasive and tissue-
specific nature. Thus, local
delivery of antisense oligonucleotides directly to the target tissue enables
the therapeutic use of these
compounds. Fomivirsen (ISIS 2302) is an example of a local drug delivery into
the eye to treat
cytomegalovirus (CMV) retinitis, for which a new drug application has been
filed by ISIS. The
administration of a drug through the lung offers the fiufiher advantage that
inhalation is non-invasive
whereas direct injection in to the vitreous of the eye is invasive.
The composition and formulations of this invention have been shown to have an
exceedingly
high efficacy for preventing and treating a disease or condition associated
with bronchoconstriction,
difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or
inflammation. The
examples provided below show a complete inhibition of such adenosine receptor
associated symptoms in
CA 02316994 2000-06-30
WO 99/63938 PG"T/US99/12775
21
a rabbit model for human bronchoconstriction, allergy(ies) and inflammation as
well as the elimination
of the ability of the adenosine receptor agonist par excellence, adenosine, to
cause bronchoconstriction in
hyper-responsive monkeys, which are animal models for human hyper-
responsiveness to adenosine
receptor agonists. The pharmaceutical composition and formulations of the
invention, therefore, are
suitable for preventing and alleviating the symptoms associated with
stimulation of adenosine receptors,
such as the adenosine A, receptors. The compositions and formulations of this
invention, thus, are also
suitable for prevent the untoward side effects of adenosine-mediated
hyperresponsiveness in certain
individuals, which are generally seen in diseases affecting respiratory
activity. Examples of diseases and
conditions, which may be treated preventatively, prophylactically and
therapeutically with the
compositions and formulations of this invention, are pulmonary
vasoconstriction, inflammation,
allergies, asthma, impeded respiration, Acute Respiratory Distress Syndrome
CARDS), lung, heart and
renal damage and failure, e.g. associated with ischemia as well as the
administration of certain drugs,
side effects associated with adenosine administration, e.g. in
SupraVentricular Tachycardia (SVT) and in
adenosine stress tests, infantile Respiratory Distress Syndrome (infantile
RDS), pain, cystic fibrosis
(CF), pulmonary hypertension, allergic rhinitis pulmonary vasoconstriction,
emphysema, chronic
obstructive pulmonary disease (COPD), and cancers such as leukemias,
lymphomas, carcinomas, and
the like, e.g. colon cancer, breast cancer, lung cancer, pancreatic cancer,
hepatocellular carcinoma,
kidney cancer, melanoma, hepatic metastases, etc., as well as all other
metastatic cancers, e.g. cancers
which metastasized to the lung(s), breast and prostate. The present
compositions and formulations are
suitable for administration before, during and after other treatments,
including radiation, chemotherapy,
antibody therapy, phototherapy and cancer, and other types of surgery. The
present compositions and
formulations may also be administered effectively as a substitute for
therapies that have significant
negative side effects.
All nucleotide sequences are represented in this patent by a single strand
only, and in the 5' to 3'
direction, from left to right. All nucleotide and amino acids are represented
in the manner recommended
by the ILTPAC-IUB Biochemical Nomenclature Commission, or (for amino acids) by
three letter code, in
accordance with 37 CFR ~ 1.822 and established usage. See, e.g., PatentIn User
Manual, 99-102 (Nov.
1990) (U.S. Patent and Trademark Office, Office of the Assistant Commissioner
for Patents,
Washington, D.C. 20231); U.S. Patent No. 4,871,670 to Hudson et al. at col. 3,
lines ZO-43. The
relevant sections of the disclosures of the above cited, and of all other
patents and references cited in this
patent are incorporated herein by reference.
The method of the present invention may be used as well to reduce adenosine-
mediated heart,
lung and kidney damage or failure resulting from any reason, including, but
not limited to, ischemia,
septicemia, septic shock, and the like, the administration of certain
compounds such as radiocontrast
agents used for imaging and diagnostic purposes, many of which have metal
atoms, adenosine used for
treating SVT and in stress tests, and the like. The method of the present
invention may be used as well to
reduce adenosine receptor associated bronchoconstriction in the lungs of a
subject for any reason,
including, but not limited to, brollchoconstriction, allergy(ies) and/or
inflammation, such as those
associated with COPD, ARDS, allergic rhinitis, pulmonary vasoconstriction,
asthma, the administration
of certain exogenous agents, pain, CF, emphysema, and cancer, among others.
The compositions and
formulations of the invention comprise a surfactant and an oligonucleotide
which is anti-sense to the
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
22
adenosine A,, AZb and A3 receptors have shown to be effective in the down-
regulation of the adenosine
A~, AZ" A26 or A3 receptors, respectively, in the cell. Others which are anti-
sense to the adenosine A~,
receptor are also effective as long as they have some adenosine A, inhibitory
activity or adenosine A~,
agonist activity. Similarly, non nucleic acid AZo agonists are suitable. One
novel feature of this
treatment, as compared to traditional treatments for adenosine-mediated
bronchoconstriction and other
symptoms, is that the compositions and formulations of this invention may be
administered directly into
the respiratory system of an individual, and even to his~her lungs. In
addition, the present treatment may
reduce the amount or level of a receptor protein itself rather than merely
acting at the receptor as is the
case with treatments and/or where the agent is merely an antagonist acting at
the receptor site. The
selective characteristic of the present compositions and formulations along
with their administration by a
selected route results in reduced toxicity.
The present composition, formulations and preventative, maintenance and
therapeutic methods
were designed to be applied to the treatment of side effects elicited by
either the exogenous
administration of adenosine, of other agents which have unwanted adenosine-
like effects described here,
or of agents which elicit an endogenous release of adenosine. The agent of the
invention may be
administered either alone or with other therapeutic and diagnostic agents
including adenosine,
dipyrimidol, other adenosine receptor stimulants, adenosine releasing agents,
etc. The present
compositions and formulations for systemic and topical administration may be
administered prior to, in
conjunction with, or subsequent to the administration of adenosine or other
adenosine receptor active
agents.
The present inventors unexpectedly found that the agents of the invention,
particularly those
which have at least some inhibitory activity over the adenosine A, receptor,
strongly inhibit, and in some
cases terminate, with 100% efficacy, the ability of adenosine to cause
bronchoconstriction in hyper-
responsive airways. Experimental work, some of which is provided in the
examples of this patent, has
shown a complete interference with, and cessation of, adenosine's ability to
cause bronchoconstriction
and other unwanted side effects associated with its activity at the adenosine
receptors) in each of two
animal models of human bronchial hyper-responsiveness: a hyper-responsive
rabbit model and a hyper-
responsive cynamologous monkey model, both being widely acknowledged by the
scientific community
as models for adenosine hyper-responsiveness in humans. The agents of this
invention, therefore, have
been shown to prevent the untoward side effects of adenosine in the hyper-
responsive lung mediated via
an adenosine A, receptor. The suppression of adenosine side effects seen upon
the agent's administration
is clearly applicable to the treatment of hyper-sensitized subjects jointly
with adenosine or by itself,
either prior to, simultaneously with, and subsequent to adenosine
administration to SVT afflicted
subjects. In addition, the present agents are also effective for
administration to subjects who need to
undergo an adenosine stress test but who, prior to this invention, were
prevented from the benefits
associated with the administration of such test. The present agent now permits
the free administration of
adenosine or adenosine-like agents to persons with asthma and other
respiratory diseases by preventing
or alleviating the bronchial, allergic and/or inflammatory side effects
produced by them.
To summarize, adenosine is a natural nucleoside which is used in the treatment
of paroxysmal
supraventricular tachycardia (PSVT or SVT), including SVT associated with
Wolff Parkinson-White
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
23
Syndrome, and as a pharmacologic means to evaluate cardiovascular health via
an adenosine stress test.
Many SVT patients and candidates for adenosine stress testing have hyper-
responsive airways associated
with the over-expression of adenosine receptors, particularly the adenosine A,
receptor. When activated
by adenosine, the A~ receptor may cause life threatening, and in some cases
even fatal,
bronchoconstriction in hyper-responsive airways. The present invention,
therefore, permits therapeutic
and diagnostic uses of adenosine in subjects whose health and well being would
have been previously
threatened by administration of adenosine, such as asthmatics and those
afflicted by other conditions
associated with hyper-responsiveness to this compound.
One of the present agents, i.e. Oligo I (SEQ. ID NO:1; EPI 2010) was shown to
be effective in
single-handedly eliminating with virtually 100% efficacy the ability of
adenosine to cause
bronchoconstriction in hyper-responsive airways. The complete termination of
the ability of adenosine to
cause bronchoconstriction is shown in the exemplary disclosure in two animal
models of human
bronchial hyper-responsiveness: the hyper-responsive rabbit and the hyper-
responsive cynamologous
monkey. The oligos of this invention, therefore, are suitable for preventing
untoward side effects of
adenosine administration in the hyper-responsive lung.
As used herein, the terms "prevent", "preventing", "treat" or "treating" refer
to a preventative or
therapeutic treatment which decreases the likelihood that the subject
administered such treatment will
manifest symptoms associated with adenosine receptor stimulation. The term
"down-regulate" refers to
inducing a decrease in production, secretion or availability and, thus, a
decrease in concentration, of
intracellular adenosine A" AZb or A3 receptor or an increase in concentration
of the adenosine A2,
receptor. Also suitable is the use of AZ, agonists. Although the present
invention is primarily concerned
with the treatment of human subjects, it is also applicable to the treatment
of animals, such as other
vertebrates, including mammals, large and small, wild and domesticated,
including pets, e.g. dogs and
cats, for veterinary purposes. In general, "anti-sense" refers to small, many
times synthetic,
oligonucleotides, resembling single-stranded DNA, targeted to a specific gene,
its flanlang regions,
mRNA or protein encoded by the gene and mRNA, which may be utilized for
inhibiting gene expression
by inhibiting the function of the target messenger RNA (mRNA). Milligan, J. F.
et al., J. Med. Chem.
36(14), 1923-1937 {1993). The present invention, thus, is intended for
inhibiting gene expression of the
adenosine A,, AZb or A3 receptor as well as for promoting the gene expression
of the adenosine AZ,
receptor. As is generally known in the art, the inhibition of gene expression
may be I brought about
through anti-sense oligonucleotide hybridization to the coding (sense)
sequences in a specific messenger
RNA (mRNA) target, e.g. by hydrogen bonding according to Watson-Crick base
pairing rules. In
general, the exogenously, administered anti-sense oligos decrease the mRNA and
protein levels of the
target gene or cause changes in the growth characteristics or shapes of the
cells. Ibid. See, also Helene,
C. and Toulme, J., Biochim. Biophys. Acta 1049: 99-125 (1990); Cohen, J. S.,
Ed.,
Oligodeoxynucleotides as Anti-sense Inhibitors of Gene Expression; CRC Press:
Boca Raton, FL {1987).
As used herein, "adenosine receptor anti-sense oligonucleotide (oligo)" is a
short sequence of synthetic
nucleotide that (1) hybridizes to any coding sequence in an mRNA which codes
for an adenosine
receptor, e.g., the adenosine Al, AZb or A3 receptor, under in vivo
hybridization conditions described
below, and that (2) upon hybridization causes a decrease in gene expression of
the adenosine A,, AZb or
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
24
A3 receptor. As used in this patent an adenosine Au agonist is any compound or
agent that triggers an ,
mediated agonist response or increases the level of A~, receptor. As used in
this patent, an adenosine A~,
agonist is any compound or agent that triggers an A2, mediated agonist
response or increases the level of
A~, receptor.
The mRNA sequence of the adenosine At, AZ" A2b and A3 receptors may be derived
from the
DNA base sequences of the genes expressing either the adenosine At, AZb and A3
receptors. The
sequence of the genomic human adenosine At receptor is known and is disclosed
in U.S. Patent No.
5,320,962 to G. Stiles et al. The adenosine AZb receptor is also known. See,
for example, GenBank,
Accession No. X68486; GenBank Accession No. X68487. The adenosine A3 receptor
has been cloned,
sequenced and expressed in rat and humans. See, F. Zhou et al., Proc. Nat' 1.
Acad. Sci. (USA) 89:7432
(1992); M.A. Jacobson et al., U.K. Patent Application No. 9304582.1 (1993).
The anti-sense
oligonucleotides that down-regulate the production of the adenosine A,, AZb
and A3 receptor and to up-
regulate the adenosine A~, receptor and to up-regulate the adenosine A2,
receptor may be produced in
accordance with standard techniques. Adenosine A2, agonists are known in the
art and need not be listed
here.
The agent of this invention binds specifically with any sequence of a mRNA
molecule which is
associated with or encodes an adenosine A,, AZ" AZb or A3 receptor, and
prevents translation of the
mRNA molecule. In one embodiment of the present invention, the anti-sense
oligonucleotide has one of
the following sequences. In another preferred embodiment, the agent of the
invention comprises
fragments of these sequences or their combinations as well as sequences with
decreased adenosine
contents when compared with the natural sequences, where one or more
adenosines are replaced by a
universal base or adenosine analogue which does not activate adenosine
receptors, particularly adenosine
A, receptors.
5' -GAT GGA GGG CGG CAT GGC GGG-3' (SEQ ID NO:1 )
5' -GTT GTT GGG CAT CTT GCC-3' (SEQ ID N0:3)
5' -GTG GGC CTA GCT CTC GCC-3' (SEQ ID NO:S)
In still another embodiment, oligos that are anti-sense to the adenosine A~,
receptor and have
agonistic activity and other adenosine AZ, receptor agents are used for the
treatment of RDS and other
respiratory problems in "preemies."
In another embodiment of the invention, the sequence of the anti-sense
oligonucleotide brackets
the initiation codon of the adenosine A~ receptor, for example that of the
human receptor mRNA.
Preferred human adenosine At receptor anti-sense oligonucleotide may have the
SEQ. lD NO: 7 or any
one of its fragments, including one of the following sequences. In another
preferred embodiment,
fragments of these sequences and/or their combinations are also within the
confines of the invention.
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'(SEQ.
ID N0:7) ,
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-
3'(Frag~rnnt 1 ) (sEQ. ID NO:8) 5'-GGC GGC
CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 2)
(SEQ. m No:9)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -
3'(Fragrtxnt 3) (SEQ. ID NO:10) 5'-GGC GGC
CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 4) (SEQ.
ID NO:11 )
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment
5) (SEQ. ID N0:12)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment
6) (SEQ. ID N0:13)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 7)
(SEQ. ID NO:14)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 8)
(SEQ. ID NO:15)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 9)
(SEQ. ID NO: t 6)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 10)
(SEQ. ID N0:17)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Ftag~nent 11 )
(SEQ. ID N0:18)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 12) (SEQ.
ID N0:19)
S-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 13) (SEQ. ID
N0:20)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 14) (SEQ. ID
N0:21 )
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment I 5) (SEQ. ID
N0:22)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 16) (SEQ. ID
N0:23)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 17) (SEQ. ID
N0:24)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 18) (SEQ. ID
N0:25)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CA-3' (Fn~gmettt 19) (SEQ. ID
N0:26)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG C-3' (Fragment 20) (SEQ. ID N0:27)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG -3' (Fragmatt 21 ) (SEQ. ID N0:28)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CG -3' (Fragma~t 22) (SEQ. ID N0:29)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG C -3' (Fragment 23) (SEQ. ID N0:30)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG -3' (Fragmcnt 24) (SEQ.1D N0:31 )
5'-GGC GGC CTG GAA AGC TGA GAT GGA GG -3' (Fragment 25) (SEQ. ID N0:32)
5'-GGC GGC CTG GAA AGC TGA GAT GGA G -3' (Fragment 26) (SEQ. ID N0:33)
5'~GC GGC CTG GAA AGC TGA GAT GGA -3' (Fragment 27) (SEQ. ID N0:34)
5'-GGC GGC CTG GAA AGC TGA GAT GG -3' (Fragment 28) (SEQ. ID N0:35)
5'-GGC GGC CTG GAA AGC TGA GAT G -3' (Fragment 29) (SEQ. ID N0:36)
5'-GGC GGC CTG GAA AGC TGA GAT -3' (Fragment 30) (SEQ. ID N0:37)
5'-GGC GGC CTG GAA AGC TGA GA-3' (Fragment 31 ) (SEQ. ID N0:38)
5'-GGC GGC CTG GAA AGC TGA G-3' (Fragment 32) (SEQ. ID N0:39)
5'-GGC GGC CTG GAA AGC TGA-3' (Fragment 33) (SEQ. ID N0:40)
5'-0GC GGC CTG GAA AGC TG-3' (Fragment 34) (SEQ. ID N0:41 )
5'-GGC GGC CTG GAA AGC T-3 ' (Fragment 35) (SEQ. ID N0:42)
5'-GGC GGC CTG GAA AGC-3' (Fragment 36) (SEQ.1D N0:43)
5'-GGC GGC CTG GAA AG-3' (Fragment 37) (SEQ.1D N0:44)
5'-GGC GGC CTG GAA A-3' (Fragment 38) (SEQ. ID N0:45)
5'-GGC GGC CTG GAA-3' (Fragment 39) (SEQ. ID N0:46)
5'-GGC GGC CTG GA-3' (Fragment 40) (SEQ. ID N0:47)
5'-GGC GGC CTG G-3' (Fragment 41 ) (SEQ. ID N0:48)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'
(Fragment 42) (SEQ. ID N0:49)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3'
(Fragment 43) (SEQ. ID N0:50)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3'
(Fragment 44) (SEQ. ID N0:51 )
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3'
(Fragment 45) (SEQ. ID N0:52)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment
46) (SEQ. ID N0:53)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment
47) (SEQ. ID N0:54)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGO CGG CAT GGC GGG CAC AGG -3' (Fmgmcnt 48)
(SEQ. ID NO:55)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 49)
(SEQ. ID N0:56)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 50)
(SEQ.1D N0:57)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 51 )
(SEQ. ID N0:58)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 52)
(SEQ. ID N0:59)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 53) (SEQ.
ID N0:60)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 54) (SEQ.
ID N0:61 )
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 55) (SEQ. ID
N0:62)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 56) (SEQ. ID
N0:63)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 57) (SEQ. ID
N0:64)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 58) (SEQ. ID
N0:65)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 59) (SEQ. ID
N0:66)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 60) (SEQ. ID
N0:67)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CA-3' (Fragment 61 ) (SEQ. ID N0:68)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG C-3' (Fragtrxnt 62) (SEQ. ID N0:69)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG -3' (Fragment 63) (SEQ. ID N0:70}
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CG -3' (Fragmcnt 64) (SEQ. ID N0:71 )
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG C -3' (Fr~gtnent 65) (SEQ. ID N0:72)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG -3' (Fragment 66) (SEQ. ID N0:73)
5'-GC GGC CTG GAA AGC TGA GAT GGA GG -3' (Fragment 67) (SEQ. ID N0:74)
5'-0C GGC CTG GAA AGC TGA GAT GGA G -3' (Fragment 68) (SEQ. ID N0:75)
5'-GC GGC CTG GAA AGC TGA GAT GGA ~3' (Fragment 69) (SEQ. ID N0:76)
5'-GC GGC CTG GAA AGC TGA GAT GG -3' (Fragment 70) (SEQ. ID N0:77)
5'-GC GGC CTG GAA AGC TGA GAT G -3' (Fragment 71 ) (SEQ. ID N0:78)
5'-GC GGC CTG GAA AGC TGA GAT -3' (Fragment 72) (SEQ. ID N0:79)
5'-GC GGC CTG GAA AGC TGA GA-3' (Fragment 73) (SEQ. ID N0:80)
5'-GC GGC CTG GAA AGC TGA G-3' (Fragment 74) (SEQ. ID NO:81 )
5'-GC GGC CTG GAA AGC TGA-3' (Fragment 75) (SEQ. ID N0:82)
5'-GC GGC CTG GAA AGC TG-3' (Fragment 76) (SEQ. ID N0:83)
5'-GC GGC CTG GAA AGC T-3' (Fragment 77) (SEQ. ID N0:84)
5'-GC GGC CTG GAA AGC-3' (Fragment 78) (SEQ. ID N0:85)
5'-GC GGC CTG GAA AG-3' (Fragment 79) (SEQ. ID N0:86)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
26
5'-GC GGC CTG GAA A-3' (Fragment 80) (SEQ. ID N0:87)
5'-GC GGC CTG GAA-3' (Fragment 81 ) (SEQ. ID N0:88)
5'-GC GGC CTG GA-3' (Fragment 82) (SEQ. ID N0:89)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'
(Fragment 83) (SEQ. ID N0:90)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3
'(Ftsgmnnt 84) (SEQ. ID N0:91 )
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3'
(Fragment 85) (SEQ. ID N0:92)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3'(Fragment
86) (SEQ. ID N0:93)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment
87} (SEQ. ID N0:94)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment
88) (SEQ. ID N0:95)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragmatt 89)
(SEQ. ID N0:96)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Ftagrttent 90}
(SEQ. ID N0:97)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 91 )
(SEQ. ID N0:98)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 92)
(SEQ. ID N0:99)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 93) (SEQ.
ID NO:100)
5'-C GGC CTG GAp AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 94) (SEQ.
ID NO:101 )
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 95) (SEQ.
ID N0:102)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 96) (SEQ. ID
N0:103)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 97) (SEQ. ID
N0:104)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 98) (SEQ. ID
NO:105)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 99) (SEQ. ID
N0:106)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 100) (SEQ. ID
N0:107)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 101 ) (SEQ. ID
NO:108)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CA-3' (Fragrrxnt 102) (SEQ. ID
N0:109)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG C-3' (Fragment 103) (SEQ. ID NO:110)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG -3' (Fragment 104) (SEQ. ID NO:11 I )
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CG -3' (Fragment 105) (SEQ. ID N0:112)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG C -3' (Fragment 106) (SEQ. ID NO: t 13)
5'-C GGC CTG GAA AGC TGA GAT GGA GGG -3' (Fragment 107) (SEQ. ID NO:114)
5'-C GGC CTG GAA AGC TGA GAT GGA GG -3' (Fragment 108) (SEQ.1D NO:I 15)
5'-C GGC CTG GAA AGC TGA GAT GGA G -3' (Fragment 109) (SEQ. ID NO:116)
5'-C GGC CTG GAA AGC TGA GAT GGA -3' (Fragment 110) (SEQ. ID NO:1 i 7)
5'-C GGC CTG GAA AGC TGA GAT GG -3' (Fragment 111 ) (SEQ. ID NO:118)
5'-C GGC CTG GAA AGC TGA GAT G -3' (Fragment 112) (SEQ. ID N0:119)
5'-C GGC CTG GAA AGC TGA GAT -3' (Fntgment 113) (SEQ. ID NO:120)
5'-C GGC CTG GAA AGC TGA GA-3' (Fragmart 114) (SEQ. ID N0:121 )
5'-C GGC CTG GAA AGC TGA G-3' (Fragment 115) (SEQ. ID N0:122)
5'-C GGC CTG GAA AGC TGA-3' (Fragment 116) (SEQ. ID N0:123)
5'-C GGC CTG GAA AGC TG-3' (Fragment 117) (SEQ. ID N0:124)
5'-C GGC CTG GAA AGC T-3' (Fragment 118) (SEQ. ID N0:125)
5'-C GGC CTG GAA AGC-3' (Fragrrxtrt 119) (SEQ. ID N0:126)
5'-C GGC CTG GAA AG-3' (Fragment 120} (SEQ. ID N0:127)
5'-C GGC CTG GAA A-3' (Fragment 121} (SEQ. ID N0:128)
5'-C GGC CTG GAA-3' (Fragment 122) (SEQ. ID N0:129)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'
(Fragment 123) (SEQ, iD N0:130)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CG(i CAT GGC GGG CAC AGG CTG GG-3'
(Fragment 124) (SEQ. 1D N0:131 )
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3'
(Fragment 125) (SEQ. ID N0:132) ,
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3 (Fragm~mt
126) (SEQ. ID N0:133)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment
127) (SEQ. ID N0:134)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment
128) (SEQ. ID N0:135)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 129)
(SEQ. ID N0:136)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 130)
(SEQ. ID N0:137)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 131)
(SEQ. ID N0:138)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 132)
(SEQ. ID N0:139)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3'(Fragmemt 133) (SEQ.
ID N0:140)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 134) (SEQ.
ID N0:141 )
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment i 35) (SEQ.
ID N0:142)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment i 36) (SEQ. ID
N0:143)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 137) (SEQ. ID
N0:144)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 138) (SEQ. ID
N0:145)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 139) (SEQ. ID
N0:146)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 140) (SEQ. ID
N0:147)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 141 ) (SEQ. ID
N0:148)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG CA-3' (Fragment l42) (SEQ. ID N0:149)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG C-3' (Fragment 143) (SEQ. ID NO:150)
5'- GGC CTG GAA AGC TGA GAT GGA GGG CGG -3' (Fragment 144) (SEQ. ID NO:lSI )
5'- GGC CTG GAA AGC TGA GAT GGA GGG CG -3' (Fragment 145) (SEQ. iD N0:152)
5'- GGC CTG GAA AGC TGA GAT GGA GGG C -3' (Fragment 146) (SEQ. ID N0:153)
CA 02316994 2000-06-30
WO 99/63938 PCT/ITS99/12775
27
5'- GGC CTG GAA AGC TGA GAT GGA GGG -3' (Fragment 147) (SEQ. ID N0:154)
5'- GGC CTG GAA AGC TGA GAT GGA GG -3' (Fragment 148) (SEQ. ID N0:155)
5'- GGC CTG GAA AGC TGA GAT GGA G -3' (Fragment 149) (SEQ. ID N0:156)
5'- GGC CTG GAA AGC TGA GAT GGA -3' (Fr'sgment 150) (SEQ. ID N0:157)
5'- GGC CTG GAA AGC TGA GAT GG -3' (Fragment 151 ) (SEQ. ID NO: l58)
5'- GGC CTG GAA AGC TGA GAT G -3' (Fragment 152) (SEQ. ID N0:159)
5'- GGC CTG GAA AGC TGA GAT -3' (Fragment 153) (SEQ. ID N0:160)
5'- GGC CTG GAA AGC TGA GA-3' (Fragment 154) (SEQ. ID N0:161 )
5'- GGC CTG GAA AGC TGA G-3' (Fragment 155) (SEQ. ID N0:162)
5'- GGC CTG GAA AGC TGA-3' (Fragment 156) (SEQ. ID N0:163)
5'- GGC CTG GAA AGC TG-3' (F~agment 157) (SEQ. ID N0:164)
5'- GGC CTG GAA AGC T-3' (Fragment 158) (SEQ. ID N0:165)
5'- GGC CTG GAA AGC-3' (Fragment 159) (SEQ. ID N0:166)
5'- GGC CTG GAA AG-3' (Fragment 160) (SEQ. ID N0:167)
5'- GGC CTG GAA A-3' (Fragment 161 ) (SEQ. ID N0:168)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'
(Fragment 162) (SEQ. ID N0:169)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3'
(Fragrrxnt 163) (SEQ. ID N0:170)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment
164) (SEQ. ID N0:171 ) 5'- GC CTG
GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 165) (SEQ.
ID N0:172)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment
166) (SEQ. ID N0:173)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 167)
(SEQ. ID N0:174)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 168)
(SEQ. ID N0:175)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 169)
(SEQ. ID N0:176)
5'- GC CTG GAA AGC TGA GAT G(iA GGG CGG CAT GGC GGG CAC A-3' (Fragment 170)
(SEQ. ID N0:177)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 171 )
(SEQ. ID N0:178)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 172) (SEQ.
ID N0:179)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 173) (SEQ.
ID N0:180)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 174) (SEQ. ID
N0:181 )
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragrtxnt 175) (SEQ. ID
N0:182)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (FragrtKnt 176) (SEQ. ID
N0:183)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 177) (SEQ. ID
N0:184)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 178) (SEQ. ID
N0:185)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 179) (SEQ. ID NO:I
B6)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 180) (SEQ. ID N0:187)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG CA-3' (Fragment 181 ) (SEQ. ID N0:188)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG C-3' (Fragment 182) (SEQ. ID N0:189)
5'- GC CTG GAA AGC TGA GAT GGA GGG CGG -3' (Fragment 183} (SEQ. ID N0:190)
5'- GC CTG GAA AGC TGA GAT GGA GGG CG -3' (Fragment 184) (SEQ. ID N0:19I )
5'- GC CTG GAA AGC TGA GAT GGA GGG C -3' (Fragment 185) (SEQ. ID N0:192)
5'- GC CTG GAA AGC TGA GAT GGA GGG -3' (Fragment 186) (SEQ. ID N0:193)
5'- GC CTG GAA AGC TGA GAT GGA GG -3' (Fragment t 87) (SEQ. ID N0:194)
5'- GC CTG GAA AGC TGA GAT GGA G -3' (Fragment 188) (SEQ. ID N0:195)
5'- GC CTG GAA AGC TGA GAT GGA -3' (Fragment 189) (SEQ. ID N0:196)
5'- GC CTG GAA AGC TGA GAT GG -3' (Fragment 190) (SEQ. ID N0:197)
5'- GC CTG GAA AGC TGA GAT G -3' (Fragment 191 ) (SEQ. ID N0:198)
5'- GC CTG GAA AGC TGA GAT -3' (Fragment 192) (SEQ. ID N0:199)
5'- GC CTG GAA AGC TGA GA-3' (Fragm~mt 193) (SEQ. ID N0:200)
5'- GC CTG GAA AGC TGA G-3' (Fragment i 94) (SEQ. ID N0:201 )
5'- GC CTG GAA AGC TGA-3' (Fragment 195) (SEQ. ID N0:202)
5'- GC CTG GAA AGC TG-3' (Fragment 196) (SEQ. ID N0:203)
5'- GC CTG GAA AGC T-3' (Fragment 197) (SEQ. ID N0:204)
5'- GC CTG GAA AGC-3' (Fragment 198) (SEQ. ID N0:205)
5'- GC CTG GAA AG-3' (Fragment 199) (SEQ. ID N0:206)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment
200) (sEQ. ID N0:2o~
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment
201 ) (SEQ. ID N0:208)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment
202) (SEQ. ID N0:209)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment
203) (SEQ. ID N0:210)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3'(Fragment 204)
(SEQ. ID N0:211 )
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 205)
(SEQ. ID N0:212)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 206)
(SEQ. ID N0:213)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 207)
(SEQ. ID N0:214)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 208)
(SEQ. ID N0:215)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 209) (SEQ.
ID N0:216)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 210) (SEQ.
ID N0:217)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 211 ) (SEQ.
ID N0:218)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 212) (SEQ. ID
N0:219)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 213) (SEQ. ID
N0:220)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (F~sgment 214) (SEQ. ID
N0:221 )
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 215) (SEQ. ID
N0:222)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT GG .3' (Fragment 216) (SEQ. ID
N0:223}
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 217) (SEQ. ID
N0:224)
CA 02316994 2000-06-30
WO 99/63938 PGT/US99/12775
28
S'- C CTG GAA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 218) (SEQ. ID N0:22S)
5'- C CTG GAA AGC TGA GAT GGA GGG CGG CA-3' (Fragment 219) (SEQ. ID N0:226)
S'- C CTG GAA AGC TGA GAT GGA GGG CGG C-3' (Fragment 220) (SEQ. ID N0:227)
S'- C CTG GAA AGC TGA GAT GGA GGG CGG -3' (Fragment 221) (SEQ. ID N0:228)
5'- C CTG GAA AGC TGA GAT GGA GGG CG -3' (Fragment 222) (SEQ.1D N0:229)
S'- C CTG GAA AGC TGA GAT GGA GGG C -3' (Fragment 223) (SEQ. ID TI0:230)
S'- C CTG GAA AGC TGA GAT GGA GGG -3' (Fragment 224) (SEQ. ID N0:23 i )
S'- C CTG GAA AGC TGA GAT GGA GG -3' (Fragment 22S) (SEQ. ID N0:232)
S'- C CTG GAA AGC TGA GAT GGA G -3' (Fragment 226) (SEQ. ID N0:233)
S'- C CTG GAA AGC TGA GAT GGA -3' (Fragment 227) (SEQ. ID N0:234)
S'- C CTG GAA AGC TGA GAT GG -3' (Fragment 228) (SEQ. ID N0:235)
S'- C CTG GAA AGC TGA GAT G -3' (Fragment 229) (SEQ. ID N0:236)
S'- C CTG GAA AGC TGA GAT -3' (Fragment 230) (SEQ. ID N0:237)
S'- C CTG GAA AGC TGA GA-3' (Fragment 231 ) (SEQ. ID N0:238)
5'- C CTG GAA AGC TGA G-3' (Fragment 232) (SEQ. ID N0:239)
S'- C CTG GAA AGC TGA-3' (Fragment 233) (SEQ. ID N0:240)
S'- C CTG GAA AGC TG-3' (Fragment 234) (SEQ. ID N0:241 )
5'- C CTG GAA AGC T-3' (Fragment 235) (SEQ. ID N0:242)
S'- C CTG GAA AGC-3' (Fragment 236) (SEQ. ID N0:243)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment
237) (SEQ. ID N0:244) S'- CTG GAA
AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 238) (SEQ. ID
N0:24S)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment
239) (SEQ. ID N0:246)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 240)
(SEQ. ID N0:247)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 241)
(SEQ. ID N0:248)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 242)
(SEQ. ID N0:249)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 243)
(SEQ. ID N0:2S0)
5'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 244) (SEQ.
ID N0:2S1)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 24S) (SEQ.
ID N0:252)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 246) (SEQ. ID
N0:253)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 247) (SEQ. ID
N0:254)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 248) (SEQ. ID
N0:2S5)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 249) (SEQ. ID
N0:2S6)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 250) (SEQ. ID
N0:257)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 2S 1) (SEQ. ID
N0:2S8)
5'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 252) (SEQ. ID
N0:259)
5'- CTG GAA AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 2S3) (SEQ. ID N0:260)
S'- CTG GAA AGC TGA OAT GGA GGG CGG CAT G -3' (Fragment 254) (SEQ. ID N0:261 }
5'- CTG GAA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 2SS) (SEQ. ID N0:262)
S'- CTG GAA AGC TGA GAT GGA GGG CGG CA-3' (Fragment 2S6) (SEQ. ID N0:263)
5'- CTG GAA AGC TGA GAT GGA GGG CGG C-3' (Fragment 257) (SEQ. ID N0:264)
S'- CTG GAA AGC TGA GAT GGA GGG CGG -3' (Fragment 2S8) (SEQ. ID N0:26S)
S'- CTG GAA AGC TGA GAT GGA GGG CG -3' (Fragment 259) (SEQ. ID N0:266)
S'- CTG GAA AGC TGA GAT GGA GGG C -3' (Fragment 260) (SEQ. ID N0:267)
S'- CTG GAA AGC TGA GAT GGA GGG -3' (Fragment 261 ) (SEQ. ID NO:268)
S'- CTG GAA AGC TGA GAT GGA GG -3' (Fragment 262) (SEQ. ID N0:269)
5'- CTG GAA AGC TGA GAT GGA G -3' (Fragment 263) (SEQ. 1D N0:270)
S'- CTG GAA AGC TGA GAT GGA -3' (Fragment 264) (SEQ. ID N0:271 )
S'- CTG GAA AGC TGA GAT GG -3' (Fragment 26S) (SEQ. ID N0:272)
5'- CTG GAA AGC TGA GAT G -3' (Fragment 266) (SEQ. ID N0:273)
S'- CTG GAA AGC TGA GAT -3' (Fragment 267) (SEQ. ID N0:274)
S'- CTG GAA AGC TGA GA-3' (Fragment 268) (SEQ. ID N0:275)
S'- CTG GAA AGC TGA G-3' (Fragment 269) (SEQ. ID N0:276)
S'- CTG GAA AGC TGA-3' (Fragment 270) (SEQ. ID N0:277)
S'- CTG GAA AGC TG-3' (Fragment 271 ) (SEQ. ID N0:278)
S'- CTG GAA AGC T-3' (Fragment 272) (SEQ. ID N0:279)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment
273) (SEQ. ID N0:280)
5'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment
274) (SEQ. ID N0:281 )
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 27S)
(SEQ. ID N0:282)
5'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 276)
(SEQ. ID N0:283)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 277)
(SEQ. ID N0:284)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 278)
(SEQ. ID N0:285)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 279)
(SEQ. ID N0:286)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 280) (SEQ.
ID N0:287)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 281 ) (SEQ.
ID N0:288)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 282) (SEQ. ID
N0:289)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 283) (SEQ. ID
N0:290)
5'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 284) (SEQ. ID
N0:291 )
S'- TG GM AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 28S) (SEQ. ID
N0:292)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragm~mt 286) (SEQ. ID
N0:293)
5'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 287) (SEQ. ID
N0:294)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 288) (SEQ. ID N0:29S)
5'- TG GAA AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 289) (SEQ. ID N0:296)
S'- TG GAA AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 290) (SEQ. ID N0:297)
CA 02316994 2000-06-30
WO 99/63938 PC'T/US99/12775
29
5'- TG GAA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 291 ) (SEQ. ID N0:298)
5'- TG GAA AGC TGA GAT GGA GGG CGG CA-3' (Fngmart 292) (SEQ. ID N0:299)
5'- TG GAA AGC TGA GAT GGA GGG CGG C-3' (Fragment 293) (SEQ. ID N0:300)
5'- TG GAA AGC TGA GAT GGA GGG CGG -3' (Fragment 294) (SEQ. ID N0:301 )
5'- TG GAA AGC TGA GAT GGA GGO CG -3' (Fragment 295) (SEQ. ID N0:302)
5'- TG GAA AGC TGA GAT GGA GGG C -3' (Fragment 296) (SEQ. ID N0:303)
5'- TG GAA AGC TGA GAT GGA GGG -3' (Fragment 297) (SEQ. ID N0:304)
5'- TG GAA AGC TGA GAT GGA GG -3' (Fragment 298) (SEQ.1D N0:305)
5'- TG GAA AGC TGA GAT GGA G -3' (Fragmrnt 299) (SEQ. ID N0:306)
5'- TG GAA AGC TGA GAT GGA -3' (Fragment 300) (SEQ. ID N0:307)
5'- TG GAA AGC TGA GAT GG -3' (Fragment 301 ) (SEQ. ID N0:308)
5'- TG GAA AGC TGA GAT G -3' (Fragment 302) (SEQ. ID N0:309)
5'- TG GAA AGC TGA GAT -3' (Fragment 303) (SEQ. ID N0:310)
5'- TG GAA AGC TGA GA-3' (Fragment 304) (SEQ. ID N0:311 )
5'- TG GAA AGC TGA G-3' (Fragment 305) (SEQ. ID N0:312)
5'- TG GAA AGC TGA-3' (Fragment 306) (SEQ. ID N0:313)
5'- TG GAA AGC TG-3' (Fragment 307) (SEQ. ID N0:314)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment
308) (SEQ. ID N0:315)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3'(Fngment 309)
(SEQ. ID N0:316)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 310)
(SEQ. ID N0:317)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 311 )
(SEQ. ID N0:318)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 312)
(SEQ. ID N0:319)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 313)
(SEQ. ID N0:320)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 314) (SEQ.
ID N0:321 )
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 315) (SEQ.
ID N0:322)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 316) (SEQ. ID
N0:323)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragrrxnt 317) (SEQ. ID
N0:324)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 318) (SEQ. ID
N0:325)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 319) (SEQ. ID
N0:326)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 320) (SEQ. ID
N0:327)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC GG -3' (Fragment 321 ) (SEQ.1D
N0:328)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 322) (SEQ. ID N0:329)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GGC -3 (Fragment 323) (SEQ. ID N0:330)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 324) (SEQ. ID N0:331 )
5'- G GAA AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 325) (SEQ. ID N0:332)
5'- G GAA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 326) (SEQ. ID N0:333)
5'- G GAA AGC TGA GAT GGA GGG CGG CA-3' (Fragment 327) (SEQ. ID N0:334)
5'- G GAA AGC TGA GAT GGA GGG CGG C-3,' (Fragment 328) (SEQ. ID N0:335)
5'- G GAA AGC TGA GAT GGA GGG CGG -3' (Fragment 329) (SEQ. ID N0:336)
5'- G GAA AGC TGA GAT GGA GGG CG -3' (Fragment 330) (SEQ. ID N0:337)
5'- G GAA AGC TGA GAT GGA GGG C -3' (Fragment 331) (SEQ. ID N0:338)
5'- G GAA AGC TGA GAT GGA GGG -3' (Fragment 332) (SEQ. ID N0:339)
5'- G GAA AGC TGA GAT GGA GG -3' (Fragment 333) (SEQ. ID N0:340)
5'- G GAA AGC TGA GAT GGA G -3' (Fragment 334) (SEQ. ID N0:341 )
5'- G GAA AGC TGA GAT GGA -3' (Fragment 335) (SEQ. ID N0:342)
5'- G GAA AGC TGA GAT GG -3' (Fragment 336) (SEQ. ID N0:343)
5'- G GAA AGC TGA GAT G -3' (Fngmcnt 33T) (SEQ. ID N0:344)
5'- G GAA AGC TGA GAT -3' (Fragment 338) (SEQ. ID N0:345)
5'- G GAA AGC TGA GA-3' (Fngmcnt 339) (SEQ. ID N0:346)
5'- G GAA AGC TGA G-3' (Fragment 340) (SEQ. ID N0:347)
5'- G GAA AGC TGA-3' (Fragment 341 ) (SEQ. ID N0:348)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC OGG CAC AGG CTG GGC-3' (Fngmertt 342)
(SEQ. ID N0:349)
5'- GAA AGC TGA GAT GGA GGG CGO CAT GGC GGG CAC AGG CTG GG-3' (Fragment 343)
(SEQ. ID NO:350)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 344)
(SEQ. ID N0:351 )
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 345)
(SEQ. ID N0:352)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 346) (SEQ.
ID N0:353)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 347) (SEQ.
ID N0:354)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fngm~mt 348) (SEQ. ID
N0:355)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 349) (SEQ. ID
N0:356)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 350) (SEQ. ID
N0:357)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 351 ) (SEQ. ID
N0:358)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 352) (SEQ. ID
N0:359)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 353) (SEQ. ID
N0:360)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 354) (SEQ. iD N0:361
)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 355) (SEQ. ID N0:362)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 356) (SEQ. ID N0:363)
5'- GAA AGC TGA GAT GGA GGG CGG CAT'GGC -3' (Fragment 357) (SEQ. ID N0:3ti4)
5'- GAA AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 358) (SEQ. ID N0:365)
5'- GAA AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 359) (SEQ. ID N0:366)
5'- GAA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 360) (SEQ. ID N0:367)
5'- GAA AGC TGA GAT GGA GGG CGG CA-3' (Fragment 361 ) (SEQ. ID N0:368)
5'- GAA AGC TGA GAT GGA GGG CGG C-3' (Fragment 362) (SEQ. ID N0:369)
5'- GAA AGC TGA GAT GGA GGG CGG -3' (Fragment 363) (SEQ. ID N0:370)
CA 02316994 2000-06-30
WO 99/63938 PCTNS99/12775
S'- GAA AGC TGA GAT GGA GGG CG -3' (Fragment 364) (SEQ. ID N0:371 )
5'- GAA AGC TGA GAT GGA GGG C -3' (Fragment 36S) (SEQ. ID N0:372)
S'- GAA AGC TGA GAT GGA GGG -3' (Ft 366) (SEQ. ID N0:373)
S'- GAA AGC TGA GAT GGA GG -3' (Fragmcnt 367) (SEQ. ID N0:374)
S'- GAA AGC TGA GAT GGA G -3' (Fragment 368) (SEQ. ID N0:375)
S'- GAA AGC TGA GAT GGA -3' (Fragment 369) (SEQ. ID N0:376)
S'- GAA AGC TGA GAT GG -3' (Fragment 370) (SEQ. ID N0:377)
S'- GAA AGC TGA GAT G -3' (Fragment 371 ) (SEQ. ID N0:378)
5'- GAA AGC TGA GAT -3' (Fragment 372) (SEQ. ID N0:379)
S'- GAA AGC TGA GA-3' (Fragment 373) (SEQ. ID N0:380)
5'- GAA AGC TGA G-3' (Fragmcnt 374) (SEQ. ID N0:381)
S'- -AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 37S)
(SEQ. ID N0:382)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 376)
(SEQ. ID N0:383)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 377)
(SEQ. ID N0:384)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 378)
(SEQ. ID N0:38S)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 379) (SEQ.
ID N0:386)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 380) (SEQ.
ID N0:387)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 381 ) (SEQ.
ID N0:388)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fngmcnt 382) (SEQ. ID
N0:389)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 383) (SEQ. ID
N0:390)
5'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 384) (SEQ. ID
N0:391 )
5'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 385) (SEQ. ID
N0:392)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Frsgmcnt 386) (SEQ. ID
N0:393)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 387) (SEQ. ID N0:394)
5'- AA AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 388) (SEQ. ID N0:395)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 389) (SEQ. ID N0:396)
S'- AA AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 390) (SEQ. ID N0:397)
S'- AA AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragtrxnt 391 ) (SEQ. ID N0:398)
S'- AA AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 392) (SEQ. ID N0:399)
S'- AA AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 393) (SEQ. ID N0:400)
S'- AA AGC TGA GAT GGA GGG CGG CA-3' (Fragment 394) (SEQ.1D N0:401 )
S'- AA AGC TGA GAT GGA GGG CGG C-3' (Fragment 395) (SEQ. ID N0:402)
S'- AA AGC TGA GAT GGA GGG CGG -3' (Fragment 396) (SEQ. ID N0:403)
S'- AA AGC TGA GAT GGA GGG CG -3' (Fragment 397) (SEQ. ID N0:404)
5'- AA AGC TGA GAT GGA GGG C -3' (Fragment 398) (SEQ.1D N0:405)
5'- AA AGC TGA GAT GGA GGG -3' (Fragment 399) (SEQ. ID N0:406)
S'- AA AGC TGA GAT GGA GG -3' (Fragment 400) (SEQ. ID N0:407)
5'- AA AGC TGA GAT GGA G -3' (Fragment 401 ) (SEQ. ID N0:408)
S'- AA AGC TGA GAT GGA -3' (Fragment 402) (SEQ. ID N0:409)
S'- AA AGC TGA GAT GG -3' (Fragment 403) (SEQ. ID N0:410)
S'- AA AGC TGA GAT G -3' (Fragment 404) (SEQ. ID N0:411 )
S'- AA AGC TGA GAT -3' (Fragment 405) (SEQ. ID N0:412)
S'- AA AGC TGA GA-3' (Fragment 406) (SEQ.1D N0:413)
S'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 407)
(SEQ. ID N0:414)
5'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 408)
(SEQ. ID N0:41S)
S'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 409)
(SEQ. ID N0:416)
S'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 410) (SEQ.
ID N0:417)
5'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 411 ) (SEQ.
ID N0:418)
S'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 412) (SEQ. ID
N0:419)
S'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 413) (SEQ. ID
N0:420)
S'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 414) (SEQ. ID
N0:421 )
5'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragrtxnt 415) (SEQ.1D
N0:422)
5'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 416) (SEQ. ID
N0:423)
S'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 417) (SEQ. ID
N0:424)
5'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fr~nent 418) (SEQ. ID N0:42S)
S'- A AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 419) (SEQ. ID N0:426)
S'- A AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 420) (SEQ. ID N0:427)
5'- A AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 421 ) (SEQ. ID N0:428)
S'- A AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 422) (SEQ. ID N0:429)
S'- A AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 423) (SEQ. ID N0:430)
S'- A AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 424) (SEQ. ID N0:43I )
S'- A AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 425) (SEQ. ID N0:432)
5'- A AGC TGA GAT GGA GGG CGG CA-3' (Fragment 426) (SEQ. ID N0:433)
S'- A AGC TGA GAT GGA GGG CGG C-3' (Fragrra;nt 427) (SEQ. ID N0:434)
S'- A AGC TGA GAT GGA GGG CGG -3' (Fragment 428) (SEQ. ID N0:43S)
S'- A AGC TGA GAT GGA GGG CG -3' (Fragtpent 429) (SEQ. ID N0:436)
S'- A AGC TGA GAT GGA GGG C -3' (Fragment 430) (SEQ. ID N0:437)
S'- A AGC TGA GAT GGA GGG -3' (Fragment 431) (SEQ. ID N0:438)
S'- A AGC TGA GAT GGA GG -3' (Fragment 432) (SEQ. ID N0:439)
S'- A AGC TGA GAT GGA G -3' (Fragment 433) (SEQ. ID N0:440)
5'- A AGC TGA GAT GGA -3' (Fragrtxnt 434) (SEQ. ID N0:441 )
S'- A AGC TGA GAT GG -3' (Fragment 435) (SEQ. ID N0:442)
S'- A AGC TGA GAT G -3' (Fragment 436) (SEQ. ID N0:443)
CA 02316994 2000-06-30
WO 99/63938 PC'T/US99/12775
31
5'- A AGC TGA GAT -3' (Fragment 437) (SEQ. ID N0:444)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AOG CTG GGC-3' (Fragment 438)
(SEQ. ID N0:445)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 439) (SEQ.
ID N0:446)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 440) (SEQ.
ID N0:447)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 441 ) (SEQ.
ID N0:448)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 442) (SEQ. ID
N0:449)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 443) (SEQ. ID
N0:450)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 444) (SEQ. ID
N0:451 )
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 445) (SEQ. ID
N0:452)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 446) (SEQ. ID
N0:453)
5'- AGC TGA GAT GGA GGG CGG CAT OGC GGG CAC-3' (Fragment 447) (SEQ. ID N0:454)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GG(i CA-3' (Fragment 448) (SEQ. ID N0:455)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 449) (SEQ. ID N0:456)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 450) (SEQ. ID N0:457)
5'- AGC TGA GAT GGA GGG CGG CAT GGC GG-3' (Pngment 451 ) (SEQ. ID N0:458)
5'- AGC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 452) (SEQ. ID N0:459)
5'- AGC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 453) (SEQ. ID N0:460)
5'- AGC TGA GAT GGA GGG CGG CAT GG -3' (Fragment 454) (SEQ. ID N0:461 )
5'- AGC TGA GAT GGA GGG CGG CAT G -3' (Fragment 455) (SEQ. ID N0:462)
5'- AGC TGA GAT GGA GGG CGG CAT -3' (Fragment 456) (SEQ. ID N0:463)
5'- AGC TGA GAT GGA GGG CGG CA-3' (Fragment 457) (SEQ. ID N0:464)
5'- AGC TGA GAT GGA GGG CGG C-3' (Fragment 458) (SEQ. ID N0:465)
5'- AGC TGA GAT GGA GGG CGG -3' (Fragment 459) (SEQ. ID N0:466)
5'- AGC TGA GAT GGA GGG CG -3' (Fragment 460) (SEQ. ID N0:467)
5'- AGC TGA GAT GGA GGG C -3' (Fragment 461 ) (SEQ. ID N0:468)
5'- AGC TGA GAT GGA GGG -3' (Fragment 462) (SEQ. ID N0:469)
5'- AGC TGA GAT GGA GG -3' (Fragment 463) (SEQ. ID N0:470)
5'- AGC TGA GAT GGA G -3' (Fragment 464) (SEQ. ID N0:471 )
5'- AGC TGA GAT GGA -3' (Fragment 465) (SEQ. ID N0:472)
5'- AGC TGA GAT GG -3' (Fngmemt 466) (SEQ. ID N0:473)
5'- AGC TGA GAT G -3' (Fragment 467) (SEQ. ID N0:474)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 468) (SEQ.
ID N0:475)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 469) (SEQ.
ID N0:476)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 470) (SEQ.
ID N0:477)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 471 ) (SEQ.
ID N0:478)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 472) (SEQ. ID
N0:479)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 473) (SEQ. ID
N0:480)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 474) (SEQ. ID
N0:481 )
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 475) (SEQ. ID
N0:482)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 476) (SEQ. ID
N0:483)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 477) (SEQ. ID N0:484)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 478) (SEQ. ID N0:485)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGti C-3' (Fngrrrent 479) (SEQ. ID N0:486)
5'- GC TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 480) (SEQ. ID N0:487)
5'- GC TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 481 ) (SEQ. ID N0:488)
5'- GC TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 482) (SEQ. ID N0:489)
5'- GC TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 483) (SEQ. ID N0:490)
5'- GC TGA GAT GGA GGG CGG CAT GG -3~ (Fragment 484) (SEQ. ID N0:491 )
5'- GC TGA GAT GGA GGG CGG CAT G -3' (Fragment 485) (SEQ. ID N0:492)
5'- GC TGA GAT GGA GGG CGG CAT -3' (Fragment 486) (SEQ. ID N0:493)
5'- GC TGA GAT GGA GGG CGG CA-3' (Fragment 48T) (SEQ. ID N0:494)
5'- GC TGA GAT GGA GGG CGG C-3' (Fragment 488) (SEQ. 1D N0:495)
5'- GC TGA GAT GGA GGG CGG -3' (Fragment 489) (SEQ. ID N0:496)
5'- GC TGA GAT GGA GGG CG -3' (Fragment 490) (SEQ. ID N0:497)
5'- GC TGA GAT GGA GGG C -3' (Fragment 491) (SEQ. ID N0:498)
5'- GC TGA GAT GGA GGG -3' (Fragment 492) (SEQ. ID N0:499)
5'- GC TGA GAT GGA GG -3' (Fragment 493) (SEQ. ID NO:500)
5'- GC TGA GAT GGA G -3' (Fragment 494) (SEQ. ID N0:501 )
5'- GC TGA GAT GGA -3' (Fragment 495) (SEQ. ID N0:502)
5'- GC TGA GAT GG -3' (Fngrtxnt 496) (SEQ. ID N0:503)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 497) (SEQ.
ID N0:504)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 498) (SEQ.
ID N0:505)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 499) (SEQ. ID
N0:506)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 500) (SEQ. ID
N0:507)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 501 ) (SEQ. ID
N0:508)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 502) (SEQ. ID
N0:509)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 503) (SEQ. ID
N0:510)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 504) (SEQ. ID N0:511
)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragnxnt S05) (SEQ. ID N0:512)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 506) (SEQ. ID N0:513)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 507) (SEQ. ID N0:514)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 508) (SEQ. ID N0:515)
5'- C TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 509) (SEQ. ID N0:516)
CA 02316994 2000-06-30
WO 99/b3938 PCT/US99/12775
32
5'- C TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 510) (SEQ. ID N0:517)
5'- C TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 511 ) (SEQ. ID N0:518)
5'- C TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 512) (SEQ. ID N0:519)
5'- C TGA GAT GGA GGG CGG CAT GG -3' (Fragment 513) (SEQ. ID N0:520)
5'- C TGA GAT GGA GGG CGG CAT G -3' (Fragment 514) (SEQ. ID N0:521 )
5'- C TGA GAT GGA GGG CGG CAT -3' (Fragment 515) (SEQ. ID N0:522)
5'- C TGA GAT GGA GGG CGG CA-3' (Fragment 516) (SEQ. ID N0:523)
5'- C TGA GAT GGA GG(i CGG C-3' (Fragment 517) (SEQ. ID N0:524)
5'- C TGA GAT GGA GGG CGG -3' (Fragment 518) (SEQ. ID N0:525)
5'- C TGA GAT GGA GGG CG -3' (Fragment 519) (SEQ. ID N0:526)
5'- C TGA GAT GGA GGG C -3' (Fragment 520) (SEQ. ID N0:527)
5'- C TGA GAT GGA GGG -3' (Fragment 521 ) (SEQ. ID N0:528)
5'- C TGA GAT GGA GG -3' (Fragment 522} (SEQ. ID N0:529)
5'- C TGA GAT GGA G -3' (Fragment 523) (SEQ. ID N0:530)
5'- C TGA GAT GGA -3' (Fragment 524) (SEQ. ID N0:531 )
5'- TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 525) (SEQ. ID
N0:532)
5'- TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 526) (SEQ. ID
N0:533)
5'- TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 527) (SEQ. ID
N0:534)
5'- TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 528) (SEQ. ID
N0:535)
5'- TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 529) (SEQ. ID
N0:536)
5'- TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 530) (SEQ. ID
N0:537)
5'- TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 531 ) (SEQ. ID
N0:538)
5'- TGA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 532) (SEQ. ID N0:539)
5'- TGA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 533) (SEQ. ID N0:540)
5'- TGA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 534) (SEQ. ID N0:541 )
5'- TGA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fngmcnt 535) (SEQ. ID N0:542)
5'- TGA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 536) (SEQ. ID N0:543)
5'- TGA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 537) (SEQ. ID N0:544)
5'- TGA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 538) (SEQ. ID N0:545)
5'- TGA GAT GGA GGG CGG CAT GGC G-3' (Fragment 539) (SEQ. ID N0:546)
5'- TGA GAT GGA GGG CGG CAT GGC -3' (Fragment 540) (SEQ. ID N0:547)
5'- TGA GAT GGA GGG CGG CAT GG -3' (Fragment 541 ) (SEQ. ID N0:548)
5'- TGA GAT GGA GGG CGG CAT G -3' (Fragment 542} (SEQ. ID N0:549)
5'- TGA GAT GGA GGG CGG CAT -3' (Fragment 543) (SEQ. ID NO:550)
5'- TGA GAT GGA GGG CGG CA-3' (Fragment 544) (SEQ. ID N0:551 )
5'- TGA GAT GGA GGG CGG C-3' (Fragment 545) (SEQ. ID N0:552)
5'- TGA GAT GGA GGG CGG -3' (Fragment 546) (SEQ. ID N0:553)
5'- TGA GAT GGA GGG CG -3' (Fragment 547) (SEQ. ID N0:554)
5'- TGA GAT GGA GGG C -3' (Fragment 548) (SEQ. ID NO:555)
5'- TGA GAT GGA GGG -3' (Fragment 549) (SEQ. ID N0:556)
5'- TGA GAT GGA GG -3' (Fragment 550) (SEQ.1D N0:557)
5'- TGA GAT GGA G -3' (Fragment 551) (SEQ. ID NO:SSB)
5'- GA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 552) (SEQ. ID
N0:559)
5'- GA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 553) (SEQ. ID
N0:560)
5'- GA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 554) (SEQ. ID
N0:561 )
5'- GA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 555) (SEQ. ID
N0:562)
5'- GA GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 556) (SEQ. ID
N0:563)
5'- GA GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 557) (SEQ. ID
N0:564)
5'- GA GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fngrtunt 558) (SEQ. ID N0:565)
5'- GA GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 559) (SEQ. ID N0:566)
5'- GA GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 560) (SEQ.1D N0:567)
5'- GA GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 561 ) (SEQ. ID N0:568)
5'- GA GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 562) (SEQ. ID N0:569)
5'- GA GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 563) (SEQ. ID N0:570)
5'- GA GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 564) (SEQ. ID N0:571 )
5'- GA GAT GGA GGG CGG CAT GGC GG-3' (Fragment 565) (SEQ. ID N0:572)
5'- GA GAT GGA GGG CGG CAT GGC G-3' (Fragment 566) (SEQ. ID N0:573)
5'- GA GAT GGA GGG CGG CAT GGC -3' (Fragment 567) (SEQ. ID N0:574)
5'- GA GAT GGA GGG CGG CAT GG -3' (Fragment 568) (SEQ. ID N0:575)
5'- GA GAT GGA GGG CGG CAT G -3' (Fragment 569) (SEQ. ID N0:576)
5'- GA GAT GGA GGG CGG CAT -3' (Fragment 570) (SEQ. ID N0:577)
5'- GA GAT GGA GGG CGG CA-3' (Fragment 571 ) (SEQ. ID N0:578)
5'- GA GAT GGA GGG CGG C-3' (Fragment 572) (SEQ. ID N0:579)
5'- GA GAT GGA GGG CGG -3' (Fragment 573) (SEQ. ID NO:580)
5'- GA GAT GGA GGG CG -3' (Fragment 574) (SEQ. ID N0:581 )
5'- GA GAT GGA GGG C -3' (Fragment 575) (SEQ. ID N0:582)
5'- GA GAT GGA GGG -3' (Fragment 576) (SEQ. ID N0:583)
5'- GA GAT GGA GG -3' (Fngme~tt 5'T7) (SEQ. ID N0:584)
S'- A GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 578) (SEQ. ID
N0:585)
5'- A GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 579) (SEQ. ID
N0:586)
5'- A GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 580) (SEQ. ID
N0:587)
5'- A GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 581 ) (SEQ. ID
N0:588)
5'- A GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 582) (SEQ. ID
N0:589)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
33
5'- A GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Ftagma~t 583) (SEQ. ID N0:590)
5'- A GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 584) (SEQ. ID N0:591 )
5'- A GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragmatt 585) (SEQ. ID N0:592)
5'- A GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 586) (SEQ. ID N0:593)
5'- A GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 587) (SEQ. ID N0:594)
5'- A GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 588) (SEQ. ID N0:595)
5'- A GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 589) (SEQ. ID N0:596)
5'- A GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 590) (SEQ. ID N0:597)
5'- A GAT GGA GGG CGG CAT GGC GG-3' (Fragment 591) (SEQ. ID N0:598)
5'- A GAT GGA GGG CGG CAT GGC G-3' (Fragment 592) (SEQ. ID N0:599)
5'- A GAT GGA GGG CGG CAT GGC -3' (Fragment 593) (SEQ. ID N0:600)
5'- A GAT GGA GGG CGG CAT GG -3' (Fragment 594) (SEQ. ID N0:601 )
5'- A GAT GGA GGG CGG CAT G -3' (Frag~rxnt 595) (SEQ. ID N0:602)
5'- A GAT GGA GGG CGG CAT -3' (F~agment 596) (SEQ. ID N0:603)
5'- A GAT GGA GGG CGG CA-3' (Fragrtxnt 597} (SEQ. ID N0:604)
5'- A GAT GGA GGG CGG C-3' (Fragment 598) (SEQ.1D N0:605)
5'- A GAT GGA GGG CGG -3' (Fragment 599) (SEQ. ID N0:606)
5'- A GAT GGA GGG CG -3' (Fragment 600) (SEQ. ID N0:607)
5'- A GAT GGA GGG C -3' (Fragment 601) (SEQ. ID N0:608)
5'- A GAT GGA GGG -3' (Fragment 602) (SEQ. ID N0:609)
5'- GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 603) (SEQ. ID
N0:610)
5'- GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 604) (SEQ. ID
NO:611 )
5'- GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (F~agment 605) (SEQ. ID
N0:612)
5'- GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 606) (SEQ. ID
N0:613)
5'- GAT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fisgment 607) (SEQ. ID N0:614)
5'- GAT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 608) (SEQ.1D N0:615)
5'- GAT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Frngment 609) (SEQ. ID N0:616)
5'- GAT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 610) (SEQ. ID N0:617)
5'- GAT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 611 ) (SEQ. ID N0:618)
5'- GAT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 612) (SEQ. ID N0:619)
5'- GAT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 613) (SEQ. iD N0:620)
5'- GAT GGA GGG CGG CAT GGC GGG C-3' (Fragment 614) (SEQ. ID N0:621 )
5'- GAT GGA GGG CGG CAT GGC GGG -3' (Fragment 615) (SEQ. ID N0:622)
5'- GAT GGA GGG CGG CAT GGC GG-3' (Fragment 616) (SEQ. ID N0:623)
5'- GAT GGA GGG CGG CAT GGC G-3' (Fragment 617) (SEQ. ID N0:624)
5'- GAT GGA GGG CGG CAT GGC -3' (Fragment 618) (SEQ. ID N0:625)
5'- GAT GGA GGG CGG CAT GG -3' (Fragment 619) (SEQ. ID N0:626)
5'- GAT GGA GGG CGG CAT G -3' (Fragment 620) (SEQ. ID N0:627)
5'- GAT GGA GGG CGG CAT -3' (Fragment 621 ) (SEQ. ID N0:628)
5'- GAT GGA GGG CGG CA-3' (Fragment 622) (SEQ. ID N0:629)
5'- GAT GGA GGG CGG C-3' (Fragment 623) (SEQ. ID N0:630)
5'- GAT GGA GGG CGG -3' (Fragment 624) (SEQ. ID N0:631 )
5'- GAT GGA GGG CG -3' (Fragment 625) (SEQ. ID N0:632)
5'- GAT GGA GGG C -3' (Fragment 626) (SEQ. ID N0:633)
5'- AT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 627) (SEQ. ID
N0:634)
5'- AT GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 628) (SEQ. ID
N0:635)
5'- AT GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 629) (SEQ. ID
N0:636)
5'- AT GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 630) (SEQ. ID N0:637)
5'- AT GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 631 ) (SEQ. 1D N0:638)
5'- AT GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 632) (SEQ. ID N0:639)
5'- AT GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 633) (SEQ. ID N0:640)
5'- AT GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 634) (SEQ. ID N0:641 )
5'- AT GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 635) (SEQ. ID N0:642)
5'- AT GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 636) (SEQ. ID N0:643)
5'- AT GGA GGG CGG CAT GGC GGG CA-3' (Fragment 637) (SEQ. ID N0:644)
5'- AT GGA GGG CGG CAT GGC GGG C-3' (Fragment 638) (SEQ. ID N0:645)
5'- AT GGA GGG CGG CAT GGC GGG -3' (Fragtttent 639) (SEQ. ID N0:646)
5'- AT GGA GGG CGG CAT GGC GG-3' (Fragment 640) (SEQ. ID N0:647)
5'- AT GGA GGG CGG CAT GGC G-3' (Fragment 641 ) (SEQ. ID N0:648)
5'- AT GGA GGG CGG CAT GGC -3' (Fragment 642) (SEQ. ID N0:649)
5'- AT GGA GGG CGG CAT GG -3' (Fragment 643) (SEQ. ID N0:6S0)
5'- AT GGA GGG CGG CAT G -3' (Fragment 644) (SEQ. ID N0:651 )
5'- AT GGA GGG CGG CAT -3' (Fragment 645) (SEQ. ID N0:652)
5'- AT GGA GGG CGG CA-3' (Fragment 646) (SEQ. ID N0:653)
5'- AT GGA GGG CGG C-3' (Fragment 647) (SEQ. ID N0:654)
5'- AT GGA GGG CGG -3' (Fragment 648) (SEQ. ID N0:655)
5'- AT GGA GGG CG -3' (Fragment 649) (SEQ. ID N0:656)
5'- T GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 650) (SEQ. ID
N0:657)
5'- T GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 651) (SEQ. ID
N0:658)
5'- T GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 652) (SEQ. ID N0:659)
5'- T GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 653) (SEQ. ID N0:660)
5'- T GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 654) (SEQ. ID N0:661 )
5'- T GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 655) (SEQ. ID N0:662)
CA 02316994 2000-06-30
WO 99/63938 PCT/CTS99/12775
34
5'- T GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 656) (SEQ. ID N0:663)
5'- T GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 657) (SEQ. ID N0:664)
5'- T GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 658) (SEQ. ID N0:665)
5'- T GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 659) (SEQ. ID N0:666)
5'- T GGA GGG CGG CAT GGC GGG CA-3' (Fragment 660) (SEQ. ID N0:667)
5'- T GGA GGG CGG CAT GGC GGG C-3' (Fragment 661) (SEQ. ID N0:668)
5'- T GGA GGG CGG CAT GGC GGG -3' (Fragment 662) (SEQ. ID N0:669)
5'- T GGA GGG CGG CAT GGC GG-3' (Fragment 663) (SEQ. ID N0:670)
5'- T GGA GGG CGG CAT GGC G-3' (Fragment 664) (SEQ. ID N0:671 )
5'- T GGA GGG CGG CAT GGC -3' (Fragment 665) (SEQ. ID N0:672)
5'- T GGA GGG CGG CAT GG -3' (Fragment 666) (SEQ. ID N0:673)
5'- T GGA GGG CGG CAT G -3' (Fragment 667) (SEQ. ID N0:674)
5'- T GGA GGG CGG CAT -3' (Fragment 668) (SEQ. ID N0:675)
5'- T GGA GGG CGG CA-3' (Fragment 669) (SEQ. ID N0:676)
5'- T GGA GGG CGG C-3' (Fragment 670) (SEQ. ID N0:677)
5'- T GGA GGG CGG -3' (Fragment 671 ) (SEQ. ID N0:678)
5'- GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 672) (SEQ. ID N0:679)
5'- GGA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 673) (SEQ. ID N0:680)
5'- GGA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 674) (SEQ. ID N0:681 )
5'- GGA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 675) (SEQ. ID N0:682)
5'- GGA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 676) (SEQ. ID N0:683)
5'- GGA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 677) (SEQ. ID N0:684)
5'- GGA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 678) (SEQ. ID N0:685)
5'- GGA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 679) (SEQ. ID N0:686)
5'- GGA GGG CGG CAT GGC GGG CAC A-3' (Fragment 680) (SEQ. ID N0:687)
5'- GGA GGG CGG CAT GGC GGG CAC-3' (Fragment 681 ) (SEQ. ID N0:688)
5'- GGA GGG CGG CAT GGC GGG CA-3' (Fragment 682) (SEQ. ID N0:689)
5'- GGA GGG CGG CAT GGC GGG C-3' (Fragment 683) (SEQ. ID N0:690)
5'- GGA GGG CGG CAT GGC GGG -3' (Fragment 684) (SEQ. ID N0:691 )
5'- GGA GGG CGG CAT GGC GG-3' (Fragment 685) (SEQ. ID N0:692)
5'- GGA GGG CGG CAT GGC G-3' (Fragment 686) (SEQ. ID N0:693)
5'- GGA GGG CGG CAT GGC -3' (Fragment 687) (SEQ. ID N0:694)
5'- GGA GGG CGG CAT GG -3' (Fragment 688) (SEQ. ID N0:695)
5'- GGA GGG CGG CAT G -3' (Fragment 689) (SEQ. ID N0:696)
5'- GGA GGG CGG CAT -3' (Fragment 690) (SEQ. ID N0:697)
5'- GGA GGG CGG CA-3' (Fragment 691 ) (SEQ. ID N0:698)
5'- GGA GGG CGG C-3' (Fragment 692) (SEQ. ID N0:699)
5'- GA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 693) (SEQ. ID N0:700)
5'- GA GGG CGG CAT GGC GGG CAC AGG CTG GG-3' {Fragment 694) (SEQ. ID N0:701 )
5'- GA GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 695) (SEQ. ID N0:702)
5'- GA GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 696) (SEQ. ID N0:703)
5'- GA GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 697) (SEQ. ID N0:704)
5'- GA GGG CGG CAT GGC GGG CAC AGG C-3' (Fragment 698) (SEQ. ID N0:705)
5'- GA GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 699) (SEQ. ID N0:706)
5'- GA GGG CGG CAT GGC GGG CAC AG-3' (Fragment 700) (SEQ. ID N0:707)
5'- GA GGG CGG CAT GGC GGG CAC A-3' (Fragment 701 ) (SEQ.1D N0:708)
5'- GA GGG CGG CAT GGC GGG CAC-3' (Fragment 702) (SEQ. ID N0:709)
5'- GA GGG CGG CAT GGC GGG CA-3' (Fragment 703) (SEQ. ID N0:710)
5'- OA GGG CGG CAT GGC GGG C-3' (Fragment 704) (SEQ. ID N0:711 )
5'- GA GGG CGG CAT GGC GGG -3' (Fragment 705) (SEQ. ID N0:712)
5'- GA GGG CGG CAT GGC GG-3' (Fragment 706) (SEQ. ID N0:713)
5'- GA GGG CGG CAT GGC G-3' (Fragment 707) (SEQ. ID N0:714)
5'- GA GGG CGG CAT GGC -3' (Fragment 708) (SEQ. tD N0:715)
5'- GA GGG CGG CAT GG -3' (Fragment 709) (SEQ. ID N0:716)
5'- GA GGG CGG CAT G -3' (Fragment 710) (SEQ. ID N0:717)
5'- GA GGG CGG CAT -3' (Fragment 711 ) (SEQ. ID N0:718)
5'- GA GGG CGG CA-3' (Fragment 712) (SEQ. ID N0:719)
5'- A GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 713) (SEQ. ID N0:720)
5'- A GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 714) (SEQ. ID N0:721 )
5'- A GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 715) (SEQ. ID N0:722)
5'- A GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 716) (SEQ. ID N0:723)
5'- A GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 717) (SEQ. ID N0:724)
5'- A GGG CGG CAT GGC GGG CAC AGG C-3' (Fngmcnt 7l8) (SEQ. ID N0:725)
5'- A GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 719) (SEQ. ID N0:726)
5'- A GGG CGG CAT GGC GGG CAC AG-3' (Fragment 720) (SEQ. ID N0:727)
5'- A GGG CGG CAT GGC GGG CAC A-3' (Fragment 721 ) (SEQ. ID N0:728)
5'- A GGG CGG CAT GGC OGG CAC-3' (Fragment 722) (SEQ. ID N0:729)
5'- A GGG CGG CAT GGC GGG CA-3' (Fragment 723) (SEQ. ID N0:730)
5'- A GGG CGG CAT GGC GGG C-3' (Fragment 724) (SEQ. ID N0:731 )
5'- A GGG CGG CAT GGC GGG -3' (Fngmait 725) (SEQ. ID N0:732)
5'- A GGG CGG CAT GGC GG-3' (Fragment 726) (SEQ. ID N0:733)
5'- A GGG CGG CAT GGC G-3' (Fragment 727) (SEQ. ID N0:734)
5'- A GGG CGG CAT GGC -3' (Fragment 728) (SEQ. ID N0:735)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
5'- A GGG CGG CAT GG -3' (Fragment 729) (SEQ. ID N0:736)
5'- A GGG CGG CAT G -3' (Fragment 730) (SEQ. ID N0:737)
5'- A GGG CGG CAT -3' (Fragment 731 ) (SEQ. ID N0:738)
5'- GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 732) (SEQ. ID N0:739)
5'- GGG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 733) (SEQ. ID N0:740)
5'- GGG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 734) (SEQ. ID N0:741 )
5'- GGG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 735) (SEQ. ID N0:742)
5'- GGG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 736) (SEQ. ID N0:743)
5'- GGG CGG CAT GGC GGG CAC AGO C-3' (Fragment 737) (SEQ. ID N0:744)
5'- GGG CGG CAT GGC GGG CAC AGG -3' (Fragment 738) (SEQ. ID N0:745)
5'- GGG CGG CAT GGC GGG CAC AG-3' (Fragment 739) (SEQ. ID N0:746)
5'- GGG CGG CAT GGC GGG CAC A-3' (Fragment 740) (SEQ. ID N0:747)
5'- GGG CGG CAT GGC GGG CAC-3' (Fragment 741 ) (SEQ. ID N0:748)
5'- GGG CGG CAT GGC GGG CA-3' (Fragment 742) (SEQ. ID N0:749)
5'- GGG CGG CAT GGC GGG C-3' (Fragment 743) (SEQ. ID N0:750)
5'- GGG CGG CAT GGC GGG -3' (Fragment 744) (SEQ, ID N0:751 )
5'- GGG CGG CAT GGC GG-3' (Fragment 745) (SEQ.1D N0:752)
5'- GGG CGG CAT GGC G-3' (Fragment 746) (SEQ. ID N0:753)
5'- GGG CGG CAT GGC -3' (Fragment 747) (SEQ. ID N0:754)
5'- GGG CGG CAT GG -3' (Fragment 748) (SEQ. ID N0:755)
5'- GGG CGG CAT G -3' (Fragment 749) (SEQ. ID N0:756)
5'- GG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 750) (SEQ. 1D N0:757)
5'- GG CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 751 ) (SEQ. ID N0:758)
5'- GG CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 752) (SEQ. ID N0:759)
5'- GG CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 753) (SEQ. ID N0:760)
5'- GG CGG CAT GGC GGG CAC AGG CT-3' (Fragment 754) (SEQ. ID N0:761 )
5'- GG CGG CAT GGC GGG CAC AGG C-3' (Fragment 755) (SEQ. ID N0:762)
5'- GG CGG CAT GGC GGG CAC AGG -3' (Fragment 756) (SEQ. ID N0:763)
5'- GG CGG CAT GGC GGG CAC AG-3' (Fragment 757) (SEQ. ID N0:764)
5'- GG CGG CAT GGC GGG CAC A-3' (Fragment 758) (SEQ. ID N0:765)
5'- GG CGG CAT GGC GGG CAC-3' (Fragment 759) (SEQ. ID N0:766)
5'- GG CGG CAT GGC GGG CA-3' (Fragment 760) (SEQ. ID N0:767)
5'- GG CGG CAT GGC GGG C-3' (Fragment 761 ) (SEQ. ID N0:768)
5'- GG CGG CAT GGC GGG -3' (Fragment 762) (SEQ. ID N0:769)
5'- GG CGG CAT GGC GG-3' (Fragment 763) (SEQ. ID N0:770)
S'- GG CGG CAT GGC G-3' (Fragment 764) (SEQ. ID N0:771 )
5'- GG CGG CAT GGC -3' (Fragment 765) (SEQ. ID N0:772)
5'- GG CGG CAT GG -3' (Fragment 766) (SEQ. ID N0:773)
5'- G CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 767) (SEQ. ID N0:774)
5'- G CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 768) (SEQ. ID N0:775)
5'- G CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 769) (SEQ. ID N0:776)
5'- G CGG CAT GGC GGG CAC AGCi CTG -3' (Fragment 770) (SEQ. ID N0:777)
5'- G CGG CAT GGC GGG CAC AGG CT-3' (Fragment 771 ) (SEQ. ID N0:778)
5'- G CGG CAT GGC GGG CAC AGG C-3' (Fragment 772) (SEQ. ID N0:779)
5'- G CGG CAT GGC GGG CAC AGG -3' (Fragment 773) (SEQ. ID N0:780)
5'- G CGG CAT GGC GGG CAC AG-3' (Fragment 774) (SEQ. ID N0:781 )
5'- G CGG CAT GGC GGG CAC A-3' (Fragment 775) (SEQ. ID N0:782)
5'- G CGG CAT GGC GGG CAC-3' (Fragment 776) (SEQ. ID N0:783)
5'- G CGG CAT GGC GGG CA-3' (Fragment 777) (SEQ. ID N0:784)
5'- G CGG CAT GGC GGG C-3' (Fragment 778) (SEQ. ID N0:785)
5'- G CGG CAT GGC GGG -3' (Fragment 779) (SEQ. ID N0:786)
5'- G CGG CAT GGC GG-3' (Fragment 780) (SEQ. ID N0:787)
5'- G CGG CAT GGC G-3' (Fragment 781 ) (SEQ. ID N0:788)
5'- G CGG CAT GGC -3' (Fragment 782) (SEQ. ID N0:789)
5'- CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 783) (SEQ. ID N0:790)
5'- CGG CAT GGC GGG CAC AGG CTG GG-3' (Fragment 784) (SEQ. ID N0:791 )
5'- CGG CAT GGC GGG CAC AGG CTG G-3' (Fragment 785) (SEQ. ID N0:792)
5'- CGG CAT GGC GGG CAC AGG CTG -3' (Fragment 786) (SEQ. ID N0:793)
5'- CGG CAT GGC GGG CAC AGG CT-3' (Fragment 787) (SEQ. iD N0:794)
5'- CGG CAT GGC GGG CAC AGG C-3' (Fragment 788) (SEQ. ID N0:795)
5'- CGG CAT GGC GGG CAC AGG -3' (Fragment 789) (SEQ. ID N0:796)
5'- CGG CAT GGC GGG CAC AG-3' (Fragment 790) (SEQ. ID N0:797)
5'- CGG CAT GGC GGG CAC A-3' (Fragment 791 ) (SEQ. ID N0:798)
5'- CGG CAT GGC GGG CAC-3' (Fragment 792) (SEQ. ID N0:799)
5'- CGG CAT GGC GGG CA-3' (Fragment 793) (SEQ. ID N0:800)
5'- CGG CAT GGC GGG C-3' (Fragment 794) (SEQ. ID N0:801 )
5'- CGG CAT GGC GGG -3' (Fragment 795) (SEQ. ID N0:802)
5'- CGG CAT GGC GG-3' (Fragment 796) (SEQ. ID N0:803)
5'- CGG CAT GGC G-3' (Fragment 797) (SEQ. ID N0:804)
5'- GG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 798) (SEQ. ID NO:805)
5'- GG CAT GGC GGG CAC AGG CTO GG-3' (Fragment 799) (SEQ. ID N0:806)
5'- GG CAT GGC GGG CAC AGG CTG G-3' (Fragment 800) (SEQ.1D N0:807)
5'- GG CAT GGC GGG CAC AGG CTG -3' (Fragment 801 ) (SEQ. ID NO:808)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
36
5'- GG CAT GGC GGG CAC AGG CT-3' (Fragment 802) (SEQ. ID N0:809)
5'- GG CAT GGC GGG CAC AGG C-3' (Fragment 803) (SEQ. ID N0:810)
5'- GG CAT GGC GGG CAC AGG -3' (Frsgrt~ent 804) (SEQ. ID N0:811 )
S- GG CAT GGC GGG CAC AG-3' (Fngtrxnt 805) (SEQ. ID N0:812)
5'- GG CAT GGC GGG CAC A-3' (Fragment 806) (SEQ. ID N0:813)
5'- GG CAT GGC GGG CAC-3' (Fragment 807) (SEQ. ID N0:814)
5'- GG CAT GGC GGG CA-3' (Fragment 808) (SEQ. ID N0:815)
5'- GG CAT GGC GGG C-3' (Fragment 809) (SEQ. ID N0:816)
5'- GG CAT GGC GGG -3' (Fragment 810) (SEQ. ID N0:817)
5'- GG CAT GGC GG-3' (Fragment 811 ) (SEQ. ID N0:818)
5'- G CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 812) (SEQ. ID N0:819)
5'- G CAT GGC GGG CAC AGG CTG GG-3' (Fragment 813) (SEQ. ID N0:820)
5'- G CAT GGC GGG CAC AGG CTG G-3' (Fragment 814) (SEQ. ID N0:821
5'- G CAT GGC GGG CAC AGG CTG -3' (Fragment 81 S) (SEQ. ID N0:822)
5'- G CAT GGC GGG CAC AGG CT-3' (Fragment 816) (SEQ. ID N0:823)
5'- G CAT GGC GGG CAC AGG C-3' (Fragment 817) (SEQ. ID N0:824)
5'- G CAT GGC GGG CAC AGG -3' (Fragment 818) (SEQ. ID N0:825)
5'- G CAT GGC GGG CAC AG-3' (Fragment 819) (SEQ. ID N0:826)
5'- G CAT GGC GGG CAC A-3' (Fragment 820) (SEQ. ID N0:827)
5'- G CAT GGC GGG CAC-3' (Fragment 821 ) (SEQ. ID N0:828)
5'- G CAT GGC GGG CA-3' (Fragment 822) (SEQ. ID N0:829)
5'- G CAT GGC GGG C-3' (Fragment 823) (SEQ. ID N0:830)
5'- G CAT GGC GGG -3' (Fragment 824) (SEQ. ID N0:831 )
5'- CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 825) (SEQ. ID N0:832)
5'- CAT GGC GGG CAC AGG CTG GG-3' (Fragment 826) (SEQ. ID N0:833)
5'- CAT GGC GGG CAC AGG CTG G-3' (Fragment 827) (SEQ. ID N0:834)
5'- CAT GGC GGG CAC AGG CTG -3' (Fragment 828} (SEQ. ID N0:835)
5'- CAT GGC GGG CAC AGG CT-3' (Fragment 829) (SEQ. ID N0:836)
5'- CAT GGC GGG CAC AGG C-3' (Fragment 830) (SEQ. ID N0:837)
5'- CAT GGC GGG CAC AGG -3' (Fragment 831) (SEQ. ID N0:838)
5'- CAT GGC GGG CAC AG-3' (Fragment 832) (SEQ.1D N0:839)
5'- CAT GGC GGG CAC A-3' (Fragment 833) (SEQ. ID N0:840)
5'- CAT GGC GGG CAC-3' (Fragment 834) (SEQ. ID N0:841 )
5'- CAT GGC GGG CA-3' (Fragment 835) (SEQ. ID N0:842)
5'- CAT GGC GGG C-3' (Fragment 836) (SEQ. ID N0:843)
5'- AT GGC GGG CAC AGG CTG GGC-3' (Fragment 837) (SEQ. ID NO:B44)
5'- AT GGC GGG CAC AGG CTG GG-3' (Fragment 838) (SEQ. ID N0:845)
5'- AT GGC GGG CAC AGG CTG G-3' (Fragment 839) (SEQ. ID N0:846)
5'- AT GGC GGG CAC AGG CTG -3' (Fragment 840) (SEQ. ID N0:847)
5'- AT GGC GGG CAC AGG CT-3' (Fragment 841 ) (SEQ. ID N0:848)
5'- AT GGC GGG CAC AGG C-3' (Fragment 842) (SEQ. ID N0:849)
5'- AT GGC GGG CAC AGG -3' (Fragment 843) (SEQ. ID N0:850)
5'- AT GGC GGG CAC AG-3' (Fragment 844) (SEQ. ID N0:851 )
5'- AT GGC GGG CAC A-3' (Fragment 845) (SEQ. ID N0:852)
5'- AT GGC GGG CAC-3' (Fragment 846) (SEQ. ID N0:853)
5'- AT GGC GGG CA-3' (Fragment 847) (SEQ. ID N0:854)
5'- T GGC GGG CAC AGG CTG GGC-3' (Fragment 848) (SEQ.1D N0:855)
5'- T GGC GGG CAC AGG CTG GG-3' (Fngmait 849) (SEQ. ID N0:856)
5'- T GGC GGG CAC AGG CTG G-3' (Fragment 850) (SEQ. ID N0:857)
5'- T GGC GGG CAC AGG CTG -3' (Fragment 851 ) (SEQ. ID N0:858)
5'- T GGC GGG CAC AGG CT-3' (Fragment 852) (SEQ. ID N0:859)
5'- T GGC GGG CAC AGG C-3' (Fragment 853) (SEQ. ID N0:860)
5'- T GGC GGG CAC AGG -3' (Fragment 854) (SEQ. ID N0:861 )
5'- T GGC GGG CAC AG-3' (Fragment 855) (SEQ. ID N0:862)
5'- T GGC GGG CAC A-3' (Fragment 856) (SEQ. ID N0:863)
5'- T GGC GGG CAC-3' (Fragment 857) (SEQ. ID N0:864)
5'- GCC GGG CAC AGG CTG GGC-3' (Fragment 858) (SEQ. ID N0:865)
5'- GGC GGG CAC AGG CTG GG-3' (Fragment 859) (SEQ. ID N0:866)
5'- GGC GGG CAC AGG CTG G-3' (Fragment 860) (SEQ. ID N0:867)
5'- GGC GGG CAC AGG CTG -3' (Fragment 861 ) (SEQ. ID N0:868)
5'- GGC GGG CAC AGG CT-3' (Fragment 862) (SEQ. ID N0:869)
5'- GGC GGG CAC AGG C-3' (Fragment 863) (SEQ. ID N0:870)
5'- GGC GGG CAC AGG -3' (Fragment 864) (SEQ. ID N0:871 }
5'- GGC GGG CAC AG-3' (Fragment 865) (SEQ. ID N0:872)
5'- GGC GGG CAC A-3' (Fragment 866) (SEQ. ID N0:873)
5'- GC GGG CAC AGG CTG GGC-3' (Fragment 867) (SEQ. ID N0:874)
5'- GC GGG CAC AGG CfG GG-3' (Fragment 868) (SEQ. ID N0:875)
5'- GC GGG CAC AGG CTG G-3' (Fragment 869) (SEQ.1D N0:876)
5'- GC GGG CAC AGG CTG -3' (Fragment 870) (SEQ.1D N0:877)
5'- GC GGG CAC AGG CT-3' (Fragment 871 ) (SEQ. ID N0:878)
5'- GC GGG CAC AGG C-3' (Fragment 872) (SEQ. ID N0:879)
5'- GC GGG CAC AGG -3' (Fragment 873) (SEQ. ID N0:880)
5'- GC GGG CAC AG-3' (Fragment 874) (SEQ. ID N0:881 )
CA 02316994 2000-06-30
WO 99/63938 PCTNS99l1Z775
37
5'- C GGG CAC AGG CTG GGC-3' (Fragment 875) (SEQ. ID N0:882)
5'- C GGG CAC AGG CTG GG-3' (Fragment 876) (SEQ. ID N0:883)
5'- C GGG CAC AGG CTG G-3' (Fragment 877) (SEQ. ID N0:884)
5'- C GGG CAC AGG CTG -3' (Fragment 878) (SEQ. ID NO:885)
5'- C GGG CAC AGG CT-3' (Fragment 879) (SEQ. ID N0:886)
5'- C GGG CAC AGG C-3' (Fngmcnt 880) (SEQ. ID N0:887)
5'- C GGG CAC AGG -3' (Fragment 881 ) (SEQ. ID N0:888)
5'- GGG CAC AGG CTG GGC-3' (Fragment 882) (SEQ. ID N0:889)
5'- GGG CAC AGG CTG GG-3' (Fragment 883) (SEQ. ID N0:890)
5'- GGG CAC AGG CTG G-3' (Fragment 884) (SEQ. ID N0:891 )
5'- GGG CAC AGG CTG -3' (Fragment 885) (SEQ. ID N0:892)
5'- GGG CAC AGG CT-3' (Fragment 886) (SEQ. ID N0:893)
5'- GGG CAC AGG C-3' (Fragment 887) (SEQ. ID N0:894)
5'- GG CAC AGG CTG GGC-3' (Fragment 888) (SEQ. ID N0:895)
5'- GG CAC AGG CTG GG-3' (Fragment 889) (SEQ. ID N0:896)
5'- GG CAC AGG CTG G-3' (Fragment 890) (SEQ. ID N0:897)
5'- GG CAC AGG CTG -3' (Fragment 891 ) (SEQ. ID N0:898)
5'- GG CAC AGG CT-3' (Fragment 892) (SEQ. ID N0:899)
5'- G CAC AGG CTG GGC-3' (Fragment 893) (SEQ. ID N0:900)
5'- G CAC AGG CTG GG-3' (Fragment 894) (SEQ. ID N0:901 )
5'- G CAC AGG CTG G-3' (Fngrtxnt 895) (SEQ. ID N0:902)
5'- G CAC AGG CTG -3' (Fragment 896) (SEQ. ID N0:903)
5'- CAC AGG CTG GGC-3' (Fragment 897) (SEQ. ID N0:904)
5'- CAC AGG CTG GG-3' (Fragment 898) (SEQ. ID N0:905)
5'- CAC AGG CTG G-3' (Fragment 899) (SEQ. ID N0:906)
5'- AC AGG CTG GGC-3' (Fragment 900) (SEQ. ID N0:907)
5'- AC AGG CTG GG-3' (Fragment 901 ) (SEQ. ID N0:908)
5'- C AGG CTG GGC-3' (Fragment 902) (SEQ. ID N0:909)
5'-GGC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'
(Fragment 903) (SEQ. ID N0:910)
5'-GC GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'
(Fragment 904) (SEQ. ID N0:911 )
5'-C GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'
(Fragment 905) (SEQ. ID N0:912)
5'-GGC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'
(Fragment 906) (SEQ. ID N0:913)
5'-GC CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'
(Ft 907) (SEQ. ID N0:914)
5'-C CTG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment
908) (SEQ. ID N0:915) 5'-CTG GAA
AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 909) (SEQ. ID
N0:916)
5'-TG GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'(Fngnxnt 910)
(SEQ. ID N0:917)
5'-G GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 911
} (SEQ. ID N0:918)
5'-GAA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 912)
(SEQ. ID N0:919)
5'-AA AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 913)
(SEQ. ID N0:920)
5'-A AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 914)
(SEQ. ID N0:921 )
5'-AGC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3'(Fragment 91 S) (SEQ.
ID N0:922)
5'-GC TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 916) (SEQ.
ID N0:923)
5'-C TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 917) (SEQ.
ID N0:924)
5'-TGA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 918) (SEQ. ID
N0:925)
5'-GA GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 9l9) (SEQ. ID
N0:926)
=A GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 920) (SEQ. ID
N0:927)
5'-GAT GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 921 ) (SEQ. ID
N0:928)
S'-AT GGA GCiG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 922) (SEQ. ID
N0:929)
5'-T GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 923) (SEQ. ID
N0:930)
5'-GGA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 924) (SEQ. ID N0:931 )
5'-GA GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 925) (SEQ. ID N0:932)
5'-A GGG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 926) (SEQ. ID N0:933)
5'-GGG CGG CAT GCC GGG CAC AGG CTG GGC-3' (Fragment 927) (SEQ. ID N0:934)
5'-GG CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 928) (SEQ. ID N0:935)
5'-G CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 929) (SEQ. ID N0:936}
5'-CGG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 930) (SEQ. ID N0:937)
5'-GG CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 931 ) (SEQ. ID N0:938)
5'-G CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 932) (SEQ. ID N0:939)
5'-CAT GGC GGG CAC AGG CTG GGC-3' (Fragment 933) (SEQ. ID N0:940)
5'-AT GGC GGG CAC AGG CTG GGC-3' (Fragment 934) (SEQ. ID N0:941 )
5'-T GGC GGG CAC AGG CTG GGC-3' (Fragment 935) (SEQ. ID N0:942)
5'-GGC GGG CAC AGG CTG GGC-3' (Fragmcnt 936) (SEQ. ID N0:943)
5'-GC GGG CAC AGG CTG GGC-3' (Fragment 937) (SEQ. ID N0:944)
5'-C GGG CAC AGG CTG GGC-3' (Fragment 938) (SEQ. ID N0:945)
5'-GGG CAC AGG CTG GGC-3' (Fragment 939) (SEQ. ID N0:946)
5'-GG CAC AGG CTG GGC-3' (Fragment 940) (SEQ. ID N0:947)
5'-G CAC AGG CTG GGC-3' (Fragment 941 ) (SEQ. ID N0:948)
5'-CAC AGG CTG GGC-3' (Fragment 942) (SEQ. ID N0:949)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
38
5'-AC AGG CTG GGC-3' (Fragment 943) (SEQ. ID N0:950)
5'-C AGG CTG GGC-3' (Fragment 944) (SEQ. ID N0:951 )
5'-AGG CTG GGC-3' (Fragment 945) (SEQ. ID NO: 952)
Other adenosine fragments, for example those with low adenosine content or
lacking adenosine
altogether, are also suitable and in some cases even preferred, for use with
the invention. The following
sequences, their fragments and combinations, are one particularly preferred
group of anti-sense oligos.
TTT TCC TTC CTT TGT CTC TCT TC (FRAG 946) (SEQ. ID NO: 953)
GCT CCC GGC TGC CTG (FRAG 947) (SEQ. ID NO: 954)
CTC GGC CGT GCG GCT CTG TCG CTC CCG GT (FRAG 948) (SEQ. ID NO: 955)
CCG CCG CCC TCC GGG GGG TC (FRAG 949) (SEQ. ID NO: 956)
TGC TGC CGT TGG CTG CCC (FRAG 950) (SEQ. ID NO: 957)
CTT CTG CGG GTC GCC GG (FRAG 951 ) (SEQ. ID NO: 958)
TGC TGG GCT TGT GGC (FRAG 952) (SEQ. ID NO: 959)
GGC CTC TCT TCT GGG (FRAG 953) (SEQ. ID NO: 960)
CCT GGT CCC TCC GT (FRAG 954) (SEQ. ID NO: 961)
GGT GGC TCC TCT GC (FRAG 955) (SEQ. ID NO: 962)
GCT TGG TCC TGG GGC TGC (FRAG 956) (SEQ. ID NO: 963)
TGC TCT CCT CTC CTT (FRAG 957} (SEQ. ID NO: 964)
In another embodiment of this invention, the oligos are anti-sense to an
adenosine A2a receptor,
and must either "up-regulate" it, or if they have some adenosine A, activity
they are treated as the other
anti-sense oligos. The following sequences are preferred examples of anti-
sense oligos associated with
the human adenosine A~, receptor. Another preferred group is composed of
fragments of these sequences
as generally described above, and combinations thereof, as well as mixtures.
Also preferred are these
sequences, fragments and their combinations where one or more adenosines are
substituted by a
universal base or an adenosine analogue which either is not an agonist or a
ligand for the adenosine A~
receptor, or which acts as an antagonist of the A, receptor, such as, for
example, theophylline or
enprophylline.
5'-TGC TTT TCT TTT CTG GGC CTC-3' (FRAG 958) (SEQ. ID NO: 965)
5'-TGT GGT CTG TTT TTT TCT G-3' (FRAG 959) (SEQ. ID NO: 966)
5'-GCC CTG CTG GGG CGC TCT CC-3' (FRAG 960) (SEQ. ID NO: 967)
5'-GCC GCC CGC CTG GCT CCC-3' (FRAG 961 ) (SEQ. ID NO: 968)
5'-GGB GCC CBT GBT GGG CBT GCC-3' (FRAG 962) (SEQ. ID NO: 969)
5'-GTG GTT CTT GCC CTC CTT TGG CTG-3' (FRAG 963) (SEQ. ID NO: 970)
5'-CCG TGC CCG CTC CCC GGC-3' (FRAG 964) (SEQ. ID NO: 97I)
5'-C'fC CTG GCG GGT GGC CGT TG-3' (FRAG 965) (SEQ. ID NO: 972)
5'-GGC CCG TGT TCC CCT GGG-3' (FRAG 966) (SEQ. ID NO: 973)
5'-GCC TGG GGC TCC CTT CTC TC-3' (FRAG 967) (SEQ. ID NO: 974)
5'-GCC CTT CTT GCT GGG CCT C-3' (FRAG 968) (SEQ. ID NO: 975)
5'-TGC TGC TGC TGG TGC TGT GGC CCC C-3' (FRAG 969) (SEQ. ID NO: 976)
GTACACCGAGGAGCCCATGATGGGCATGCCACAGACGACAGGC (FRAG 970) (SEQ. ID NO: 977)
GTBCBCCGBGGBGCCCBTGBTGGGCBTGCCBCBGBCGBCBGGC (FRAG 971 ) (SEQ. ID NO: 978)
As indicated above, also included in this patent are all types of adenosine
A2g agonists, whether
or not they are nucleic acids. These are known in the art and must generally
have agonistic A2a activity
and either lack or have low adenosine A, agonistic activity and/or have
antagonistic adenosine A~
activity.
In another embodiment, the anti-sense oligo of the invention may be a sequence
which is anti-
sense to the adenosine A26 receptor. By means of example, the following
sequences associated with the
human receptor are provided. These sequences as well as their fragments and
combinations,
desadenosine fragments and those where one or more A are substituted with a
universal base or
adenosine analogue as described above are preferred.
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
39
5'-GGC GCC GTG CCG CGT CTT GGT GGC GGC GG-3' (FRAG 972) (SEQ. ID NO: 979)
5'-GTT CGC GCC CGC GCG GGG CCC CTC CGG TCC-3' (FRAG 973) (SEQ. ID NO: 980)
5'-TTG GCC CGC GCG CCC GCC CGT CTC GGG CTG GGC GG-3 (FRAG 974) (SEQ. ID NO:
981)
5'-CGG GTC GGG GCC CCC CGC GGC C-3' (FRAG 975) (SEQ. ID NO: 982)
5'-GCC TCG GGG CTG GGG CGC TGG TGG CCG GG-3' (FRAG 976) (SEQ. ID NO: 983)
5'-CCG CGC CTC CGC CTG CCG CTT CTG-3' (FRAG 977) (SEQ. ID NO: 984)
5'-GCT GGG CCC CGG GCG CCC CCT-3' (FRAG 978) (SEQ. ID NO: 985)
5'-CCC CTC TTG CTC GGG TCC CCG TG-3' (FRAG 979) (SEQ. ID NO: 986)
ACAGCGCGTCCTGTGTCTCCAGCAGCATGGCCGGGCCAGCTGGGCCCC (FRAG 980) (SEQ. ID NO: 987)
BCBGCGCGTCCTGTGTCTCCBGCBGCBTGGCCGGGCCBGCTGGGCCCC (FRAG 981 ) (SEQ. ID NO: 988)
In still another embodiment, the oligo of this invention may be anti-sense to
any fragment of the
adenosine A3 receptor gene or mRNA, including overlapping regions with the
flanking regions or
introns. The following are examples of these fragments associated with the
human receptor. These are
preferred sequences. Also preferred are their fragments and combinations, as
well as desadenosine
fragments and those where one or more A are substituted by a universal base or
A analogue as described
above.
ACA GAG CA TGC TGT TGT TGG GCA TCT TGC CTT CCC AGG G (FRAG 982) (SEQ. ID NO:
989)
BCB GBG CB TGC TGT TGT TGG GCB TCT TGC CTT CCC BGG G (FRAG 983) (SEQ. ID NO:
990)
CCC TTT TCT GGT GGG GTG (FRAG 984) (SEQ. ID NO: 994)
GTG CTG TTG TTG GGC (FRAG 985) (SEQ. ID NO: 992)
TTT CTT CTG TTC CC (FRAG 986) (SEQ. ID NO: 993)
CCC TTT TCT GGT GGG GTG (FRAG 987) (SEQ. ID NO: 994)
GTG CTG TTG TTG GGC (FRAG 988) (SEQ. ID NO: 995)
TTT CTT CTG TTC CC (FRAG 989) (SEQ. ID NO: 996)
In the anti-sense oligonucleotides of the present invention, exemplified by
the preceding
sequences, a number of adenosine bases may be replaced with an appropriate
"spacer" or universal base
(e.g., 1-[[i-D-2'-deoxyribofuranosyl]-5-nitroindole], or with an adenosine
agonist or antagonist that does
not stimulate (or inhibit) adenosine A,, AZb or A3 receptors but may stimulate
the Aza receptor. A
preferred universal base for the treatment of SVT is one that exhibits
adenosine AZ, agonsitic activity. In
this manner, a specific adenosine receptor gene may be targeted to obtain one
or more anti-sense
oligonucleotide(s) (oligos) that selectively binds) to the corresponding mRNA,
and then, if necessary,
their content of adenosine may be reduced by substituting one or more
universal bases or adenosine
analogues incapable of activating adenosine A, ~ AZb or A3 receptors or which
activate the adenosine AZa
receptor. Thus, in addition to "down-regulating" specific adenosine receptor
genes, the present oligos
have an increased effect when administered by either selection of genes, RNA
and flanking regions that
are devoid, or have a low A content, or alternatively one or more of the
adenosine(s) present in the
oligonucleotide(s) are substituted with other nucleotide bases, so called
universal bases, which bind to
thymidine (T) but lack the ability to activate adenosine receptors and
otherwise may not activate
adenosine receptors. Given that adenosine (A) is a nucleotide base
complementary to thymidine (T),
when a T appears in the RNA, the anti-sense oligo will have an A at the same
position.
The method of the present invention may be used to treat ailments associated
with or causing
cardiac, lung and/or renal damage, and even failure in a subject, regardless
of its cause. The anti-sense
agents) of the invention have preferably a low (or reduced) A content to
prevent its liberation upon in
vivo degradation of the agent(s), preferably up to about 15%, more preferably
up to about 10%, still
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
more preferably up to about 5%, and even more preferred being devoid of A
("desadenosine oligos").
The oligos of this invention may be obtained by first selecting fragments of a
target nucleic acid
having at least 4 contiguous nucleic acids selected from the group consisting
of G and C, and then
obtaining a first oligonucleotide 4 to 60 nucleotides long which comprises the
selected fragment and has
a C and G nucleic acid content of up to and including about 15%. The latter
step may be conducted by
obtaining a second oligonucleotide 4 to 60 nucleotides long comprising a
sequence which is anti-sense to
the selected fragment, the second oligonucleotide having an adenosine base
content of up to and
including about 15%. This method may also comprise, when the selected fragment
comprises at least one
thymidine base, substituting an adenosine base in the corresponding nucleotide
of the anti-sense
fragment with a universal base selected from the group consisting of
heteroaromatic bases which bind to
a thymidine base but have antagonist activity and less than about 0.3 of the
adenosine base agonist
activity at the adenosine A,, Azb and A3 receptors, and heteroaromatic bases
which have no activity or
have an agonist activity at the adenosine A~, receptor. The analogue
heteroaromatic bases may be
selected from all pyrimidines and purines, which may be substituted by O,
halo, NH2, SH, SO, SO2, S03,
COOH and branched and fused primary and secondary amino, alkyl, alkenyl,
alkynyl, cycloalkyl,
heterocycloalkyl, aryl, heteroaryl, alkoxy, alkenoxy, acyl, cycloacyl,
arylacyl, alkynoxy, eycloalkoxy,
aroyl, arylthio, arylsulfoxyl, halocycloalkyl, alkylcycloalkyl,
alkenylcycloalkyl, alkynylcycloalkyl,
haloaryl, alkylaryl, alkenylaryl, alkynylaryl, arylalkyl, arylalkenyl,
arylalkynyl, arylcycloalkyl, which
may be further substituted by O, halo, NH2, primary, secondary and tertiary
amine, SH, SO, SO2, S03,
cycloalkyl, heterocycloalkyl and heteroaryl. The pyrimidines and purines may
be substituted at all
positions as is known in the art, but preferred are those which are
substituted at positions 1, 2, 3, 4, 7
and/or 8. More preferred are pyrimidines and purines such as theophylline,
caffeine, dyphylline,
etophylline, acephylline piperazine, bamifylline, enprofylline and xantine
having the chemical formula
O N
11 1
~/j iC~~~
' 11 1~3
05~~11fC\11/
s
wherein R' and RZ are independently H, alkyl, alkenyl or alkynyl and R3 is H,
aryl, dicycloalkyl,
dicycloalkenyl, dicycloalkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, O-
cycloalkyl, O-cycloalkenyl,
O-cycloalkynyl, NHZ-alkylamino-ketoxyalkyloxy-aryl, mono and dialkylaminoalkyl-
N-alkylamino-
SOZaryI, among others. However, other methods may also be employed. The
inventor reduced the
adenosine content of the anti-sense oligos corresponding to the thymidines (T)
present in the target gene,
RNA, flanking regions, and bridging sections to less than about 15%, or fully
eliminated A from the
oligonucleotide sequence as a means for preventing their breakdown products
from freeing adenosine
into the lung tissue environment and, thereby, aggravating the subject's
ailment and/or countering the
beneficial effect of the administered agent. ,
Also part of this invention are chemical analogues of oligonucleotides in
which, for example, the
phosphodiester bonds have been modified, e.g., to a methylphosphonate, a
phosphotriester, a
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
41
phosphorothioate, a phosphorodithioate, or a phosphoramidate, or that other
portions of the molecule
have been modified, so as to render the oligonucleotide more stable in vivo.
The naturally occurring
phosphodiester linkages in oligonucleotides are susceptible to degradation by
endogenously occurring
cellular nucleases, while many analogous linkages are highly resistant to
nuclease degradation. See
Milligan et al., and Cohen, J. S., supra. The use of a "3'-end cap" strategy
by which nuclease-resistant
linkages are substituted for phosphodiester linkages at the 3'-end of the
oligonucleotide protects
oligonucleotides from degradation. See, Tidd, D. M. and Warenius, H.M., Br. J.
Cancer 60, 343-350
(1989); Shaw, J.P. et al., Nucleic Acids Res. 19, 747-750 (1991).
Phosphoramidate, phosphorothioate,
and methylphosphonate linkages are suitable for use in this invention. In
addition, extensive
modification of the phosphodiester.backbone has been shown to impart stability
and may allow for
enhanced affinity and increased cellular permeation of oligonucleotides. See
Milligan, et al., supra.
Many different chemical strategies have been employed to replace the entire
phosphodiester backbone
with novel linkages. Id. The analogues of the oligonucleotides of the
invention include phosphorothioate,
phosphorodithioate, methylphosphonate, phosphoramidate, boranophosphate,
phosphotriester,
formacetal, 2'-0-methyl, 3'-thioformacetal, 5'-thioformacetal, 5'-thioether,
carbonate, 5'-N-carbamate,
sulfate; sulfonate, sulfamate, sulfonamide, sulfone, sulfite, sulfoxide,
sulfide, hydroxylamine, methylene
(methylimino) (MMI) and methyleneoxy (methylimino) (MOMI) linkages, among
others. The
oligonucleotides of the invention may also be modified by addition of a
terminal 1,3-propanediol or a
terminal dodecanol, among others, or they may be conjugated to a polyethylene
glycol, cholesterol,
cholesteryl, dehydroepiandrosterone, dehydroepiandrosterone sulfate,
dehydroepiandrosterone sulfatide,
ubiquinone, dolichol, poly L-lysine, sulfatidic acid and fatty acid, among
others. The oligos of the
invention may also be modified by 2'-O-methoxyethy, C-5-propynyl pyrimidine, C-
S methyl cytidine,
C-5 ethynyl pyrimidine, 2'-propoxy, C-18 amine, N3'-PS' phosphoramidates, 3'-
alkylamino, 2'-fluoro;
S-fluoro pyrimidine, 5-iodo pyrimidine, 5-bromo pyrimidine, 2'-borano, C-5
hexynyl pyrimidine,
2'-O-(2-methoxy)ethyl, 2'-O-aminopropyl, 5-(phenylethyl) and peptide nucleic
acid interbase linkages.
Phosphorothioate and methylphosphonate-modified oligonucleotides are
particularly preferred because
of their availability and suitability for automated oligonucleotide synthesis.
Id. Antisense
oligonucleotides containing modifications to the nucleotide base itself (e.g.,
a C-5 propyne) or to the
sugar (e.g., a carbohydrate modification), are also aspects of the present
invention.
Where appropriate, the antisense nucleotide may be administered in the form of
their
pharmaceutically acceptable salts or as a mixture. Anti-sense oligonucleotides
may be of any suitable
length, e.g., from about 7 to 60 nucleotide in length, depending on the
particular target being bound and
their mode of delivery. Preferably the antisense oligonucleotide is directed
to a gene or mRNA region
containing a junction between intron and exon. Where the anti-sense
oligonucleotide is directed to an
intron/exon junction, it may either entirely overlie the junction or may be
sufficiently close to the
junction to inhibit the splicing out of the intervening exon during processing
of precursor mRNA to
mature mRNA, e.g., with the 3' or 5' terminus of the antisense oligonucleotide
being positioned within
about, for example, 10, 5, 3, or 2 nucleotide of the intron/exon junction.
Also preferred are anti-sense
oligonucleotides which overlap the initiation codon. When practicing the
present invention, the anti-
sense oligonucleotides administered may be related in origin to the species to
which it is administered.
When treating humans, the anti-sense may be derived from human sequences.
However, sequences
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
42
obtained from one species are also suitable for administration to a second
species.
The pharmaceutical compositions provided herein comprise the anti-sense oligos
given above.
Optionally, the pharmaceutical compositions may also comprise one or more
surfactants. Suitable
surfactants or surfactant components for enhancing the uptake of the anti-
sense oligonucleotides of the
invention include synthetic and natural as well as full and truncated forms of
surfactant protein A,
surfactant protein B, surfactant protein C, surfactant protein D and
surfactant Protein E, di-saturated
phosphatidylcholine (other than dipalmitoyl), dipalmitoylphosphatidylcholine,
phosphatidylcholine,
phosphatidylglycerol, phosphatidylinositol, phosphatidylethanolamine,
phosphatidylserine; phosphatidic
acid, ubiquinones, lysophosphatidylethanolamine, lysophosphatidylcholine,
palmitoyl-lysophosphatidylcholine, dehydroepiandrosterone, dolichols,
sulfatidic acid,
glycerol-3-phosphate, dihydroxyacetone phosphate, glycerol, glycero-3-
phosphocholine,
dihydroxyacetone, palmitate, cytidine diphosphate (CDP) diacylglycerol, CDP
choline, choline, choline
phosphate; as well as natural and artificial lamelar bodies which are the
natural carrier vehicles for the
components of surfactant, omega-3 fatty acids, polyenic acid, polyenoic acid,
lecithin, palmitinic acid,
non-ionic block copolymers of ethylene or propylene oxides, polyoxypropylene,
monomeric and
polymeric, polyoxyethylene, monomeric and polymeric, poly (vinyl amine) with
dextran and/or alkanoyl
side chains, Brij 35, Triton X-100 and synthetic surfactants ALEC, Exosurf,
Survan and Atovaquone,
among others. These surfactants may be used either as single or part of a
multiple component surfactant
in a formulation, or as covalently bound additions to the 5' and/or 3' ends
ofthe anti-sense
oligonucleotides (oligos). These compositions are administered in amounts
effective to reduce the
expression of an adenosine receptor, such as the adenosine A" Azb or A3
receptor by passing through a
cell membrane and binding specifically with mRNA encoding an adenosine A,, Azb
or A3 receptor in the
cell and prevent its translation. In addition, the present oligos and other
agents in general may be targeted
to the adenosine A~, receptor to activate this receptor or increase the amount
present (agonist activity).
Such compositions may contain a suitable pharmaceutically acceptable carrier
e.g., sterile pyrogen-free
saline solution, and the like. The anti-sense oligonucleotides may be
formulated as topical and systemic
formulations, in a variety of types, including oral, buccal, nasal, otical,
rectal, inhalable, slow release,
enteric coated, dermal, intradermal, injectable, and many more as is known in
the art. The formulation of
the invention may also comprise a hydrophobic carrier capable of passing
through a cell membrane, e.g.,
in a liposome, with the liposomes carried in a pharmaceutically acceptable
aqueous carrier. The
oligonucleotides may also be coupled to a substance which inactivates mRNA,
such as a ribozyme. The
present oligonucleotides may be administered to a subject aflicted with any
disease or condition
associated with the lung adenosine receptors to inhibit the activation of A~
or A3 adenosine receptors.
The pharmaceutical formulation may also contain chimeric molecules comprising
antisense
oligonucleotides attached to molecules which are known to be internalized by
cells. These
oligonucleotide conjugates utilize cellular uptake pathways to increase the
cellular concentrations of
oligonucleotides. Examples of macromolecules used in this manner include
tcansferrin,
asialoglycoprotein (bound to oligonucleotides via polylysine or other chemical
linkages) and
streptavidin.
In the pharmaceutical formulation the anti-sense compound may be contained
within a lipid
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
43
particle or vesicle, such as a liposome or microcrystal. The lipid particles
may be of any suitable
structure, such as unilamellar or plurilamellar, so long as the antisense
oligonucleotide is contained
therein. Positively charged lipids such as N- [1-(2, 3 -dioleoyloxi) propyl] -
N, N, N-trimethyl-
ammoniumethylsulfate, or "DOTAP," are particularly preferred for such
particles and vesicles. The
preparation of such lipid particles is well known. See, e.g., U.S. Patent Nos.
4,880,635 to Janoff et al.;
4,906,477 to Kurono et al.; 4,911,928 to Wallach; 4,917,951 to Wallach;
4,920,016 to Allen et al.;
4,921,757 to Wheatley et al.; etc.
The composition of the invention may be administered by any means which
transports the anti-
sense nucleotide composition to the lung. The antisense compounds disclosed
herein may be
administered to the lungs of a patient by any suitable means, but are
preferably administered by
inhalation of an aerosol comprised of respirable particles which comprise the
anti-sense compound. The
respirable particles may be liquid or solid, and they may optionally contain
other therapeutic or
diagnostic ingredients as well as other typical ingredients for a particular
formulation. Examples of other
agents are analgesics such as acetominophen, anilerdine, aspirin,
buprenorphine, butabital, butorpphanol,
Choline Salicylate, Codeine, Dezocine, Diclofenac, Diflunisal, Dihydrocodeine,
Elcatoninin, Etodolac,
Fenoprofen, Hydrocodone, Hydromorphone, Ibuprofen, Ketoprofen, Ketorolac,
Levorphanol,
Magnesium Salicylate, Meclofenamate, Mefenamic Acid, Meperidine, Methadone,
Methotrimeprazine,
Morphine, Nalbuphine, Naproxen, Opium, Oxycodone, Oxymorphone, Pentazocine,
Phenobarbital,
Propoxyphene, Salsalate, Sodium Salicylate, Tramadol and Narcotic analgesics
in addition to those listed
above. See, Mosby's Physician's GenRx. Anti- anxiety agents are also useful
including Alprazolam,
Bromazepam, Buspirone, Chlordiazepoxide, Chlormezanone, Clorazepate, Diazepam,
Halazepam,
Hydroxyzine, Ketaszolam, Lorazepam, Meprobamate, Oxazepam and Prazepam, among
others.
Anti-anxiety agents associated with mental depression, such as
Chlordiazepoxide, Amitriptyline,
Loxapine Maprotiline and Perphenazine, among others. Anti-inflammatory agents
such as non-rheumatic
Aspirin, Choline Salicylate, Diclofenac, Diflunisal, Etodolac, Fenoprofen,
Floctafenine, Flurbiprofen,
Ibuprofen, Indomethacin, Ketoprofen, Magnesium Salicylate, Meclofenamate,
Mefenamic Acid,
Nabumetone, Naproxen, Oxaprozin, Phenylbutazone, Piroxicam, Salsalate, Sodium
Salicylate, Sulindac,
Tenoxicam, Tiaprofenic Acid, Tolmetin, anti-inflammatories for ocular
treatment such as Diclofenac,
Flurbiprofen, Indomethacin, Ketorolac, Rimexolone (generally for post-
operative treatment),
anti-inflammatories for, non-infectious nasal applications such as
Beclomethaxone, Budesonide,
Dexamethasone, Flunisolide, Triamcinolone, and the like. Soporifics (anti-
insomnia/sleep inducing
agents) such as those utilized for treatment of insomnia, including
Alprazolam, Bromazepam, Diazepam,
Diphenhydramine, Doxylamine, Estazolam, Flurazepam, Halazepam, Ketazolam,
Lorazepam,
Nitrazepam, Prazepam Quazepam, Temazepam, Triazolam, Zolpidem and Sopiclone,
among others.
Sedatives including Diphenhydramine, Hydroxyzine, Methotrimeprazine,
Promethazine, Propofol,
Melatonin, Trimeprazine, and the like. Sedatives and agents used for treatment
of petit mal and tremors,
among other conditions, such as Amitriptyline HCI; Chlordiazepoxide,
Amobarbital; Secobarbital,
Aprobarbital, Butabarbital, Ethchiorvynol, Glutethimide, L-Tryptophan,
Mephobarbital, MethoHexital
Na, Midazolam Hcl, Oxazepam, Pentobarbital Na, Phenobarbital, Secobarbital Na,
Thiamylal Na, and
many others. Agents used in the treatment of head trauma (Brain
Injury/Ischemia), such as Enadoline
HCl (e.g. for treatment of severe head injury; orphan status, Warner Lambert),
cytoprotective agents, and
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
44
agents for the treatment of menopause, menopausal symptoms (treatment), e.g.
Ergotamine, Belladonna
Alkaloids and Phenobarbital, for the treatment of menopausal vasomotor
symptoms, e.g. Clonidine,
Conjugated Estrogens and Medroxyprogesterone, Estradiol, Estradiol Cypionate,
Estradiol Valerate,
Estrogens, conjugated Estrogens, esterified Estrone, Estropipate, and Ethinyl
Estradiol. Examples of
agents for treatment of pre menstrual syndrome (PMS) are Progesterone,
Progestin, Gonadotrophic
Releasing Hormone, Oral contraceptives, Danazol, Luprolide Acetate, Vitamin
B6. Examples of agents
for treatment of emotional/psychiatric treatments such as Tricyclic
Antidepressants, including
Amitriptyline HCl (Elavil), Amitriptyline HCI, Perphenazine (Triavil) and
Doxepin HCl (Sinequan).
Examples of tranquilizers, anti-depressants and anti-anxiety agents are
Diazepam (Valium), Lorazepam
(Ativan), Alprazolam (Xanax), SSRI's (selective Ssrotonin reuptake
inhibitors), Fluoxetine HCl (Prozac),
Sertaline HCl (Zoloft), Paroxetine HCI (Paxil), Fluvoxamine Maleate (Luvox),
Venlafaxine HCl
(Effexor), Serotonin, Serotonin Agonists (Fenfluramine), and other over the
counter (OTC) medications.
Also suitable are heart medicines, renal agents, and the like, which are known
in the art.
The anti-sense compound may be administered in an anti-cardiac, anti-
cardiopulmonary and/or
anti-renal damage or failure effective amount which depends upon the disease
being treated, the
condition of the subject, the particular formulation, the route of
administration, the timing of
administration to a subject, etc. In general, intracellular concentrations of
the oligonucleotide of from
about 0.05 to about 50 ItM, or more particularly about 0.2 to about 5 ~M, are
desirable. For
administration to a subject such as a human, a dosage of about 0.01, 0.1, or 1
mg/Kg up to about 50,
100, or 150 mg/Kg or more is typically employed. However, other doses are also
contemplated in this
patent, particularly when varying the route of administration. Depending on
the solubility of the active
compound in any particular formulation, the daily dose may be divided among
one or several unit dose
administrations. The administration of the anti-sense compound may be carried
out therapeutically, i.e.,
as a rescue treatment, or prophylactically, alone or in conjunction with other
therapeutic or diagnostic
agents as described above.
The anti-sense compound of the present invention is preferably administered
into the respiratory
system, e.g. by inhalation, nasal spraying, or generally into the lungs, as a
formulation including particles
of respirable size, e.g. particles of a. size sufficiently small to pass
through the nose, mouth and larynx
upon inhalation and through the bronchi and alveoli of the lungs. In general,
respirable particles range
from about 0.5 to 10 microns in size. Particles of non-respirable size which
are included in, for example,
an aerosol tend to deposit in the throat and be swallowed, and the quantity of
non-respirable particles in
the aerosol is thus minimized. For nasal administration, a particle size in
the range of about 10-500 ltm
is preferred to ensure retention in the nasal cavity. Other sizes, however,
are also suitable as are other
routes of administration.
Liquid pharmaceutical compositions of active compound for producing an aerosol
may be
prepared by combining the antisense compound with a suitable vehicle, such as
sterile pyrogen free
water. Other therapeutic compounds may optionally be included.
Solid particulate compositions containing respirable dry particles of
micronized antisense
compound may be prepared by grinding dry antisense compound with a mortar and
pestle, and then
passing the micronized composition through a 400 mesh screen to break up or
separate out large
agglomerates. A solid particulate composition comprising of the antisense
compound may optionally
CA 02316994 2000-06-30
WO 99/6393$ PC"T/ITS99/12775
contain a dispersant which serves to facilitate the formation of an aerosol as
well as other therapeutic
compounds. A suitable dispersant is lactose, which may be blended with the
antisense compound in any
suitable ratio, e.g., a 1 to 1 ratio by weight.
The aerosols of liquid particles comprising the antisense compound may be
produced by any
suitable means, such as with a nebulizer. See, e.g., U.S. Patent No.
4,501,729. Nebulizers are
commercially available devices which transform solutions or suspensions of the
active ingredient into a
therapeutic aerosol mist either by means of acceleration of a compressed gas,
typically air or oxygen,
through a narrow venturi orifice or by means of ultrasonic agitation. Suitable
formulations for use in
nebulizers comprise the active ingredient in a liquid cannier in an amount of
up to 40% w/w preferably
less than 20% w/w of the formulation. The carrier is typically water or a
dilute aqueous alcoholic
solution, preferably made isotonic with body fluids by the addition of, for
example, sodium chloride.
Optional additives include preservatives if the formulation is not prepared
sterile, for example, methyl
hydroxybenzoate, antioxidants, flavoring agents, volatile oils, buffering
agents and surfactants.
The aerosols of solid particles comprising the active compound may likewise be
produced with
any solid particulate medicament aerosol generator. Aerosol generators for
administering solid
particulate medicaments to a subject produce particles which are respirable,
as explained above, and
generate a volume of aerosol containing a predetermined metered dose of a
medicament at a rate suitable
for human administration. One illustrative type of solid particulate aerosol
generator is an insufflator.
Suitable formulations for administration by insufflation include finely
comminuted powders which may
be delivered by means of an insufflator or taken into the nasal cavity in the
manner of a snuff. In the
insufflator, the powder, e.g., a metered dose thereof effective to carry out
the treatments described
herein, is contained in capsules or cartridges, typically made of gelatin or
plastic, which are either
pierced or opened in situ and the powder delivered by air drawn through the
device upon inhalation or by
means of a manually-operated pump. The powder employed in the insufflator
consists either solely of
the active ingredient or of a powder blend comprising the active ingredient, a
suitable powder diluent,
such as lactose, and an optional surfactant. The active ingredient typically
comprises from 0.1 to 100
w/w of the formulation. A second type of illustrative aerosol generator
comprises a metered dose
inhaler. Metered dose inhalers are pressurized aerosol dispensers, typically
containing a suspension or
solution formulation of the active ingredient in a liquified propellant.
During use these devices discharge
the formulation through a valve adapted to deliver a metered volume, typically
from 10 to 150 ~,1, to
produce a fine particle spray containing the active ingredient. Suitable
propellants include certain
chlorofluorocarbon compounds, for example, dichlorodifluoromethane,
trichlorofluoromethane,
dichlorotetrafluoroethane and mixtures thereof. The formulation may
additionally contain one or more
co-solvents, for example, ethanol, surfactants, such as oleic acid or sorbitan
trioleate, antioxidants and
suitable flavoring agents.
The aerosol, whether formed from solid or liquid particles, may be produced by
the aerosol
generator at a rate of from about 10 to 150 liters per minute, more preferably
from about 30 to 150 liters
per minute, and most preferably about 60 liters per minute. Aerosols
containing greater amounts of
medicament may be administered more rapidly.
The following examples are provided to illustrate the present invention, and
should not be
construed as limiting thereon. In these examples, ~,M means micromolar, mL
means milliliters, wm
CA 02316994 2000-06-30
WO 99/63938 PC"T/tTS99/12775
46
means micrometers, mm means millimeters, cm means centimeters, °C means
degrees Celsius, ~,g
means micrograms, mg means milligrams, g means grams, kg means kilograms, M
means molar, and h
means hours.
EXAMPLES
Example 1: Design and Synthesis of Anti-sense Oligonucleotides & Controls
The design of anti-sense oligonucleotides against the adenosine receptors is
based on the primary
and secondary structure of the target receptor mRNA. The anti-sense
oligonucleotide are selected, and
optimally modified, to target regions of mRNA which confer functional activity
or stability to the
mRNA and which preferably may overlap the initiation codon. For instance,
regions that afford
particularly strong binding, such as CG strings are preferred, i.e. runs of G
and/or C preferably at the S-
end of the target region within the target gene or mRNA. However, other target
sites within the molecule
are suitable as well, particularly those which have low sequence overlapping
with other gene sequences,
thus increasing the specificity of the treatment.
Other oligonucleotides not totally complementary to the target mRNA, but
containing identical
nucleotide compositions on a w/w basis (controls), are included as controls in
anti-sense experiments to
demonstrate the specificity of the activity of the agents of this invention.
The primary and secondary structure of the human adenosine A, receptor mRNA
was analyzed
and used as described above to design anti-sense oligonucleotides, including
the ones, whose sequences
are provided. One anti-sense oligonucleotide (Oligo I) was synthesized as a
phosphorothioate, designated
HAdAIAS, and has the following sequence:
5' -GAT GGA GGG CGG CAT GGC GGG-3' (SEQ ID NO:1)
As a control, a mis-matched phosphorothioate anti-sense nucleotide designated
HAdAIMM was
synthesized with the following sequence.
S' -GTA GCA GGC GGG GAT GGG GGC-3' (SEQ ID N0:2)
The oligonucleotides of SEQ. ID NOS: 1 and 2 shown above have identical base
contents and
general sequence structures. Homology searches in GENBANK (release 85.0) and
EMBL (release 40.0)
indicated that the anti-sense oligonucleotide was specific for the human and
rabbit adenosine A, receptor
genes, and that the mis-matched control was not a candidate for hybridization
with any known gene
sequence.
In the same manner, the primary and secondary structure of the human adenosine
A3 receptor
mltNA was analyzed and various oligos selected, and the following two
synthesized as phosphorothioate
anti-sense oligonucleotides. The first anti-sense oligonucleotide (HAdA3AS1)
synthesized has the
following sequence.
5' -GTT GTT GGG CAT CTT GCC-3' (SEQ ID N0:3)
As a control, a mis-matched phosphorothioate anti-sense oligonucleotide
(HAdA3MM1) was
synthesized, which has the following sequence.
5' -GTA CTT GCG GAT CTA GGC-3' (SEQ ID N0:4)
The second phosphorothioate anti-sense oligonucleotide (HadA3AS2) has the
following
sequence.
CA 02316994 2000-06-30
WO 99/63938 PGT/IJS99/12775
47
5' -GTG GGC CTA GCT CTC GCC-3' (SEQ 11? NO:S)
As a control, its mis-matched oligonucleotide ( HAdA3MM2) has the following
sequence.
5' -GTC GGG GTA CCT GTC GGC-3' (SEQ )D N0:6)
All phosphorothioate oligonucleotides were synthesized on an Applied
Biosystems Model 396
Oligonucleotide Synthesizer, and purified using NENSORB chromatography
(DuPont, MD).
Example 2: In Vitro Testing of A,-Adenosine
Receptor Anti-sense Oligonucleotides
The anti-sense oligonucleotide against the human A, receptor (SEQ ID NO:1)
described above
was tested for efficacy in an in vitro model utilizing lung adenocarcinoma
cells HTB-54. HTB-54 lung
adenocarcinoma cells were demonstrated to express the A, adenosine receptor
using standard northern
blotting procedures and receptor probes designed and synthesized in the
laboratory.
HTB-54 human lung adenocarcinoma cells (106/100 mm tissue culture dish) were
exposed to 5.0
~tM HAdAIAS or HAdAIMM for 24 hours, with a fresh change of media and
oligonucleotides after 12
hours of incubation. Following 24 hour exposure to the oligonucleotides, cells
were harvested and their
RNA extracted by standard procedures. A 21-mer probe corresponding to the
region of mRNA targeted
by the anti-sense (and therefore having the same sequence as the anti-sense,
but not phosphorothioated)
was synthesized and used to probe northern blots of RNA prepared from HAdAIAS-
treated, HAdAIMM-
treated and non-treated HTB-54 cells. These blots showed clearly that HAdAIAS
but not HAdAIMM
effectively reduced human adenosine receptor mRNA by >SO%. This result showed
that HAdAIAS is a
good candidate for an anti-asthma drug since it depletes intracellular mRNA
for the adenosine A,
receptor, which is involved in asthma.
Example 3: In Vivo Efficacy of A1 Adenosine
Receptor Anti-sense Oligonucleotides
A fortuitous homology between the rabbit and human DNA sequences within the
adenosine A,
gene overlapping the initiation codon permitted the use of the
phosphorothioate anti-sense
oligonucleotides initially designed for use against the human adenosine A,
receptor in a rabbit model.
Neonatal New Zealand white Pasteurella-free rabbits were immunized
intraperitoneally within
24 hours of birth with 312 antigen units/mL house dust mite (D. farinae)
extract (Berkeley Biologicals,
Berkeley, CA), mixed with 10% kaolin. Immunizations were repeated weekly for
the first month and
then biweekly for the next 2 months. At 3-4 months of age, eight sensitized
rabbits were anesthetized
and relaxed with a mixture of ketamine hydrochloride (44 mg/kg) and
acepromazine maleate (0.4 mg/kg)
administered intramuscularly.
The rabbits were then laid supine in a comfortable position on a small molded,
padded animal
board and intubated with a 4.0-mm intratracheal tube (Mallinkrodt, Inc., Glens
Falls, NI'). A
polyethylene catheter of external diameter 2.4 mm with an attached latex
balloon was passed into the
esophagus and maintained at the same distance (approximately 16 cm) from the
mouth throughout the
experiments. The intratracheal tube was attached to a heated Fleisch
pneumotachograph (size 00; DOM
Medical, Richmond, VA), and flow was rizeasured using a Validyne differential
pressure transducer
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
48
(Model DP-45161927; Validyne Engineering Corp., Northridge, CA) driven by a
Gould carrier amplifier
(Model 11-4I 13; Gould Electronic, Cleveland, OIL. The esophageal balloon was
attached to one side of
the differential pressure transducer, and the outflow of the intratracheal
tube was connected to the
opposite side of the pressure transducer to allow recording of transpulmonary
pressure. Flow was
integrated to give a continuous tidal volume, and measurements of total lung
resistance (RL) and
dynamic compliance (Cdyn) were calculated at isovolumetric and flow zero
points, respectively, using
an automated respiratory analyzer (Model 6; Buxco, Sharon, CT).
Animals were randomized and on Day 1 pretreatment values for PC50 were
obtained for
aerosolized adenosine. Anti-sense (HAdAIAS) or mismatched control (HAdAIMM)
oligonucleotides
were dissolved in sterile physiological saline at a concentration of 5000 ~g
(5 mg) per 1.0 ml. Animals
were subsequently administered the aerosolized anti-sense or mismatch
oligonucleotide via the
intratracheal tube (approximately 5000 ~,g in a volume of 1.0 ml), twice daily
for two days. Aerosols of
either saline, adenosine, or anti-sense or mismatch oligonucleotides were
generated by an ultrasonic
nebulizer (DeVilbiss, Somerset, PA), producing aerosol droplets 80% of which
were smaller than 5 ltm
in diameter.
In the first arm of the experiment, four randomly selected allergic rabbits
were administered anti-
sense oligonucleotide and four the mismatched control oligonucleotide. On the
morning of the third day,
PC50 values (the concentration of aerosolized adenosine in mg/ml required to
reduce the dynamic
compliance of the bronchial airway 50% from the baseline value) were obtained
and compared to PC50
values obtained for these animals prior to exposure to oligonucleotide.
Following a I week interval, animals were crossed over, with those previously
administered
mismatch control oligonucleotide now administered anti-sense oligonucleotide,
and those previously
treated with anti-sense oligonucleotide now administered mismatch control
oligonucleotide. Treatment
methods and measurements were identical to those employed in the first arm of
the experiment. It
should be noted that in six of the eight animals treated with anti-sense
oligonucleotide, adenosine-
mediated bronchoconstriction could not be obtained up to the limit of
solubility of adenosine, 20 mg/ml.
For the purpose of calculation, PC50 values for these animals were set at 20
mg/ml. The values given
therefore represent a minimum figure for anti-sense effectiveness. Actual
effectiveness was higher. The
results of this experiment are illustrated in both Figure 1 and Table 1.
Table 1: Adenosine A1 Receptor Anti-sense Oligonucleotide
Effect upon PC50 Valves in Asthmatic Rabbits
Mismatch Control A1 Receptor Anti-sense Oligonucleotide
Pre Post Pre Post
oligonucleotide oligonucleotide oligonucleotideoligonucleotide
3.56 t 1.02 5.16 t 1.93 2.36 t 0.68 >19.5 t 0.34**
1ZCSUItS 8!C tfresetltedRl"CRMCivnifieanrrnnri by ra,w~r.A_..,.ee...~e.. ..o..-
..:-..,.-
ac the mean In= wac rlrtermi e..et....: ~wwtnm v __~ ...a.__.n_
protected t test. ~~Significantly different from all other groups, P < 0.01. -
' " _ __ ______ , _ _ _ _ " .._ _ _.__, _
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
49
In both arms of the experiment, animals receiving the anti-sense
oligonucleotide showed an
order of magnitude increase in the dose of aerosolized adenosine required to
reduce dynamic compliance
of the lung by 50%. No effect of the mismatched control oligonucleotide upon
PC50 values was
observed. No toxicity was observed in any animal receiving either anti-sense
or control inhaled
oligonucleotide.
These results show clearly that the lung has exceptional potential as a target
for anti-sense
oligonucleotide-based therapeutic intervention in lung disease. They further
show, in a model system
which closely resembles human asthma, that down regulation of the adenosine A,
receptor largely
eliminates adenosine-mediated bronchoconstriction in asthmatic airways.
Bronchial hyper-
responsiveness in the allergic rabbit model of human asthma is an excellent
endpoint for anti-sense
intervention since the tissues involved in this response lie near to the point
of contact with aerosolized
oligonucleotides, and the model closely simulates an important human disease.
Example 4: Specificity of A,-adenosine Receptor Anti-sense Oligonucleotide
At the conclusion of the crossover experiment of Example 3, airway smooth
muscle from all
rabbits was quantitatively analyzed for adenosine A, receptor number. As a
control for the specificity of
the anti-sense oligonucleotide, adenosine Az receptors, which should not have
been affected, were also
quantified.
Airway smooth muscle tissue was dissected from each rabbit and a membrane
fraction prepared
according to described methods (Kleinstein, J., and Glossmann, H., Naunyn-
Schmiedeberg's Arch.
Pharmacol. 305, 191-200 (1978), with slight modifications. Crude plasma
membrane preparations were
stored at -70 ° C until the time of assay. Protein content was
determined by the method of Bradford (M.
Bradford, Anal. Biochem. 72, 240-254 (1976)). Frozen plasma membranes were
thawed at room
temperature and were incubated with 0.2 U/ml adenosine deaminase for 30
minutes at 37°C to remove
endogenous adenosine. The binding of ['H] DPCPX (A, receptor-specific) or (3H]
CGS-21680 (AZ
receptor-specific) was measured as previously described. See, Ali, S., et al.,
J. Pharmacol. Exp. Ther.
268, 1328-1334 (1994); S. Ali et al., Am. J. Physiol. 266, L271-277 (1994).
As illustrated in both Figure 2 and Table 2, animals treated with adenosine A,
anti-sense
oligonucleotide in the crossover experiment had a nearly 75% decrease in A,
receptor number compared
to controls, as assayed by specific binding of the A,-specific antagonist
DPCPX. There was no change in
adenosine AZ receptor number, as assayed by specific binding of the AZ
receptor-specific agonist 2- [p-
(2-carboxyethyl)-phenethylamino] -5'-(N-ethylcarboxamido) adenosine (CGS-
21680).
CA 02316994 2000-06-30
WO 99/63938 PCT/ITS99/12775
Table 2: Specificity or Action of Adenosine A
Receptor Anti-sense Oligonncleotide
Mismatch Control At-Anti-sense
Oligonucleotlde Oligonucleotide
(Mean ~ SD) (Mean ~ SD)
n'8 n=8
A~-Specific Binding 1,105 t 48** 293 t 18
302 t 22** ~ 442 t 171
mgmncance was aetermmw uy repeatea-measures anatys~s of variance (ANOVA), and
Tukey's protected t test.
mismatch control, p < 0.01.
Ezample 5: In Vivo Response to Adenosine Challenge
with & without Oligo I Pretreatment
Two hyper responsive monkeys (ascaris sensitive) were challenged with inhaled
adenosine, with
and without pre-treatment with anti-sense oligo I (SEQ.ID NO: 1). The PC40
adenosine was calculated
from the data collected as being equivalent to that amount of adenosine in mg
that causes a 40% decrease
in dynamic compliance in hyper-responsive airways.
The Oligo I (SEQ. )D NO:1; EPI 2010) was subsequently administered at 10
mg/day for 2 days
by inhalation. On the third day, PC adenosine was again measured. The results
are shown in Figure 3
accompanying this patent. The left bar shows the PC40 adenosine value prior to
treatment with Oligo I
whereas the right bar shows the PC40 adenosine taken after administration of
Oligo I. As can be seen in
Figure 3, any sensitivity to adenosine was completely eliminated by the
administration of the oligo of
this invention in one animal, and substantially reduced in the second.
Eaamole 6: Anti-sense Oligos directed to other Target Nucleic Acids
This work was conducted to demonstrate that the present invention is broadly
applicable to anti-
sense oligonucleotides ("oligos") specific to nucleic acid targets broadly.
The following experimental
studies were conducted to show that the method of the invention is broadly
suitable for use with anti-
sense oligos designed as taught by this application and targeted to any and
all adenosine receptor
mRNAs. For this purpose, various anti-sense oligos were prepared to adenosine
receptor mRNAs
exemplified by the adenosine A,, AZb and A3 receptor mRNAs.
Anti-sense Oligo I was disclosed above (SEQ. ID NO: 1). Five additional anti-
sense
phosphorothioate oligos were designed asnd synthesized as indicated above.
1- Oligo II (SEQ. ID NO: 997) also targeted to the adenosine At receptor, but
to a different
region than Oligo I.
2- Oligo V (SEQ. ID NO: 1000) targeted to the adenosine Alb receptor.
3- Oligos III (SEQ. ID NO: 998) and IV (SEQ. ID NO: 999) targeted to different
regions of the
adenosine A3 receptor.
4- Oligo I-PD (SEQ. ID NO:1)(a phosphodiester oligo of the same sequence as
Oligo I).
These anti-sense oligos were designed for therapy on a selected species as
described above and
are generally specific for that species, unless the segment of the target mRNA
of other species happens
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
51
to contain a similar sequences. All anti-sense oligos were prepared as
described below, and tested in vivo
in a rabbit model for bronchoconstriction, inflammation and allergy, which
have breathing difficulties
and impeded lung airways, as is the case in ailments such as asthma, as
described in the above-identifed
application.
Example 7: Design & Sequences of other Anti-sense OIigos
Six oligos and their effects in Sa rabbit model were studied and the results
of these studies are
reported and discussed below. Five of these oligos were selected for this
study to complement the data
on Oligo I (SEQ ID NO: 1) provided in Examples 1 to 4 above. This oligo is
anti-sense to one region of
the adenosine A, receptor mIZNA.
The oligos tested are identified as anti-sense Oligos I (SEQ ID NO: 1) and II
(SEQ. ID
No: 997) targeted to a different region of the adenosine A, receptor mlZNA,
Oligo V (SEQ. ID No: 998)
targeted to the adenosine AZb receptor mRNA, and anti-sense Oligos III and IV
(SEQ. ID NOS: 999 and
1000) targeted to two different regions of the adenosine A3 receptor mRNA. The
sixth oligo (Oligo I-PD)
is a phosphodiester version of Oligo I (SEQ. ID NO: 1). The design and
synthesis of these anti-sense
oligos was performed in accordance with Example 1 above.
(1) Anti-sense Oligo I
The anti-sense oligonucleotide I referred to in Examples 1 to 5 above is
targeted to the human A,
adenosine receptor mRNA (EPI 2010). Anti-sense oligo I is 21 nucleotide long,
overlaps the initiation
codon, and has the following sequence.
5'- GAT GGA GGG CGG CAT GGC GGG -3' (SEQ. ID No:l)
The oligo I was previously shown to abrogate the adenosine-induced
bronchoconstriction in
allergic rabbits, and to reduce allergen-induced airway obstruction and
bronchial hyperresponsiveness
(BHR), as discussed above and shown by Nyce, J. W. & Metzger, W. J., Nature,
385:721 (1977), the
relevant portions of which reference are incorporated in their entireties
herein by reference.
(11) Anti-sense Oligo II
A phosphorothioate anti-sense oligo (SEQ. ID N0:997) was designed in
accordance with the
invention to target the rabbit adenosine A~ receptor mRNA region +936 to +956
relative to the initiation
codon (start site). The anti-sense oligo II is 21 nucleotide long, and has the
following sequence.
5'-CTC GTC GCC GTC GCC GGC GGG3' (SEQ. ID N0:997)
(111) Anti-sense Ollgo III
A phosphorothioate anti-sense oligo other than that provided in Example 1
above (SEQ. ID
N0:998) was designed in accordance with the invention to target the anti-sense
A3 receptor mIZNA
region +3 to + 22 relative to the initiation codon start site. The anti-sense
oligo III is 20 nucleotide long,
and has the following sequence.
5'-GGG TGG TGC TAT TGT CGG GC-3' (SEQ. ID N0:998)
(IV) Anti-sense Oligo IV
Yet another phosphorothioate anti-sense oligo (SEQ. ID N0:999) was designed in
accordance
with the invention to target the adenosine A3 receptor mRNA region + 386 to +
401 relative to the
initiation codon (start site). The anti-sense oligo IV is 15 nucleotide long,
and has the following
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
52
sequence.
5'-GGC CCA GGG CCA GCC-3' (SEQ. ID N0:999)
(V) Anti-sense Oligo V
A phosphorothioate anti-sense oligo (SEQ. ID NO:1000) was designed in
accordance with the
invention to target the adenosine AZb receptor mRNA region -21 to -1 relative
to the initiation codon
(start site). The anti-sense oligonucleotide V is 21 nucleotide long, and has
the following sequence.
5'-GGC CGG GCC AGC CGG GCC CGG3' (SEQ. ID NO:1000)
(Vn A, Mismatch OLtgos
Two different mismatched oligonucleotides having the following sequences were
used as
controls for anti-sense oligo I (SEQ. ID NO: 1) described in Example 6 above.
A, MM2 5'-GTA GGT GGC GGG CAA GGC GGG3' (SEQ. ID N0:1002)
A, MM3 5'-GAT GGA GGC GGG CAT GGC GGG3' (SEQ. ID N0:1003)
Anti-sense oligo I and the two mismatch anti-sense oligos had identical base
content and general
sequence structure. Homology searches in GENBANK (release 85.0) and EMBL
(release 40.0) indicated
that the anti-sense oligo I was specific, not only for the human, but also for
the rabbit, adenosine A,
receptor genes, and that the mismatched controls were not candidates for
hybridization with any known
human or animal gene sequence.
(Vl~ Anti-sense Oligo A,-PD (Oligo VI)
A phosphodiester anti-sense oligo (Oligo VI; SEQ. ID N0:1004) having the same
nucleotide
sequence as Oligo I was designed as disclosed in the above-identified
application. Anti-sense oligo I-PD
is 21 nucleotide long, overlaps the initiation codon, and has the following
sequence.
5'- GAT GGA GGG CGG CAT GGC GGG -3' (SEQ. ID N0:1004)
V)~ Controls
Each rabbit was administered 5.0 ml aerosolized sterile saline following the
same schedule as for
the anti-sense oligos in (In, (III), and (IV) above.
Example 8: Synthesis of Anti-sense Oligos
Phosphorothioate anti-sense oligos having the sequences described in (a)
above, were
synthesized on an Applied Biosystems Model 396 Oligonucleotide Synthesizer,
and purified using
NENSORB chromatography (DuPont, DE). TETD (tetraethylthiuram disulfide) was
used as the
sulfurizing agent during the synthesis. Anti-sense oligonucleotide II (SEQ. ID
N0:997), anti-sense
oiigonucleotide III (SEQ. ID NO: 998) and anti-sense oligonucleotide IV (SEQ.
ID NO: 999) were each
synthesized and purified in this manner.
Example 9: Preparation of Allergic Rabbits
Neonatal New Zealand white Pasturella-free rabbits were immunized
intraperitoneally within 24
hours of birth with 0.5 ml of 312 antigen units/rnl house dust mite (D.
farinae) extract (Berkeley
Biologicals, Berkeley, CA) mixed with 10% kaolin as previously described
(Metzger, W. J., in Late
Phase Allergic Reactions, Dorsch, W., Ed., CRC Handbook, pp. 347-362, CRC
Press, Boca Raton
(I990); Ali, S., Metzger, W. J. and Mustafa, S. J., Am. J. Resp. Crit. Care
Med. 149: 908 (1994)), the
CA 02316994 2000-06-30
WO 99/63938 PGT/ITS99/12775
53
relevant portions of which are incorporated in their entireties here by
reference. Immunizations were
repeated weekly for the first month and then biweekly until the age of 4
months. These rabbits
preferentially produce allergen-specific IgE antibody, typically respond to
aeroallergen challenge with
both an early and late-phase asthmatic response, and show bronchial hyper
responsiveness (BHR).
Monthly intraperitoneal administration of allergen (312 units dust mite
allergen, as above) continues to
stimulate and maintain allergen-specific IgE antibody and BHR. At 4 months of
age, sensitized rabbits
were prepared for aerosol administration as described by Ali et al. (Ali, S.,
Metzger, W. J. and Mustafa,
S. J., Am. J. Resp. Crit. Care Med. 149 (1994)), the relevant section being
incorporated in its entirety
here by reference.
DOSE-RESPONSE STUDIES
Example 10: Experimental Setnp
Aerosols of either adenosine (0-20 mg/ml), or anti-sense or one of two
mismatch
oligonucleotides (5 mg/ml) were separately prepared with an ultrasonic
nebulizer (Model 646, DeVilbiss,
Somerset, PA), which produced aerosol droplets, 80% of which were smaller than
S~m in diameter.
Equal volumes of the aerosols were administered directly to the lungs via an
intratracheal tube.
The animals were randomized, and administered aerosolized adenosine. Day 1 pre-
treatment
vaiues for sensitivity to adenosine were calculated as the dose of adenosine
causing a 50% loss of
compliance (PCSO Adenosine). The animals were then administered either the
aerosolized anti-sense or
one of the mismatch anti-sense oligos via the intratracheal tube (5 mg/1.0
ml), for 2 minutes, twice daily
for 2 days (total dose, 20 mg). Post-treatment PC50 values were recorded (post-
treatment challenge) on
the morning of the third day. The results of these studies are provided in
Example 21 below.
Example 11: Crossover Experiments
For some experiments utilizing anti-sense oligo I (SEQ. ID NO:1) and a
corresponding
mismatch control oligonucleotide A1MM2, following a 2 week interval, the
animals were crossed over,
with those previously administered the mismatch control A,MM2, now receiving
the anti-sense oligo I,
and those previously treated with the anti-sense oligo I, now receiving the
mismatch control A,MM2
oligo.
The number of animals per group was as follows. For mismatch A~MM2 (Control
1), n=7, since
one animal was lost in the second control arm of the experiment due to
technical difficulties, for
mismatch A,MM3 n=4 (Control 2) and for ACAS anti-sense oligo I, n=8. The A,MM3
oligo-treated
animals were analyzed separately and were not part of the cross-over
experiment. The treatment
methods and measurements employed following the cross-over were identical to
those employed in the
first arm of the experiment.
In 6 of the 8 animals treated with the anti-sense oligo I (SEQ. ID NO:1), no
PCSp value could
be obtained for adenosine doses of up to 20 mg/ml, which is the limit of
solubility of adenosine.
Accordingly, the PC50 values for these animals were assumed to be 20 mg/ml for
calculation purposes.
The values given, therefore, represent a minimum figure for the effectiveness
of the anti-sense
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
54
oligonucleotides of the invention. Other groups of allergic rabbits (n=4 for
each group) were
administered 0.5 or 0.05 mg doses of the anti-sense oligo I (SEQ ID NO:1), or
the AIMM2 oligo in the
manner and according to the schedule described above (the total doses being
2.0 or 0.2 mg). The results
of these studies are provided in Example 23 below.
Example 12: Anti-sense Oligo Formulation
Each one of anti-sense oligos were separately solubilized in an aqueous
solution and
administered as described for anti-sense oligo I (SEQ. ID NO:1) in (e) above,
in four S mg aliquots (20
mg total dose) by means of a nebulizer via endotracheal tube, as described
above.
The results obtained for anti-sense oligo I and its mismatch controls
confirmed that the mismatch
controls are equivalent to saline, as described in Example 20 below and in
Table 1 of Nyce & Metzger,
Nature 385, 721-725 (1997). Because of this finding, saline was used as a
control for pulmonary function
studies employing anti-sense oligos II, III and IV (SEQ. ID NOS: 997, 998 and
999).
Example 13: Specificity of Oligo I for Adenosine A, Receptor
(Receptor Binding Studies)
Tissue from airway smooth muscle was dissected to primary, secondary and
tertiary bronchi
from rabbits which had been administered 20 mg oligo I (SEQ. ID NO:1) in 4
divided doses over a
period of 48 hours as described above. A membrane fraction was prepared
according to the method of
Ali et al. (Ali, S., et al., Am. J. Resp. Crit. Care Med. 149: 908 ( 1994),
the relevant section relating to the
preparation of the membrane fraction is incorporated in its entirety hereby by
reference).
The protein content was determined by the method of Bradford and plasma
membranes were
incubated with 0.2 U/ml adenosine deaminase for 30 minutes at 37°C to
remove endogenous adenosine.
See, Bradford, M. M. Anal. Biochem. 72, 240-254 (1976), the relevant portion
of which is hereby
incorporated in its entirety by reference. The binding of ['H]DPCPX,
[3H]NPC17731, or ['H]CGS-21680
was measured as described by Jarvis et al. See, Jarvis, M.F., et al.,
Pharmacol. Exptl. Ther. 251, 888-893
(1989), the relevant portion of which is fully incorporated herein by
reference. The results of this study
are shown in Table 8 and discussed in Example 2lbelow.
Example 14: Pulmonary Function Measurements
(Compliance cDyN and Resistance)
At 4 months of age, the immunized animals were anesthetized and relaxed with
1.5 ml of a
mixture of ketamine HCl (35 mg/kg) and acepromazine maleate (1.5 mg/kg)
administered
intramuscularly. After induction of anesthesia, allergic rabbits were
comfortably positioned supine on a
soft molded animal board. Salve was applied to the eyes to prevent drying, and
they were closed. The
animals were then intubated with a 4.0 mm intermediate high-low cuffed Murphy
1 endotracheal tube
(Mallinckrodt, Glen Falls, N7~, as previously described by Zavala and Rhodes.
See, Zavala and Rhodes,
Proc. Soc. Exp. Biol. Med. 144: 509-S 12 (1973), the relevant portion of which
is incorporated herein by
reference in its entirety. A polyethylene catheter of OD 2.4 mm (Becton
Dickinson, Clay Adams,
Parsippany NJ) with an attached thin-walled latex balloon was passed into the
esophagus and maintained
at the same distance (approximately 16 cm) from the mouth throughout the
experiment. The endotracheal
CA 02316994 2000-06-30
WO 99/63938 PCT1US99/12775
tube was attached to a heated Fleisch pneumotach (size 00; DEM Medical,
Richmond, VA), and the flow
(v) measured using a Validyne differential pressure transducer (Model DP-45-16-
1927, Validyne
Engineering, Northridge, CA), driven by a Gould carrier amplifier (Model 11-
4113, Gould Electronics,
Cleveland, OH).
An esophageal balloon was attached to one side of the Validyne differential
pressure transducer,
and the other side was attached to the outflow of the endotracheal tube to
obtain transpulmonary pressure
(Ptp). The flow was integrated to yield a continuous tidal volume, and the
measurements of total lung
resistance (R~ and dynamic compliance (Cdyn) were made at isovolumetric and
zero flow points. The
flow, volume and pressure were recorded on an eight channel Gould 2000 W high-
frequency recorder
and Cdyn was calculated using the total volume and the difference in Ptp at
zero flow, and . Rt was
calculated as the ratio of Ptp and V at midtidal lung volumes. These
calculations were made
automatically with the Buxco automated pulmonary mechanics respiratory
analyzer (Model 6, Buxco
Electronics, Sharon, CT), as previously described by Giles et al. See, Giles
et al., Arch. Int.
Pharmacodyn. Ther. 194: 213-232 (1971), the relevant portion of which
describing these calculations is
incorporated in toto hereby by reference. The results obtained upon
administration of oligo II on allergic
rabbits are shown and discussed in Example 27below.
Example 15: Measurement of Bronchial Hyperresponsiveness (BHR)
Each allergic rabbit was administered histamine by aerosol to determine their
baseline
hyperresponsiveness. Aerosols of either saline or histamine were generated
using a DeVilbiss nebulizer
(DeVilbiss, Somerset, PA) for 30 seconds and then for 2 minutes at each dose
employed. The ultrasonic
nebulizer produced aerosol droplets of which 80% were <5 micron in diameter.
The histamine aerosol
was administered in increasing concentrations (0.156 to 80 mg/ml} and
measurements of pulmonary
function were made after each dose. The B4R was then determined by calculating
the concentration of
histamine (mg/ml) required to reduce the Cdyn 50% from baseline (PCSO
Histamine)
Example 16: Cardiovascular Effect of Anti-sense Oligo I
The measurement of cardiac output and other cardiovascular parameters using
Cardiomax''""
utilizes the principal of thermal dilution in which the change in temperature
of the blood exiting the heart
after a venous injection of a known volume of cool saline is monitored. A
single rapid injection of cool
saline was made into the right atrium via cannulation of the right jugular
vein, and the corresponding
changes in temperature of the mixed injectate and blood in the aortic arch
were recorded via cannulation
of the carotid artery by a temperature-sensing miniprobe.
Twelve hours after the allergic rabbits had been treated with aerosols of
oligo I (EPI 2010; SEQ.
ID NO: 1) as described in (d) above, the animals were anesthetized with 0.3
ml/kg of 80% Ketamine and
20% Xylazine. This time point coincides with previous data showing efficacy
for SEQ. ID NO: 1, as is
clearly shown by Nyce & Metzger, (1997), supra, the pertinent disclosure being
incorporated in its
entirety here by reference. A thermocouple was then inserted into the left
carotid artery of each rabbit,
and was then advanced 6.5 cm and secured with a silk ligature. The right
jugular vein was then
cannulated and a length of polyethylene tubing was inserted and secured.
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
56
A thermodilution curve was then established on a CardiomaxTM II (Columbus
Instruments, Ohio)
by injecting sterile saline at 20°C to determine the correctness of
positioning of the thermocouple probe.
After establishing the correctness of the position of the thermocouple; the
femoral artery and vein were
isolated: The femoral vein was used as a portal for drug injections, and the
femoral artery for blood
pressure and heart rate measurements. Once constant baseline cardiovascular
parameters were
established, CardiomaxT'" measurements of blood pressure, heart rate, cardiac
output, total peripheral
resistance, and cardiac contractility were made.
Example 17: Duration of Action of Oligo I
(SEQ. ID NO: 1)
Eight allergic rabbits received initially increasing log doses of adenosine by
means of a nebulizer
via an infra-tracheal tube as described in (f) above, beginning with 0.156
mg/ml until compliance was
reduced by SO% (PC50 Adenosine) to establish a baseline. Six of the rabbits
then received four 5 mg
aerosolized doses of (SEQ. ID NO:1) as described above. Two rabbits received
equivalent amounts of
saline vehicle as controls. Beginning 18 hours after the last treatment, the
PC50 Adenosine values were
tested again. After this point, the measurements were continued for all
animals each day, for up to 10
days. The results of this study are discussed in Example 26 below.
Ezample 18: Reduction of Adenosine AZb Receptor
Number by Anti-sense Oligo V
Sprague Dawley rats were administered 2.0 mg respirable anti-sense oligo V
(SEQ.
ID NO:1000) three times over two days using an inhalation chamber as described
above. Twelve hours
after the last administration, lung parenchymal tissue was dissected and
assayed for adenosine AZb
receptor binding using [311]-NECA as described by Nyce & Metzger (1997),
supra. Controls were
conducted by administration of equal volumes of saline. The results are
significant at p<0.05 using
Student's paired t test, and are discussed in Example 29 below.
Example 19: Comparison of Oligo I & Corresponding
Phosphodiester Oiigo VI (SEQ. ID N0:1004)
Oligo I (SEQ ID NO:1) countered the effects of adenosine and eliminated
sensitivity to it for
adenosine amounte up to 20 mg adenosine/5.0 ml (the limit of solubility of
adenosine). Oligo VI (SEQ.
ID N0:1004), the phosphodiester version of the oligonucleotide sequence, was
completely ineffective
when tested in the same manner. Both compounds have identical sequence,
differing only in the presence
of phosphorothioate residues in Oligo I (SEQ ID NO:1), and were delivered as
an aerosol as described
above and in Nyce & Metzger (1997), supra. Significantly different at p<0.001,
Student's paired t test.
The results are discussed in Example 30 below.
RESULTS OBTAINED FOR ANTI-SENSE OLIGO I~SEO. ID NO: 11
Example 20: Results of Prior Work
The nucleotide sequence and other data for anti-sense oligo I (SEQ. ID NO:1},
which is specific
for the adenosine A, receptor, were provided above. The experimental data
showing the effectiveness of
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
57
oligo I in down regulating the receptor number and activity were also provided
above.
Further information on the characteristics and activities of anti-sense oligo
I is provided in Nyce,
J. W. and Metzger, W. J., Nature 385:721 (1997), the relevant parts of which
relating to the following
results are incorporated in their entireties herein by reference. The Nyce &
Metzger (1997) publication
provided data showing that the anti-sense oligo I (SEQ. ID NO:1):
( 1 ) The anti-sense oligo I reduces the number of adenosine A~ receptors in
the bronchial
smooth muscle of allergic rabbits in a dose-dependent manner as may be seen in
Table 3 below.
(2) Anti-sense Oligo I. attenuates adenosine-induced bronchoconstriction and
allergen-
induced bronchoconstriction.
(3) The Oligo I attenuates bronchial hyperresponsiveness as measured by PCSp
histamine, a
standard measurement to assess bronchial hyperresponsiveness. This result
clearly demonstrates anti-
inflammatory activity of the anti-sense oligo I as is shown in Table 2 above.
(4) As expected, because it was designed to target it, the anti-sense oligo I
is totally specific
for the adenosine A, receptor, and has no effect at all at any dose on either
the very closely related
adenosine AZ receptor or the related bradykinin BZ receptor. This is seen in
Table 3 below.
(5) In contradistinction to the above effects of the Oligo I, the mismatch
control molecules
MM2 and MM3 (SEQ. ID N0:1002 and SEQ. ID N0:1003) which have identical base
composition and
molecular weight but differed from the anti-sense oligo I (SEQ ID NO: 1) by 6
and 2 mismatches,
respectively. These mismatches, which are the minimum possible while still
retaining identical base
composition, produced absolutely no effect upon any of the targeted receptors
(A,, AZ or BZ).
These results, along with a complete lack of prior art on the use of anti-
sense oligonucleotides,
such as oligo I, targeted to the adenosine A, receptor, are unexpected
results. The showings presented in
this patent clearly enable and demonstrate the effectiveness, for their
intended use, of the claimed agents
and method for treating a disease or condition associated with lung airway,
such as bronchoconstriction,
inflammation, allergy(ies), and the like.
Example 21: OUgo I Significantly Reduces
Response to Adenosine Challenge
The receptor binding experiment is described in Example 13 above, and the
results shown in
Table 3 below which shows the binding characteristics of the adenosine A,-
selective ligand [3H)DPCPx
and the bradykinin BZ-selective ligand [3H]NPC 17731 in membranes isolated
from airway smooth
muscle of A, adenosine receptor and BZ bradykinin receptor anti-sense- and
mismatch-treated allergic
rabbits.
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
58
Table 3: Binding Characteristics of Three Anti-Sense Oligos
Treatraentt A, receptor B, receptor
Kd Be"i Kd Bmaz
Adenosine Receptor
A,
20 mg 0.3610.029 1911.52 fmoles*0.3910.031 14.8t0.99finoles
nM nM
2 mg 0.3810.030 3212.56 fmoles*0.4110.028 15.51 1.08 finoles
nM nM
U.2 mg 0.3710.030 4913.43 frnoles0.3410.024 15.01 1.06 fmoles
aM nM
AtMMl (C;ontrol)
2U mg 0.3410.027 52.013.64 0.3510.024 14.01 1.0 fmoles
nM fmoles nM
2 mg 0.3710.033 51.8f3.88 0.3810.028 14.611.02 fmoles
nM~ fmoles nM
BsA (BradykininReceptor)
2U mg 0.3610.028 45.013.15 0.3810.027 8.710.62 fmoles*
nM fmoles nM
2 mg 0.3910.035 44.312.90 0.3410.024 11.910.76 fmoles**
aM fmoles nM
U.2 mg 0.4010.028 47.013.76 0.3510.028 lS.lf 1.05 fmoles
nM fmoles nM
B~MM (C:ontrol)
2U mg 0.3910.031 42.012.94 0.4110.029 14.010.98 fmoles
nM fmoles nM
2 mg 0.4110.035 40.013.20 0.37*0.030 14.810.99 fmoles
nM fmoles nM
U.2 mg 0.3710.029 43.013.14 0.3610.025 15.111.35 fmoles
nM fmoles nM
Saline (:ontrol0.3710.041 46.015.21 0.3910.047 14.211.35 fmoles
nM
Refers to
total oligo
administered
in four
equivalently
divided
doses over
a 48 hour
period.
Treatnxnts
and analyses
were perfornxd
as
described ignificance
in methods. was determined
S by repeated-measures
analysis
of variance
(ANOVA),
and Tukey=s
protected
t test.
N = 4-6 for
all groups.
' Significantlyfrom mismatch
different control-
and saline-treated
groups,
p<O.OOI
;
'*Signtficantiy
different
from mismatch
control-
and saline-treated
groups,
p<0.05.
Ezample 21: Dose-response Effect of Oligo I
Anti-sense oligo I (SEQ ID NO:1) was found to reduce the effect of adenosine
administration to
the animal in a dose-dependent manner over the dose range tested as shown in
Table 4 below.
Table 4: Dose-Response Effect to Anti-sense Oligo I
Total Dose PC 0 denosin
(mg) (m~ A~enosm~)
Anti-sense Oligo I
0.2 8.3217.2
2.0 14.017.2
20 19.5 t 0.34
A,MM2 oligo (control)
0.2 2.51 t 0.46
2.0 3.13 0.71
20 3.25 t 0.34
The above results were studied with the Student=s paired t test and found to
bestatistically
different, p~.05
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
59
The oligo I (SEQ. ID NO:1), an anti-adenosine A, receptor oligo, acts
specifically on the
adenosine A, receptor, but not on the adenosine Az receptors. These results
stem from the treatment of
rabbits with anti-sense oligo I (SEQ. ID NO.1) or mismatch control oligo (SEQ.
ID N0:1002; A,MM2)
as described in Example 9 above and in Nyce & Metzger ( 1997), supra (four
doses of 5 mg spaced 8 to
12 hours apart via nebulizer via endotracheal tube), bronchial smooth muscle
tissue excised and the
number of adenosine A, and adenosine AZ receptors determined as. reported in
Nyce & Metzger ( 1997),
supra.
Example 23: Specificity of Oligo I (SEQ. ID NO:1)
for Target Gene Product
Oligo I (SEQ. ID No:l) is specific for the adenosine A, receptor whereas its
mismatch controls
had no activity. Figure 1 depicts the results obtained from the cross-over
experiment described in
Example 10 above and in Nyce & Metzger (1997), supra. The two mismatch
controls (SEQ. ID
N0:1002 and SEQ. ID N0:1003) evidenced no effect on the PC50 Adenosine value.
On the contrary,
the administration of anti-sense oligo I (SEQ. ID NO:1) showed a seven-fold
increase in the PC50
Adenosine value. The results clearly indicate that the anti-sense oligo I
(SEQ. ID NO:1) reduces the
response (attenuates the sensitivity) to exogenously administered adenosine
when compared with a saline
control. The results provided in Table 2 above clearly establish that the
effect of the anti-sense oligo I is
dose dependent (see, column 3 of Table 1 ).
The Oligo I was also shown to be totally specific for the adenosine A,
receptor, (see, top 3 rows
of Table), inducing no activity at either the closely related adenosine AZ
receptor or the bradykinin BZ
receptor (see, lines 8-10 of Table 2 above).
In addition, the results shown in Table 2 establish that the anti-sense oligo
I (SEQ. ID NO:1)
decreases sensitivity to adenosine in a dose dependent manner, and that it
does this in an anti-sense
oligo-dependent manner since neither of two mismatch control oligonucleotides
(A,MM2; SEQ. ID
N0:1002 and A,MM3; SEQ. ID N0:1003) show any effect on PCso Adenosine values
or on attenuating
the number of adenosine A, receptors.
Example 24: Effect on Aeroallergen-induced
Bronchoconstriction & Inflammation
The Oligo I (SEQ. ID NO:1) was shown to significantly reduce the histamine-
induced effect in
the rabbit model when compared to .the mismatch oligos. The effect of the anti-
sense Oligo I (SEQ. ID
No:l) and the mismatch oligos (A,MM2, SEQ. ID N0:1002 and A,MM3, SEQ. ID
N0:1003) on
allergen-induced airway obstruction and bronchial hyperresponsiveness was
assessed in allergic rabbits.
The effect of the anti-sense oligo I (SEQ. ID NO:1) on allergen-induced airway
obstruction was
assessed. As calculated from the area under the plotted curve, the anti-sense
oligo I significantly
inhibited allergen-induced airway obstruction when compared with the
mismatched control (55%,
p<0.05; repeated measures ANOVA, and Tukey's t test).
A complete lack of effect was induced by the mismatch oligo A,MM2 (Control) on
allergen
induced airway obstruction.
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
The effect of the anti-sense oligo I (SEQ. ID NO:1) on allergen-induced BIIR
was determined
as above. As calculated from the PCso Histamine value , the anti-sense oligo I
(SEQ. ID NO:1)
significantly inhibited allergen-induced BHR in allergic rabbits when compared
to the mismatched
control (61 %, p<0.05; repeated measures ANOVA, Tukey's t test).
A complete lack of effect, of the A~MM mismatch control on allergen-induced BI-
IR was
observed.
The results indicated that anti-sense oligo I (SEQ. ID NO: 1) is effective to
protect against
aeroallergen-induced bronchoconstriction (house dust mite). In addition, the
anti-sense oligo I (SEQ. ID
NO:1) was also found to be a potent inhibitor of dust mite-induced bronchial
hyper responsiveness, as
shown by its effects upon histamine sensitivity which indicates anti-
inflammatory activity for anti-sense
oligo I (SEQ. ID NO:1).
Ezample 25: Anti-sense Oligo I is Free
of Deleterious Side Effects
The Oligo I (SEQ. ID NO:1) was shown to be free of side effects that might be
toxic to the
recipient. No changes in arterial blood pressure, cardiac output, stroke
volume, heart rate, total peripheral
resistance or heart contractility (dPdT) were observed following
administration of 2.0 or 20 mg oligo I
(SEQ. ID NO:1}. The addition, the results of the measurement of cardiac output
(CO), stroke volume
(SV), mean arterial pressure (MAP), heart rate (HR), total peripheral
resistance (TPR), and contractility
(dPdT) with a CardiomaxT"" apparatus (Columbus Instruments, Ohio) were
assessed.
These results evidenced that oligo I (SEQ. ID NO:1) has no detrimental effect
upon critical
cardiovascular parameters. More particularly, this oligo does not cause
hypotension. This finding is of
particular importance because other phosphorothioate anti-sense
oligonucleotides have been shown in
the past to induce hypotension in some model systems. Furthermore, the
adenosine A, receptor plays an
important role in sinoatrial conduction within the heart. Attenuation of the
adenosine A, receptor by anti-
sense oligo I (SEQ. ID NO:1) might be expected t result, therefore, in
deleterious extrapulmonary
activity in response to the downregulation of the receptor. This is not the
case. The anti-sense oligo I
(SEQ. ID NO:1) does not produce any deleterious intrapulmonary effects and
renders the administration
of the low doses of the present anti-sense oligo free of unexpected,
undesirable side effects.
This demonstrates that when oligo I (SEQ. ID NO:1) is administered directly to
the lung, it does
not reach the heart in significant quantities to cause deleterious effects.
This is in contrast to traditional
adenosine receptor antagonists like theophylline which do escape the lung and
can cause deleterious,
even life-threatening effects outside the lung.
Ezample 26: Long Lasting Effect of Oligo I
The Oligo I (SEQ. ID NO:1) evidenced a long lasting effect as evidenced by the
PCSp and
Resistance values obtained upon its administration prior to adenosine
challenge.
The duration of the effect was measured for with respect to the PCSp of
adenosine anti-sense
oligo I when administered in four equal doses of 5 mg each by means of a
nebulizer via an endotracheal
tube, as described above. The effect of the agent is significant over days 1
to 8 after administration.
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/1Z775
61
When the effect of the anti-sense oligo I (SEQ. ID NO:1) had disappeared, the
animals were
administered saline aerosols (controls), and the PC50 Adenosine values for all
animals were measured
again. Saline-treated animals showed base line PCSp adenosine values -(n=6).
The duration of the effect (with respect to Resistance) was measured for six
allergic rabbits
which were administered 20 mg of anti-sense oligo I (SEQ. ID NO: 1) as
described above, upon airway
resistance measured as also described above. The mean calculated duration of
effect was 8.3 days for
both PC50 adenosine (p<0.05) and resistance (p<0.05). These results show that
anti-sense oligo I (SEQ.
ID NO:1) has an extremely long duration of action, which is completely
unexpected.
Example 27: Anti-sense Oligo II
Anti-sense oligo II, targeted to a different region of the adenosine A,
receptor mRNA, was found
to be highly active against the adenosine A~-mediated effects. The experiment
measured the effect of the
administration of anti-sense oligo II (SEQ. ID N0:997) upon compliance and
resistance values when 20
mg anti-sense oligo II or saline (control) were administered to two groups of
allergic rabbits as described
above. Compliance and resistance values were measured following an
administration of adenosine or
saline as described above in Example 13. The effect of the anti-sense oligo of
the invention was
different from the control in a statistically significant manner, p<0.05 using
paired t-test; compliance;
p<0.01 for resistance.
The results showed that anti-sense oligo II (SEQ. ID N0:997), which targets
the adenosine A~
receptor, effectively maintains compliance and reduces resistance upon
adenosine challenge.
Example 28: Antisense Oligos III and IV
Oligos III (SEQ. ID N0:998) and IV (SEQ. ID N0:999) were shown to be in fact
specifically
targeted to the adenosine A3 receptor by their effect on reducing inflammation
and the number of
inflammatory cells present upon separate administration of 20 mg of the anti-
sense oligos III (SEQ. ID
N0:998) and IV (SEQ. ID N0:999) to allergic rabbits as described above. The
number of inflammatory
cells was determined in their bronchial lavage fluid 3 hours later by counting
at least 100 viable cells per
Iavage.
The effect of anti-sense oligos III (SEQ. ID N0:998) and IV (SEQ. ID N0:999)
upon
granulocytes, and upon total cells in bronchial lavage were assessed following
exposure to dust mite
allergen. The results showed that the anti-sense oligo IV (SEQ. ID N0:999) and
anti-sense oligo III
(SEQ. ID N0:998) are very potent anti-inflammatory agents in the asthmatic
lung following exposure to
dust mite allergen. As is known in the art, granulocytes, especially
eosinophils, are the primary
inflammatory cells of asthma, and the administration of anti-sense oligos III
(SEQ. ID N0:998) and IV
(SEQ. ID N0:999) reduced their numbers by 40% and 66%, respectively.
Furthermore, anti-sense oligos
IV (SEQ. ID N0:999) and III (SEQ. ID N0:998) also reduced the total number of
cells in the bronchial
lavage fluid by 40% and 80%, respectively. This is also an important indicator
of anti-inflammatory
activity by the present anti-adenosine A3 agents of the invention.
Inflammation is known to underlie
bronchial hyperresponsiveness and allergen-induced bronchoconstriction in
asthma. Both anti-sense
oligonucleotides III (SEQ. ID N0:998) and IV (SEQ. ID N0:999), which are
targeted to the adenosine
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
62
A3 receptor, are representative of an important new class of anti-inflammatory
agents which may be
designed to specifically target the lung receptors of each species.
Ezample 29: Anti-sense Oligo V
The anti-sense oligo V (SEQ. ID NO:1000) , targeted to the adenosine AZb
adenosine receptor
mltNA was shown to be highly effective at countering adenosine AZb-mediated
effects and at reducing
the number of adenosine AZb receptors present to less than half.
Example 30: Unexpected Superiority of Substituted
over Phosphodiester-residue Oligo I-DS
(SEQ. ID N0:1681)
Oligos I (SEQ. ID NO:1) and I-DS (SEQ. ID NO:1) were separately administered
to allergic
rabbits as described above, and the rabbits were then challenged with
adenosine. The phosphodiester
oligo I-DS (SEQ. ID NO:1) was statistically significantly less effective in
countering the effect of
adenosine whereas oligo I (SEQ. ID NO:1) showed high effectiveness, evidencing
a PC50 Adenosine of
20 mg.
Example 31: Anti-sense Oligo VI
For the present work, I designed an additional anti-sense phosphorothioate
oligo targeted to the
adenosine A, receptor (Oligo VI). This anti-sense oligo was designed for
therapy on a selected species as
described in the above patent application and is generally specific for that
species, unless the segment of
the adenosine receptor mltNA of other species elected happens to have a
similar sequence. The anti-
sense oligos were prepared as described below, and tested in vivo in a rabbit
model for
bronchoconstriction, inflammation and lung allergy, which have breathing
difficulties and impeded lung
airways, as is the case in ailments such as asthma, as described in the above-
identified application.
One additional oligo and its effect in a rabbit model was studied and the
results of the study are
reported and discussed below. The present oligo (anti-sense oligo VI) was
selected for this study to
complement the data on SEQ ID NO: 1 (Oligo I), which is anti-sense to the
adenosine A, receptor
mltNA provided in the above-identified patent application. This additional
oligo is identified as anti-
sense Oligo VI, and is targeted to a~different region of the adenosine A,
receptor mltNA than Oligo I.
The design and synthesis of this anti-sense oligo was performed in accordance
with the teaching,
particularly Example 1, of the above-identified patent application.
The anti-sense Oligo VI is a phosphorothioate designed to target the coding
region of the rabbit
adenosine A, receptor mltNA region +964 to +984 relative to the initiation
codon (start site). The Oligo
VI was prepared as described in the above-indicated application, and is 20
nucleotides long. The OligoVI
is directed to the adenosine A, receptor gene, and has the following sequence.
5'-CGC CGG CGG GTG CGG GCC GG3' (SEQ. ID N0:1004)
The phosphorothioate anti-sense Oligo VI having the sequence described in (5)
above, was
synthesized on an Applied Biosystems Model 396 Oligonucleotide Synthesizer,
and purified using
NENSORB chromatography (DuPont, DE). TETD (tetraethylthiuram disulfide) was
used as the
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
63
sulfurizing agent during the synthesis.
Eaample 32: Preparation of Allergic Rabbits
Neonatal New Zealand white Pastarella-free rabbits were immunized
intraperitoneally within 24
hours of birth with 0.5 ml of 3I2 antigen units/ml house dust mite (D.
farinae) extract (Berkeley
Biologicals, Berkeley, CA) mixed with 10% kaolin as previously described
(Metzger, W. J., in Late
Phase Allergic Reactions, Dorsch, W., Ed., CRC Handbook, pp 347-362, CRC
Press, Boca Raton, 1990;
Ali, S. Et al., Am. J. Resp. Crit. Care Med. 149: 908 (1994)).
The immunizations were repeated weekly for the first month and then bi-weekly
until the
animals were 4 months old. These rabbits preferentially produce allergen-
specific IgE antibody, typically
respond to aeroallergen challenge with both an early and late-phase asthmatic
response, and show
bronchial hyper responsiveness (BHR). Monthly intraperitoneal administration
of allergen (312 units
dust mite allergen, as above) continues to stimulate and maintain allergen-
specific IgE antibody and
BHR. At 4 months of age, sensitized rabbits were prepared for aerosol
administration as described by
Ali et al. (1994), supra.
Example 33: Adenosine Aerosol Preparation
An adenosine aerosol (20 mg/ml) was prepared, with an ultrasonic nebulizer
(Model 646,
DeVilbiss, Somerset, PA), which produced aerosol droplets, 80% of which were
smaller than S~m in
diameter. Equal volumes of the aerosols were administered directly to the
lungs via an intratracheal tube
to all three rabbits.
The animals were then administered the aerosolized adenosine and Day 1 pre-
treatment values
for sensitivity to adenosine were calculated as the dose of adenosine causing
a 50% loss of compliance
(PCSp Adenosine). The animals were then administered the aerosolized anti-
sense via the intratracheal
tube (5 mg/1.0 ml), for 2 minutes, twice daily for 2 days (total dose, 20 mg).
Post-treatment PC50 values
were recorded (post-treatment challenge) on the morning of the third day. The
results of these studies are
provided in (9) below.
Example 34: Anti-sense Oligo Formulation
Each one of anti-sense oligos were separately solubilized in an aqueous
solution and
administered as described for anti-sense oligo I in (e) above, in four 5 mg
aliquots (20 mg total dose) by
means of a nebulizer via endotracheal tube, as described above.
Example 35: Oligo VI Reduces Response to Adenosine
Challenge as Well or Better than Oligo I
Oligo VI was tested in three allergic rabbits of the characteristics and
readied as described in {7)
above and in the above-indicated patent application. Oligo VI targets a
section of the coding region of
the A, receptor which is different from Oligo I. Both these target sequences
were selected randomly from
many possible coding region target sequences.
The three rabbits were treated identically as previously indicated for Oligo
I. Briefly, S mg of
CA 02316994 2000-06-30
WO 99/63938 PGT/US99/12775
64
Oligo VI were nebulized to the rabbits twice per day at 8 hour intervals, for
two days. Thereafter, PC50
adenosine studies were performed on the morning of the third day and compared
to pre-treatment PC50
values. This protocol is described in more detail in Nyce and Metzger (Nyce &
Metzger, Nature 385:
721-725 (1997)). The results obtained for the three rabbits are shown in Table
5 below.
Table 5: PCgp Adenosine before & after
Aerosolized Adenosine Treatment
Treatment Time PCSp Adenosine
(mg)
Pre-treatment 3.0 t2.1
Post-treatment >20.0*
* maximum achievable dose due to adenosine insolubility in saline
All three animals treated with Oligo VI completely eliminated sensitivity to
adenosine up to the
measurable level of the agent shown in Table 1 above. That is, the
administration of the Oligo VI
abrogated the adenosine-induced bronchoconstriction in the three allergic
rabbits. The actual efficacy of
Oligo VI is, therefore, greater than could be measured in the experimental
system used.
By comparing with the previously submitted results for the Oligo I, it may be
seen that the Oligo
VI was found to be as effective, or more, than Oligo I.
Egamnle 36: Determination of Surfactant Depletion When
A1 Receptors Are Expressed in Lung
This example shows the effect on the oligos of the invention on the level of
lung phospholipid in
an animal model for hypersensitivity to the adenosine A, receptor. The
leftmost column of Figure 4
shows the level of phospholipid present in the untreated allergic rabbit. When
the adenosine A~ receptors
in allergic rabbits were stimulated by aerosolized adenosine, there was a
significant depletion of lung
surfactant. See middle column in Figure 4. The administration of an an anti-
sense oligonucleotide
which has been shown to block adenosine A, receptor expression (SEQ. ID NO:1).
See, Nyce, JW and
Metzger, WJ, Nature (1997). When oligo I (SEQ. ID NO:1) was administered to
the allergic rabbit prior
to the administration of adenosine, this adenosine-A, receptor-induced
surfactant depletion was
completely prevented. See rightmost column in Figure 4. This indicates that
attenuation of the
adenosine A, receptor by administration of the present anti-sense
oligonucleotides establishes normal
surfactant secretion. This is applicable to the prevention of RDS by
administration during gestation of
the composition of the invention comprising either a down-regulating oligo for
the A, receptor or any
agonist capable of stimulating the A~ receptor. This would be very beneficial
because currently
available surfactant preparations used in the treatment of RDS are either
incomplete or derived from
animal sources.
Example 37:
Rabbits were administered 5 mg oligo I (SEQ. m NO:1; EPI 2010) or saline
(control) by
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
nebulizer twice a day for two days and were then challenged with bacterial
endotoxin administered by
ear vein injection. Neutrophils, a key inflammatory cell in ARDS, were then
quantitated (rl = 3). The
leftmost column represents a saline control (saline administered to the rabbit
- same volume as
treatment). The center column represents the high number of neutrophils
elicited by treatment with
endotoxin alone. The rightmost column shows a significant (statistically)
decrease in the number of
neutrophils produced upon treatment with the oligo I. The data are shown in
Figure 5. The results of the
experimental test show a clear reduction in the number of neutrophils in the
bronchial lavage fluid
obtained from the oligo I treated animals.
Example 38:
As in example 37, rabbits were administered 5 mg oligo I (SEQ. ID NO:1; EPI
2010) or saline
(control) by nebulizer twice a day ~ for two days and were then challenged
with bacterial endotoxin
administered by ear vein injection. The left-hand column represents the edema
produced by bacterial
endotoxin, and the right-hand column shows the prevention or alleviation of
edema brought about by the
oligo of the invention. Thus, the data show that oligo I (EPI 2010) reduced
the lung edema caused by
bacterial endotoxin.
Ezample 39:
Rabbits were administered 5 mg oligo I (SEQ. ID NO:1; EPI 2010) or saline
(control) by
nebulizer twice a day for two days, and were then challenged with bacterial
endotoxin administered by
ear vein injection. The total number of cells, an indication of inflammation,
was then quantitated in
bronchial lavage fluid obtained from each animal (r) = 3). The results show a
dramatic increase in the
total number of cells upon challenge with bacterial endotoxin (middle bar)
when compared to saline
(leftmost bar). Finally, the administration of 5 mg of oligo I shows a
pronounced reduction in the total
number of cells elicited by the endotoxin.
Example 40: Conclusions
The work described and results discussed in the examples clearly show that all
anti-sense
oligonucleotides designed in accordance with the teachings of this patent were
found to be highly
effective at countering or reducing effects mediated by the receptors they are
targeted to. That is, each
and all of the two anti-sense oligos targeting an adenosine A, receptor mRNA,
1 anti-sense oligo
targeting an adenosine AZb receptor mRNA, and the 2 anti-sense oligos
targeting an A3 receptor mRNA
were shown capable of countering the effect of exogenously administered
adenosine which is mediated
by the specific receptor they are targeted to.
The activity of the anti-sense oligos of this invention, moreover, is specific
to the target and
substitutively fails to inhibit another target. In addition, the results
presented also show that the
administration of the present agents results in extremely low or non-existent
deleterious side effects or
toxicity.
This represents 100% success in providing agents that are highly effective and
specific in the
treatment of bronchoconstriction and/or inflammation. This invention is
broadly applicable in the same
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/I2775
66
manner to all genes) and corresponding mRNAs encoding proteins involved in or
associated with
airway diseases.
A comparison of the phosphodiester and a version of the same oligonucleotide
wherein the
phosphodiester bonds are substituted with phosphorothioate bonds evidenced an
unexpected superiority
for the phosphothiorate oligonucleotide over the phosphodiester anti-sense
oligo.
The foregoing examples are illustrative of the present invention, but are not
to be construed as
limiting thereof. The invention is furter defined by the following claims,
with equivalents of the claims
to be included therein.
CA 02316994 2000-06-30
WO 99/63938 a,, PCT/ITS99/12775
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Nyce, Jonathan W. and Hill, Jeffrey
(ii) TITLE OF INVENTION:
(iii) NUMBER OF SEQUENCES: 1004
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: ARTER & HADDEN
(B) STREET: 725 South Figueroa St.
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: USA '
(F) ZIP: 900071
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 8-JUN-1999
(C) CLASSIFICATION:
(A) APPLICATION NUMBER: US 60/088,657
(B) FILING DATE: 9-JUN-1998
(C) CLASSIFICATION:
(A) APPLICATION NUMBER: US 60/088,501
(B) FILING DATE: 8-JUN-1998
(C) CLASSIFICATION:
(A) APPLICATION NUMBER: US 09/093,972
(B) FILING DATE: 9-JUN-1998
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Amzel, Viviana
(B) REGISTRATION NUMBER: 30,930
(C) REFERENCE/DOCKET NUMBER: EPI-179
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 213-430-3520
(B) TELEFAX: 213-617-9255
(C) TELEX:
(2) INFORMATION FOR SEQ ID N0:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:1:
GATGGAGGGC GGCATGGCGG G 21
(2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
CA 02316994 2000-06-30
WO 99/63938 2 PCT/US99/12775
GTAGCAGGCG GGGATGGGGG C 21
(2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ ID N0:3:
GTTGTTGGGC ATCTTGCC lg
(2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA'(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
GTACTTGCGG ATCTAGGC lg
(2) INFORMATION FOR SEQ ID N0:5:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:
GTGGGCCTAG CTCTCGCC lg
(2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
GTCGGGGTAC CTGTCGGC 18
(2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAGGCTGGG51
C
(2) INFORMATION FOR SEQ ID N0:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAGGCTGGG50
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:9:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG ACAGGCTGG 49
CATGGCGGGC
(2) INFORMATION FOR SEQ ID N0:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
NO:10:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG ACAGGCTG 48
CATGGCGGGC
(2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:11:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG ACAGGCT 47
CATGGCGGGC
(2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:12:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG ACAGGC 46
CATGGCGGGC
(2) INFORMATION FOR SEQ ID N0:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 95 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:13:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG ACAGG 45
CATGGCGGGC
(2) INFORMATION FOR SEQ ID 10:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:19:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG ACAG 94
CATGGCGGGC
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:15-:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACA 43
(2) INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:16:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGGCGGGC AC 42
(2) INFORMATION FOR SEQ ID N0:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGGCGGGC A 41
(2) INFORMATION FOR SEQ ID N0:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 90 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:18:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGGCGGGC 40
(2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGGCGGG 39
(2) INFORMATION FOR SEQ ID N0:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA.(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:20:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGGCGG 38
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:21:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGGCG 37
(2) INFORMATION FOR SEQ ID N0:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:22:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGGC 36
(2) INFORMATION FOR SEQ ID N0:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATGG 35
(2) INFORMATION FOR SEQ ID N0:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:24:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CATG 39
(2) INFORMATION FOR SEQ ID N0:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ ID N0:25:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CAT 33
(2) INFORMATION FOR SEQ ID N0:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:26:
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG CA 32
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(2} INFORMATION FOR SEQ ID N0:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:27:
ID
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG 31
C
(2) INFORMATION FOR SEQ ID N0:28:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:28:
ID
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG 30
(2) INFORMATION FOR SEQ ID N0:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:29:
ID
GGCGGCCTGG AAAGCTGAGA TGGAGGGCG 2g
(2) INFORMATION FOR SEQ ID N0:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:30:
ID
GGCGGCCTGG AAAGCTGAGA TGGAGGGC 2g
(2} INFORMATION FOR SEQ ID N0:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:,single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:31:
ID
GGCGGCCTGG AAAGCTGAGA TGGAGGG 27
(2) INFORMATION FOR SEQ ID N0:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:32:
ID
GGCGGCCTGG AAAGCTGAGA TGGAGG 26
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:33:
ID
GGCGGCCTGG AAAGCTGAGA TGGAG 25
(2) INFORMATION FOR SEQ ID N0:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:34:
ID
GGCGGCCTGG AAAGCTGAGA TGGA 24
(2) INFORMATION FOR SEQ ID N0:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:35:
ID
GGCGGCCTGG AAAGCTGAGA TGG 23
(2) INFORMATION FOR SEQ ID N0:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:36:
ID
GGCGGCCTGG AAAGCTGAGA TG 22
(2) INFORMATION FOR SEQ ID N0:37:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:37:
ID
GGCGGCCTGG AAAGCTGAGA T 21
(2) INFORMATION FOR SEQ ID N0:38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: ANA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:38:
ID
GGCGGCCTGG AAAGCTGAGA 20
CA 02316994 2000-06-30
WO 99/63938 PCT/I1S99/12775
(2) INFORMATION FOR SEQ ID N0:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:39:
ID
GGCGGCCTGG AAAGCTGAG 1g
(2) INFORMATION FOR SEQ ID N0:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:40:
ID
GGCGGCCTGG AAAGCTGA 18
(2) INFORMATION FOR SEQ ID N0:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:41:
ID
GGCGGCCTGG AAAGCTG 17
(2) INFORMATION FOR SEQ ID N0:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:92:
ID
GGCGGCCTGG AAAGCT 16
(2) INFORMATION FOR SEQ ID N0:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:43:
ID
GGCGGCCTGG AAAGC 15
(2) INFORMATION FOR SEQ ID N0:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:44:
ID
GGCGGCCTGG AAAG ~ 14
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:45:
ID
GGCGGCCTGG AAA 13
(2) INFORMATION FOR SEQ ID N0:46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:46:
ID
GGCGGCCTGG AA 12
(2j INFORMATION FOR SEQ ID N0:47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:47:
ID
GGCGGCCTGG A 11
(2) INFORMATION FOR SEQ ID N0:48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:48:
ID
GGCGGCCTGG 10
(2) INFORMATION FOR SEQ ID N0:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:49:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC 50
ATGGCGGGCA CAGGCTGGGC
(2) INFORMATION FOR SEQ ID N0:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:50:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC 49
ATGGCGGGCA CAGGCTGGG
CA 02316994 2000-06-30
WO 99/63938 PC'T/US99/12775
(2) INFORMATION FOR SEQ ID N0:51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:51:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC CAGGCTGG 48
ATGGCGGGCA
(2} INFORMATION FOR SEQ ID N0:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 97 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:52:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC CAGGCTG 47
ATGGCGGGCA
(2) INFORMATION FOR SEQ ID N0:53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:53:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC CAGGCT 46
ATGGCGGGCA
(2) INFORMATION FOR SEQ ID N0:54:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:54:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC CAGGC 45
ATGGCGGGCA
(2) INFORMATION FOR SEQ ID N0:55:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:55:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC CAGG 94
ATGGCGGGCA
(2} INFORMATION FOR SEQ ID N0:56:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 43 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:56:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC CAG 43
ATGGCGGGCA
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:57:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic~acid
(C) SThtANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:57:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA CA 42
(2) INFORMATION FOR SEQ ID N0:58:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 91 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:58:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA C 41
(2) INFORMATION FOR SEQ ID N0:59:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:59:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA 40
(2) INFORMATION FOR SEQ ID N0:60:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:60:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC ATGGCGGGC 39
(2) INFORMATION FOR SEQ ID N0:61:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:61:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC ATGGCGGG 38
{2) INFORMATION FOR SEQ ID N0:62:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:62:
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC ATGGCGG 37
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
rL
(2) INFORMATION FOR SEQ ID N0:63:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:63:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC 36
ATGGCG
(2) INFORMATION FOR SEQ ID N0:64:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:64:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC 35
ATGGC
(2) INFORMATION FOR SEQ ID N0:65:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:65:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC 34
ATGG
(2) INFORMATION FOR SEQ ID N0:66:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:66:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC 33
ATG
(2} INFORMATION FOR SEQ ID N0:67:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:67:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC 32
AT
(2) INFORMATION FOR SEQ ID N0:68:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:68:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC 31
A
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:69:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:69:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC 30
(2) INFORMATION FOR SEQ ID N0:70:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTIQN: SEQ N0:70:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGG 29
(2) INFORMATION FOR SEQ ID N0:71:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:71:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCG 28
(2) INFORMATION FOR SEQ ID N0:72:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:72:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGC 27
(2) INFORMATION FOR SEQ ID N0:73:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:73:
GCGGCCTGGA AAGCTGAGAT GGAGGG 26
(2) INFORMATION FOR SEQ ID N0:74:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:74:
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/LJS99/12775
GCGGCCTGGA AAGCTGAGAT GGAGG 25
(2) INFORMATION FOR SEQ ID N0:75:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:75:
ID
GCGGCCTGGA AAGCTGAGAT GGAG 24
(2) INFORMATION FOR SEQ ID N0:75:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:76:
ID
GCGGCCTGGA AAGCTGAGAT GGA 23
(2) INFORMATION FOR SEQ ID N0:77:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:77:
ID
GCGGCCTGGA AAGCTGAGAT GG 22
(2) INFORMATION FOR SEQ ID N0:78:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:78:
ID
GCGGCCTGGA AAGCTGAGAT G 21
(2) INFORMATION FOR SEQ ID N0:79:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:79:
ID
GCGGCCTGGA AAGCTGAGAT 20
(2) INFORMATION FOR SEQ ID N0:80:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
CA 02316994 2000-06-30
WO 99/63938 PCT/CTS99/12775
(ii) MOLECULE TYPE: DNA~(genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:80:
ID
GCGGCCTGGA AAGCTGAGA lg
(2) INFORMATION FOR SEQ ID N0:81:
(i.} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:81:
ID
GCGGCCTGGA AAGCTGAG lg
(2) INFORMATION FOR SEQ ID N0:82:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:82:
ID
GCGGCCTGGA AAGCTGA 17
(2) INFORMATION FOR SEQ ID N0:83:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: I6 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:83:
ID
GCGGCCTGGA AAGCTG 16
(2) INFORMATION FOR SEQ ID N0:84:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:84:
ID
GCGGCCTGGA AAGCT 15
(2) INFORMATION FOR SEQ ID N0:85:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA.(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:85:
ID
GCGGCCTGGA AAGC 14
(2) INFORMATION FOR SEQ ID N0:86:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:86:
ID
GCGGCCTGGA AAG 13
(2) INFORMATION FOR SEQ ID N0:87:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:87:
ID
GCGGCCTGGA AA 12
(2) INFORMATION FOR SEQ ID N0:88:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:88:
ID
GCGGCCTGGA A 11
(2) INFORMATION FOR SEQ ID N0:89:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B} TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:89:
ID
GCGGCCTGGA 10
(2) INFORMATION FOR SEQ ID N0:90:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:90:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA 49
TGGCGGGCAC AGGCTGGGC
(2) INFORMATION FOR SEQ ID N0:91:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:91:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA 48
TGGCGGGCAC AGGCTGGG
(2} INFORMATION FOR SEQ ID N0:92:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
CA 02316994 2000-06-30
WO 99/63938 1.1 PGT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:92:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA AGGCTGG 47
TGGCGGGCAC
(2) INFORMATION FOR SEQ ID N0:93:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:93:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA AGGCTG 46
TGGCGGGCAC
(2) INFORMATION FOR SEQ ID N0:99:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 95 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:94:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA AGGCT 45
TGGCGGGCAC
(2) INFORMATION FOR SEQ ID N0:95:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ ID
N0:95:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA AGGC 44
TGGCGGGCAC
(2) INFORMATION FOR SEQ ID N0:96:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 43 bade pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:96:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA AGG 43
TGGCGGGCAC
(2) INFORMATION FOR SEQ ID N0:97:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID
N0:97:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA AG 42
TGGCGGGCAC
(2) INFORMATION FOR SEQ ID N0:98:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:98:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA TGGCGGGCAC A 41
(2) INFORMATION FOR SEQ ID N0:99:
(iy SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(Cy STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:99:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA TGGCGGGCAC 40
(2) INFORMATION FOR SEQ ID N0:100:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA TGGCGGGCA 39
(2) INFORMATION FOR SEQ ID N0:101:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(Dy TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:101:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA TGGCGGGC 38
(2) INFORMATION FOR SEQ ID N0:102:
(i) SEQUENCE CHARACTERISTICS:
(Ay LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:102:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA TGGCGGG 37
{2) INFORMATION FOR SEQ ID N0:103:
(iy SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:103:
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA TGGCGG 36
(2) INFORMATION FOR SEQ ID N0:104:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:104:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA 35
TGGCG
(2) INFORMATION FOR SEQ ID N0:105:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:105:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA 34
TGGC
(2) INFORMATION FOR SEQ ID N0:106:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:106:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA 33
TGG
(2) INFORMATION FOR SEQ ID ~I0:107:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:107:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA 32
TG
(2) INFORMATION FOR SEQ ID N0:108:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:108:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA 31
T
(2) INFORMATION FOR SEQ ID N0:109:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:109:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA 30
(2) INFORMATION FOR SEQ ID NO:110:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:110:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCGGC 29
(2) INFORMATION FOR SEQ ID N0:111:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ NO:111:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCGG 2g
(2) INFORMATION FOR SEQ ID N0:112:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:112:
ID
CGGCCTGGAA AGCTGAGATG GAGGGCG 27
(2) INFORMATION FOR SEQ ID N0:113:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:113:
ID
CGGCCTGGAA AGCTGAGATG GAGGGC 26
(2) INFORMATION FOR SEQ ID N0:114:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:114:
ID
CGGCCTGGAA AGCTGAGATG GAGGG 25
(2) INFORMATION FOR SEQ ID N0:115:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:115:
ID
CGGCCTGGAA AGCTGAGATG GAGG 24
(2) INFORMATION FOR SEQ ID N0:116:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:116:
ID
CGGCCTGGAA AGCTGAGATG GAG 23
(2) INFORMATION FOR SEQ ID N0:117:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:117:
ID
CGGCCTGGAA AGCTGAGATG GA 22
(2) INFORMATION FOR SEQ ID N0:118:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:118:
ID
CGGCCTGGAA AGCTGAGATG G 21
(2} INFORMATION FOR SEQ ID N0:119:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:119:
ID
CGGCCTGGAA AGCTGAGATG 20
(2} INFORMATION FOR SEQ ID N0:120:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:120:
ID
CGGCCTGGAA AGCTGAGAT 1g
(2) INFORMATION FOR SEQ ID N0:121:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:121:
ID
CGGCCTGGAA AGCTGAGA lg
(2) INFORMATION FOR SEQ ID N0:122:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
CA 02316994 2000-06-30
WO 99/63938 ~Z PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:122:
ID
CGGCCTGGAA AGCTGAG 17
(2) INFORMATION FOR SEQ ID N0:123:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:123:
ID
CGGCCTGGAA AGCTGA 16
(2) INFORMATION FOR SEQ ID N0:124:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:124:
ID
CGGCCTGGAA AGCTG 15
(2) INFORMATION FOR SEQ ID N0:125:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:125:
ID
CGGCCTGGAA AGCT 14
(2) INFORMATION FOR SEQ ID N0:126:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:126:
ID
CGGCCTGGAA AGC 13
(2) INFORMATION FOR SEQ ID N0:127:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic~acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:127:
ID
CGGCCTGGAA AG 12
(2) INFORMATION FOR SEQ ID N0:128:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
CA 02316994 2000-06-30
WO 99/63938 ~~ PCT/IJS99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:128:
CGGCCTGGAA A 11
(2) INFORMATION FOR SEQ ID N0:129:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:129:
CGGCCTGGAA 10
(2) INFORMATION FOR SEQ ID N0:130:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4B base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:130:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCTGGGC48
(2) INFORMATION FOR SEQ ID N0:131:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:131:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCTGGG97
(2) INFORMATION FOR SEQ ID N0:132:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 96 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:132:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCTGG 46
(2} INFORMATION FOR SEQ ID N0:133:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ ID N0:133:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCTG 45
(2) INFORMATION FOR SEQ ID N0:134:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 base pairs
(B) TYPE: nucleic acid
CA 02316994 2000-06-30
WO 99/63938 ~ ~ PCT/US99/12775
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:134:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCACA 44
GGCT
(2) INFORMATION FOR SEQ ID N0:135:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
{C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:135:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCACA 43
GGC
(2) INFORMATION FOR SEQ ID N0:136:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:136:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCACA 42
GG
(2) INFORMATION FOR SEQ ID N0:137:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:137:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCACA 41
G
{2) INFORMATION FOR SEQ ID N0:138:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:138:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCACA 40
(2) INFORMATION FOR SEQ ID N0:139:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:139:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCAC 39
(2) INFORMATION FOR SEQ ID N0:140:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/1Z775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:140:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCA 38
(2) INFORMATION FOR SEQ ID N0:141:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:141:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGC 37
(2) INFORMATION FOR SEQ ID N0:142:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ ID N0:142:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGG 36
(2) INFORMATION FOR SEQ ID N0:143:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:143:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGG 35
(2) INFORMATION FOR SEQ ID N0:149:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:144:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCG 3q
(2) INFORMATION FOR SEQ ID N0:145:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ ID N0:145:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGC 33
(2) INFORMATION FOR SEQ ID N0:146:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(B) TYPE: nucleic_acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:146:
ID
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT 32
GG
(2) INFORMATION FOR SEQ ID N0:197:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:147:
ID
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT 31
G
(2) INFORMATION FOR SEQ ID N0:148:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:148:
ID
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT 30
(2) INFORMATION FOR SEQ ID N0:199:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:149:
ID
GGCCTGGAAA GCTGAGATGG AGGGCGGCA 29
(2) INFORMATION FOR SEQ ID N0:150:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:150:
ID
GGCCTGGAAA GCTGAGATGG AGGGCGGC 28
(2) INFORMATION FOR SEQ ID N0:151:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:151:
ID
GGCCTGGAAA GCTGAGATGG AGGGCGG 27
(2) INFORMATION FOR SEQ ID N0:152:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
CA 02316994 2000-06-30
WO 99/63938 .~ PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:152:
ID
GGCCTGGAAA GCTGAGATGG AGGGCG 26
(2) INFORMATION FOR SEQ ID N0:153:
(ij SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:153:
ID
GGCCTGGAAA GCTGAGATGG AGGGC 25
(2) INFORMATION FOR SEQ ID N0:159:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:154:
ID
GGCCTGGAAA GCTGAGATGG AGGG 2q
(2) INFORMATION FOR SEQ ID N0:155:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:155:
ID
GGCCTGGAAA GCTGAGATGG AGG 23
(2) INFORMATION FOR SEQ ID N0:156:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:156:
ID
GGCCTGGAAA GCTGAGATGG AG 22
(2} INFORMATION FOR SEQ ID N0:157:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:157:
ID
GGCCTGGAAA GCTGAGATGG A 21
(2) INFORMATION FOR SEQ ID N0:158:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
CA 02316994 2000-06-30
WO 99/63938 ZQ PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:158:
ID
GGCCTGGAAA GCTGAGATGG 20
(2) INFORMATION FOR SEQ ID N0:159:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:159:
ID
GGCCTGGAAA GCTGAGATG ~ lg
(2) INFORMATION FOR SEQ ID N0:160:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:160:
ID
GGCCTGGAAA GCTGAGAT lg
(2) INFORMATION FOR SEQ ID N0:161:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:161:
ID
GGCCTGGAAA GCTGAGA 17
(2) INFORMATION FOR SEQ ID N0:162:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
~
(C) STRANDEDNESS:
single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:162:
ID
GGCCTGGAAA GCTGAG 16
(2) INFORMATION FOR SEQ ID N0:163:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:163:
ID
GGCCTGGAAA GCTGA 15
(2) INFORMATION FOR SEQ ID N0:164:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:164:
ID
GGCCTGGAAA GCTG 14
(2) INFORMATION FOR SEQ ID N0:165:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:165:
ID
GGCCTGGAAA GCT 13
(2) INFORMATION FOR SEQ ID N0:166:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:166:
ID
GGCCTGGAAA GC 12
(2) INFORMATION FOR SEQ ID N0:167:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:167:
ID
GGCCTGGAAA G 11
(2) INFORMATION FOR SEQ ID N0:168:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:168:
ID
GGCCTGGAAA 10
(2) INFORMATION FOR SEQ ID N0:169:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:169:
ID
GCCTGGAAAG CTGAGATGGA GGGCGGCATG 47
GCGGGCACAG GCTGGGC
(2) INFORMATION FOR SEQ ID N0:170:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 46 base pairs
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:170:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGCACAG GCTGGG 46
(2) INFORMATION FOR SEQ ID N0:171:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:171:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGCACAG GCTGG 45
(2) INFORMATION FOR SEQ ID N0:172:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:172:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGCACAG GCTG 44
(2) INFORMATION FOR SEQ ID N0:173:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
.
(B) TYPE: nucleic
acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:173:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGCACAG GCT 43
(2) INFORMATIONvFOR SEQ ID N0:174:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:174:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGCACAG GC 42
(2) INFORMATION FOR SEQ ID N0:175:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA.(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:175:
GCCTGGAAAG CTGAGATGGA GGGCG6CATG GCGGGCACAG G 41
(2) INFORMATION FOR SEQ ID N0:176:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/U599/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:176:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGCACAG 40
(2) INFORMATION FOR SEQ ID N0:177:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:'single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:177:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGCACA 39
(2) INFORMATION FOR SEQ ID N0:178:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:178:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGCAC 38
(2) INFORMATION FOR SEQ ID N0:179:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:179:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGCA 37
(2) INFORMATION FOR SEQ ID N0:180:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:180:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGC 36
(2) INFORMATION FOR SEQ ID N0:181:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:181:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGG 35
(2) INFORMATION FOR SEQ ID N0:182:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
CA 02316994 2000-06-30
WO 99/63938 PGT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:182:
ID
GCCTGGAAAG CTGAGATGGA GGGCGGCATG 34
GCGG
(2) INFORMATION FOR SEQ ID N0:183:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:183:
ID
GCCTGGAAAG CTGAGATGGA GGGCGGCATG 33
GCG
(2) INFORMATION FOR SEQ ID N0:184:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:184:
ID
GCCTGGAAAG CTGAGATGGA GGGCGGCATG 32
GC
(2) INFORMATION FOR SEQ ID N0:185:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:185:
ID
GCCTGGAAAG CTGAGATGGA GGGCGGCATG 31
G
(2) INFORMATION FOR SEQ ID N0:186:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA.(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:186:
ID
GCCTGGAAAG CTGAGATGGA GGGCGGCATG 30
(2) INFORMATION FOR SEQ ID N0:187:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:187:
ID
GCCTGGAAAG CTGAGATGGA GGGCGGCAT 29
(2) INFORMATION FOR SEQ ID N0:188:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
33
(8) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:18B:
ID
GCCTGGAAAG CTGAGATGGA GGGCGGCA 2g
(2) INFORMATION FOR SEQ ID N0:189:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:189:
ID
GCCTGGAAAG CTGAGATGGA GGGCGGC 27
(2) INFORMATION FOR SEQ ID N0:190:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:190:
ID
GCCTGGAAAG CTGAGATGGA GGGCGG 26
(2) INFORMATION FOR SEQ ID N0:191:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:191:
ID
GCCTGGAAAG CTGAGATGGA GGGCG 25
(2) INFORMATION FOR SEQ ID N0:192:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:192:
ID
GCCTGGAAAG CTGAGATGGA GGGC 24
(2) INFORMATION FOR SEQ ID N0:193:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE:. nucleic~acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:193:
ID
GCCTGGAAAG CTGAGATGGA GGG 23
(2) INFORMATION FOR SEQ ID N0:194:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
{B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:194:
ID
GCCTGGAAAG CTGAGATGGA GG 22
(2) INFORMATION FOR SEQ ID N0:195:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:195:
ID
GCCTGGAAAG CTGAGATGGA G 21
(2} INFORMATION FOR SEQ ID N0:196:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:196:
ID
GCCTGGAAAG CTGAGATGGA 20
(2} INFORMATION FOR SEQ ID N0:197:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:197:
ID
GCCTGGAAAG CTGAGATGG lg
(2} INFORMATION FOR SEQ ID N0:198:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:198:
ID
GCCTGGAAAG CTGAGATG lg
(2) INFORMATION FOR SEQ ID N0:199:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:199:
ID
GCCTGGAAAG CTGAGAT 17
(2) INFORMATION FOR SEQ ID N0:200:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:200:
ID
GCCTGGAAAG CTGAGA 16
(2) INFORMATION FOR SEQ ID N0:201:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:201:
ID
GCCTGGAAAG CTGAG 15
(2) INFORMATION FOR SEQ ID N0:202:
(i} SEQUENCE CHARACTERISTICS:
(A} LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:202:
ID
GCCTGGAAAG CTGA 14
(2) INFORMATION FOR SEQ ID N0:203:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:203:
ID
GCCTGGAAAG CTG 13
(2) INFORMATION FOR SEQ ID N0:204:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:204:
ID
GCCTGGAAAG CT 12
(2) INFORMATION FOR SEQ ID N0:205:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:205:
ID
GCCTGGAAAG C 11
(2) INFORMATION FOR SEQ ID N0:206:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
3~
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:206:
GCCTGGAAAG 10
(2) INFORMATION FOR SEQ ID N0:207:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:207:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCACAGG 46
CTGGGC
(2) INFORMATION FOR SEQ ID N0:208:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 95 base pairs
(B) TYPE: nucleic acid
~
(C) STRANDEDNESS:
single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:208:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCACAGG 45
CTGGG
(2) INFORMATION FOR SEQ ID N0:209:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(iiy MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:209:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCACAGG 44
CTGG
(2) INFORMATION FOR SEQ ID N0:210:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:210:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCACAGG 43
CTG
(2) INFORMATION FOR SEQ ID N0:211:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:211:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCACAGG 42
CT
(2) INFORMATION FOR SEQ ID N0:212:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
~
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
~
(ii) MOLECULE TYPE: DNA
(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:212:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCACAGG 41
C
(2) INFORMATION FOR SEQ ID N0:213:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:213:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCACAGG 40
(2) INFORMATION FOR SEQ ID N0:214:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:214:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCACAG 39
(2) INFORMATION FOR SEQ ID N0:215:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3B base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:215:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCACA 38
(2) INFORMATION FOR SEQ ID N0:216:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ ID N0:216:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCAC 37
(2) INFORMATION FOR SEQ ID N0:217:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:217:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCA 36
(2) INFORMATION FOR SEQ ID N0:218:
(i) SEQUENCE CHARACTERISTICS:
CA 02316994 2000-06-30
WO 99/63938 ~~ PCT/US99/12775
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:218:
ID
CCTGGAAAGC TGAGATGGAG GGCGGCATGG 35
CGGGC
(2) INFORMATION FOR SEQ ID N0:219:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:219:
ID
CCTGGAAAGC TGAGATGGAG GGCGGCATGG 34
CGGG
(2) INFORMATION FOR SEQ ID N0:220:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:220:
ID
CCTGGAAAGC TGAGATGGAG GGCGGCATGG 33
CGG
(2) INFORMATION FOR SEQ ID N0:221:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:221:
ID
CCTGGAAAGC TGAGATGGAG GGCGGCATGG 32
CG
(2) INFORMATION FOR SEQ ID N0:222:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:222:
ID
CCTGGAAAGC TGAGATGGAG GGCGGCATGG 31
C
(2) INFORMATION FOR SEQ ID N0:223:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:223:
ID
CCTGGAAAGC TGAGATGGAG GGCGGCATGG 30
CA 02316994 2000-06-30
WO 99/63938 ~~ PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:229:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:229:
ID
CCTGGAAAGC TGAGATGGAG GGCGGCATG 29
(2) INFORMATION FOR SEQ ID N0:225:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:225:
ID
CCTGGAAAGC TGAGATGGAG GGCGGCAT 2g
(2) INFORMATION FOR SEQ ID N0:226:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:226:
ID
CCTGGAAAGC TGAGATGGAG GGCGGCA 27
(2) INFORMATION FOR SEQ ID N0:227:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:227:
ID
CCTGGAAAGC TGAGATGGAG GGCGGC 26
(2) INFORMATION FOR SEQ ID N0:228:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:228:
ID
CCTGGAAAGC TGAGATGGAG GGCGG 25
(2) INFORMATION FOR SEQ ID N0:229:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:229:
ID
CCTGGAAAGC TGAGATGGAG GGCG 24
CA 02316994 2000-06-30
WO 99/63938 ~ PG"T/US99/12775
(2) INFORMATION FOR SEQ ID N0:230:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0.:230:
ID
CCTGGAAAGC TGAGATGGAG GGC 23
(2) INFORMATION FOR SEQ ID N0:231:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:231:
ID
CCTGGAAAGC TGAGATGGAG GG 22
(2) INFORMATION FOR SEQ ID N0:232:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:'single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:232:
ID
CCTGGAAAGC TGAGATGGAG G 21
(2) INFORMATION FOR SEQ ID N0:233:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:233:
ID
CCTGGAAAGC TGAGATGGAG 20
(2) INFORMATION FOR SEQ ID N0:234:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:234:
ID
CCTGGAAAGC TGAGATGGA , 19
(2) INFORMATION FOR SEQ ID N0:235:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:235:
ID
CCTGGAAAGC TGAGATGG lg
CA 02316994 2000-06-30
WO 99/63938 t PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:236:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:
single
,
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:236:
ID
CCTGGAAAGC TGAGATG 17
(2} INFORMATION FOR SEQ ID N0:237:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:237:
ID
CCTGGAAAGC TGAGAT 16
(2) INFORMATION FOR SEQ ID N0:238:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:238:
ID
CCTGGAAAGC TGAGA 15
{2) INFORMATION FOR SEQ ID N0:239:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
{B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:239:
ID
CCTGGAAAGC TGAG 14
(2) INFORMATION FOR SEQ ID N0:240:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:240:
ID
CCTGGAAAGC TGA 13
(2) INFORMATION FOR SEQ ID N0:241:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/LTS99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:291:
ID
CCTGGAAAGC TG 12
(2) INFORMATION FOR SEQ ID N0:242:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:242:
ID
CCTGGAAAGC T 11
(2) INFORMATION FOR SEQ ID N0:243:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:243:
ID
CCTGGAAAGC 10
(2) INFORMATION FOR SEQ ID N0:244:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:294:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGGC 45
GGGCACAGGC TGGGC
(2) INFORMATION FOR SEQ ID N0:245:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 94 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:245:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGGC 44
GGGCACAGGC TGGG
(2) INFORMATION FOR SEQ ID N0:246:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:246:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGGC 43
GGGCACAGGC TGG
(2) INFORMATION FOR SEQ ID N0:247:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:247:
CTGGAAAGCT GAGATGGAGG GCGGCATGGC GGGCACAGGC TG 42
(2) INFORMATION FOR SEQ ID N0:248:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEL7NESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:298:
CTGGAAAGCT GAGATGGAGG GCGGCATGGC GGGCACAGGC T 41
(2) INFORMATION FOR SEQ ID N0:249:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
~(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:249:
CTGGAAAGCT GAGATGGAGG GCGGCATGGC GGGCACAGGC 40
(2) INFORMATION FOR SEQ ID N0:250:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:250:
CTGGAAAGCT GAGATGGAGG GCGGCATGGC GGGCACAGG 39
(2) INFORMATION FOR SEQ ID N0:251:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:251:
CTGGAAAGCT GAGATGGAGG GCGGCATGGC GGGCACAG 3g
(2) INFORMATION FOR SEQ ID N0:252:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic. acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:252:
CTGGAAAGCT GAGATGGAGG GCGGCATGGC GGGCACA 37
(2) INFORMATION FOR SEQ ID N0:253:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/ITS99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:253:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGGC 36
GGGCAC
(2) INFORMATION FOR SEQ ID N0:254:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:254:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGGC 35
GGGCA
(2) INFORMATION FOR SEQ ID N0:255:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:255:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGGC 34
GGGC
(2) INFORMATION FOR SEQ ID N0:256:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:256:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGGC 33
GGG
(2) INFORMATION FOR SEQ ID N0:257:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:257:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGGC 32
GG
(2) INFORMATION FOR SEQ ID N0:258:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:258:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGGC 31
G
(2) INFORMATION FOR SEQ ID N0:259:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:259:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGGC 30
(2) INFORMATION FOR SEQ ID N0:260:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:260:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATGG 2g
(2) INFORMATION FOR SEQ ID N0:261:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:261:
ID
CTGGAAAGCT GAGATGGAGG GCGGCATG 28
(2) INFORMATION FOR SEQ ID N0:262:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:262:
ID
CTGGAAAGCT GAGATGGAGG GCGGCAT 27
(2) INFORMATION FOR SEQ ID N0:263:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic'acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:263:
ID
CTGGAAAGCT GAGATGGAGG GCGGCA 26
(2) INFORMATION FOR SEQ ID N0:264:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:264:
ID
CTGGAAAGCT GAGATGGAGG GCGGC 25
(2) INFORMATION FOR SEQ ID N0:265:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99163938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:265:
ID
CTGGAAAGCT GAGATGGAGG GCGG 24
(2) INFORMATION FOR SEQ ID N0:266:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:266:
ID
CTGGAAAGCT GAGATGGAGG GCG 23
(2) INFORMATION FOR SEQ ID N0:267:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:267:
ID
CTGGAAAGCT GAGATGGAGG GC 22
(2) INFORMATION FOR SEQ ID N0:268:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:268:
ID
CTGGAAAGCT GAGATGGAGG G 21
(2) INFORMATION FOR SEQ ID N0:269:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:269:
ID
CTGGAAAGCT GAGATGGAGG 20
(2) INFORMATION FOR SEQ ID N0:270:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:270:
ID
CTGGAAAGCT GAGATGGAG 19
(2) INFORMATION FOR SEQ ID N0:271:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:271:
ID
CTGGAAAGCT GAGATGGA 18
(2) INFORMATION FOR SEQ ID N0:272:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:272:
ID
CTGGAAAGCT GAGATGG 17
(2) INFORMATION FOR SEQ ID N0:273:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xiy SEQUENCE DESCRIPTION: SEQ N0:273:
ID
CTGGAAAGCT GAGATG 16
(2) INFORMATION FOR SEQ ID N0:279:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:274:
ID
CTGGAAAGCT GAGAT 15
(2) INFORMATION FOR SEQ ID N0:275:
(i) SEQUENCE CHARACTERISTICS:
(Ay LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:275:
ID
CTGGAAAGCT GAGA 14
(2) INFORMATION FOR SEQ ID N0:276:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:276:
ID
CTGGAAAGCT GAG ~ 13
(2) INFORMATION FOR SEQ ID N0:277:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:277:
CTGGAAAGCT GA 12
(2} INFORMATION FOR SEQ ID N0:278:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic. acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:278:
CTGGAAAGCT G 11
(2) INFORMATION FOR SEQ ID N0:279:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:279:
CTGGAAAGCT 10
(2) INFORMATION FOR SEQ ID N0:280:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:280:
TGGAAAGCTG AGATGGAGGG CGGCATGGCG GGCACAGGCT 44
GGGC
(2) INFORMATION FOR SEQ ID N0:281:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:281:
TGGAAAGCTG AGATGGAGGG CGGCATGGCG GGCACAGGCT 43
GGG
(2) INFORMATION FOR SEQ ID N0:282:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:282:
TGGAAAGCTG AGATGGAGGG CGGCATGGCG GGCACAGGCT 42
GG
(2) INFORMATION FOR SEQ ID N0:283:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:283:
TGGAAAGCTG AGATGGAGGG CGGCATGGCG GGCACAGGCT 41
G
(2) INFORMATION FOR SEQ ID N0:284:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
{ii) MOLECULE TYPE: DNA (genomic)
{xi) SEQUENCE DESCRIPTION: SEQ ID N0:284:
TGGAAAGCTG AGATGGAGGG CGGCATGGCG GGCACAGGGT 40
(2) INFORMATION FOR SEQ ID N0:285:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:285:
TGGAAAGCTG AGATGGAGGG CGGCATGGCG GGCACAGGC 39
(2) INFORMATION FOR SEQ ID N0:286:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:286:
TGGAAAGCTG AGATGGAGGG CGGCATGGCG GGCACAGG 38
(2) INFORMATION FOR SEQ ID N0:287:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
~
(genomic)
(ii) MOLECULE TYPE: DNA
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:287:
TGGAAAGCTG AGATGGAGGG CGGCATGGCG GGCACAG 37
(2) INFORMATION FOR SEQ ID N0:288:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:288:
TGGAAAGCTG AGATGGAGGG CGGCATGGCG GGCACA 36
(2) INFORMATION FOR SEQ ID N0:289:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
_
SC7
(xi) SEQUENCE DESCRIPTION: SEQ N0:289:
ID
TGGAAAGCTG AGATGGAGGG CGGCATGGCG 35
GGCAC
(2) INFORMATION FOR SEQ ID N0:290:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:290:
ID
TGGAAAGCTG AGATGGAGGG CGGCATGGCG 34
GGCA
(2) INFORMATION FOR SEQ ID N0:291:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:291:
ID
TGGAAAGCTG AGATGGAGGG CGGCATGGCG 33
GGC
(2) INFORMATION FOR SEQ ID N0:292:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:292:
ID
TGGAAAGCTG AGATGGAGGG CGGCATGGCG 32
GG
(2) INFORMATION FOR SEQ ID N0:293:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:293:
ID
TGGAAAGCTG AGATGGAGGG CGGCATGGCG 31
G
(2) INFORMATION FOR SEQ ID N0:294:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bade pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:294:
ID
TGGAAAGCTG AGATGGAGGG CGGCATGGCG 30
(2) INFORMATION FOR SEQ ID N0:295:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:295:
ID
TGGAAAGCTG AGATGGAGGG CGGCATGGC 29
(2) INFORMATION FOR SEQ ID N0:296:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:296:
ID
TGGAAAGCTG AGATGGAGGG CGGCATGG 28
(2) INFORMATION FOR SEQ ID N0:297:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
{D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:297:
ID
TGGAAAGCTG AGATGGAGGG CGGCATG 27
(2) INFORMATION FOR SEQ ID N0:298:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:298:
ID
TGGAAAGCTG AGATGGAGGG CGGCAT 26
(2) INFORMATION FOR SEQ ID N0:299:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:299:
ID
TGGAAAGCTG AGATGGAGGG CGGCA 25
(2) INFORMATION FOR SEQ ID N0:300:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomicy
(xi) SEQUENCE DESCRIPTION: SEQ N0:300:
ID
TGGAAAGCTG AGATGGAGGG CGGC 24
(2) INFORMATION FOR SEQ ID N0:301:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT1I1S99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:301:
ID
TGGAAAGCTG AGATGGAGGG CGG 23
(2) INFORMATION FOR SEQ ID N0:302:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:302:
ID
TGGAAAGCTG AGATGGAGGG CG 22
(2) INFORMATION FOR SEQ ID N0:303:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:303:
ID
TGGAAAGCTG AGATGGAGGG C 21
(2) INFORMATION FOR SEQ ID N0:304:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:304:
ID
TGGAAAGCTG AGATGGAGGG 20
(2) INFORMATION FOR SEQ ID N0:305:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:305:
ID
TGGAAAGCTG AGATGGAGG 19
(2) INFORMATION FOR SEQ ID N0:306:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:306:
ID
TGGAAAGCTG AGATGGAG 18
(2) INFORMATION FOR SEQ ID N0:307:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA'(genomic)
CA 02316994 2000-06-30
WO 99/63938 ~~ PCT/IJS99/12??5
(xi) SEQUENCE DESCRIPTION: SEQ N0:307:
ID
TGGAAAGCTG AGATGGA 17
(2) INFORMATION FOR SEQ ID N0:308:
(i) SEQUENCE CHARACTERISTICS: -
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:308:
ID
TGGAAAGCTG AGATGG 16
(2) INFORMATION FOR SEQ ID N0:309:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:309:
ID
TGGAAAGCTG AGATG 15
(2) INFORMATION FOR SEQ ID N0:310:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:310:
ID
TGGAAAGCTG AGAT 14
(2) INFORMATION FOR SEQ ID N0:311:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:311:
ID
TGGAAAGCTG AGA 13
(2) INFORMATION FOR SEQ ID N0:312:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:312:
ID
TGGAAAGCTG AG 12
(2) INFORMATION FOR SEQ ID N0:313:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:313:
TGGAAAGCTG A 11
(2) INFORMATION FOR SEQ ID N0:314:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:314:
TGGAAAGCTG 10
(2) INFORMATION FOR SEQ ID N0:315:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
~
(ii) MOLECULE TYPE: DNA
(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:315:
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCACAGGCTG GGC 43
(2) INFORMATION FOR SEQ ID N0:316:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:316:
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCACAGGCTG GG 42
(2) INFORMATION FOR SEQ ID N0:317:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:317:
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCACAGGCTG G 41
(2) INFORMATION FOR SEQ ID N0:318:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:318:
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCACAGGCTG 40
(2) INFORMATION FOR SEQ ID N0:319:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 39 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~~ PC"T/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:319:
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCACAGGCT 3g
(2) INFORMATION FOR SEQ ID N0:320:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:320:
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCACAGGC 38
(2) INFORMATION FOR SEQ ID N0:321:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:321:
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCACAGG 37
(2) INFORMATION FOR SEQ ID N0:322:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:322:
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCACAG 36
(2) INFORMATION FOR SEQ ID N0:323:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:323:
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCACA 35
(2) INFORMATION FOR SEQ ID D10:324:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:324:
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCAC 34
(2) INFORMATION FOR SEQ ID N0:325:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
{ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:325:
ID
GGAAAGCTGA GATGGAGGGC GGCATGGCGG 33
GCA
(2) INFORMATION FOR SEQ ID N0:326:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:326:
ID
GGAAAGCTGA GATGGAGGGC GGCATGGCGG 32
GC
(2) INFORMATION FOR SEQ ID N0:327:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base gairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:327:
ID
GGAAAGCTGA GATGGAGGGC GGCATGGCGG 31
G
(2) INFORMATION FOR SEQ ID N0:328:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:328:
ID
GGAAAGCTGA GATGGAGGGC GGCATGGCGG 30
(2) INFORMATION FOR SEQ ID N0:329:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic!
(xi) SEQUENCE DESCRIPTION: SEQ N0:329:
ID
GGAAAGCTGA GATGGAGGGC GGCATGGCG 29
(2) INFORMATION FOR SEQ ID N0:330:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:330:
ID
GGAAAGCTGA GATGGAGGGC GGCATGGC 28
(2) INFORMATION FOR SEQ ID N0:331:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:331:
ID
GGAAAGCTGA GATGGAGGGC GGCATGG 27
(2) INFORMATION FOR SEQ ID N0:332:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:332:
ID
GGAAAGCTGA GATGGAGGGC GGCATG 26
(2) INFORMATION FOR SEQ ID N0:333:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:333:
ID
GGAAAGCTGA GATGGAGGGC GGCAT 25
(2) INFORMATION FOR SEQ ID N0:339:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:334:
ID
GGAAAGCTGA GATGGAGGGC GGCA 24
(2) INFORMATION FOR SEQ ID N0:335:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:335:
ID
GGAAAGCTGA GATGGAGGGC GGC 23
(2) INFORMATION FOR SEQ ID N0:336:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:336:
ID
GGAAAGCTGA GATGGAGGGC GG 22
(2) INFORMATION FOR SEQ ID N0:337:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:337:
ID
GGAAAGCTGA GATGGAGGGC G 21
(2} INFORMATION FOR SEQ ID N0:338:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B} TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:338:
ID
GGAAAGCTGA GATGGAGGGC 20
(2) INFORMATION FOR SEQ ID N0:339:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:339:
ID
GGAAAGCTGA GATGGAGGG lg
(2) INFORMATION FOR SEQ ID N0:340:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:340:
ID
GGAAAGCTGA GATGGAGG lg
(2) INFORMATION FOR SEQ ID N0:341:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ
ID N0:341:
GGAAAGCTGA GATGGAG 17
(2) INFORMATION FOR SEQ ID N0:342:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:342:
ID
GGAAAGCTGA GATGGA 16
(2) INFORMATION FOR SEQ ID N0:393:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:343:
ID
GGAAAGCTGA GATGG 15
(2) INFORMATION FOR SEQ ID N0:344:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
{xi) SEQUENCE DESCRIPTION: SEQ N0:344:
ID
GGAAAGCTGA GATG 14
(2) INFORMATION FOR SEQ ID N0:345:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:345:
ID
GGAAAGCTGA GAT 13
(2) INFORMATION FOR SEQ ID N0:346:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
{ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:396:
ID
GGAAAGCTGA GA 12
(2) INFORMATION FOR SEQ ID N0:347:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:347:
ID
GGAAAGCTGA G 11
(2) INFORMATION FOR SEQ ID N0:348:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:348:
ID
GGAAAGCTGA 10
(2) INFORMATION FOR SEQ ID N0:349:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:349:
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG CACAGGCTGG GC 42
(2) INFORMATION FOR SEQ ID N0:350:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:350:
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG CACAGGCTGG G 41
(2) INFORMATION FOR SEQ ID N0:351:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
{C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:351:
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG CACAGGCTGG 40
(2) INFORMATION FOR SEQ ID N0:352:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA'(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:352:
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG CACAGGCTG 39
(2) INFORMATION FOR SEQ ID N0:353:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:353:
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG CACAGGCT 3g
(2) INFORMATION FOR SEQ ID N0:354:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:354:
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG CACAGGC 37
(2) INFORMATION FOR SEQ ID N0:355:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 l PCTNS99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:355:
ID
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG 36
CACAGG
(2) INFORMATION FOR SEQ ID N0:356:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:356:
ID
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG 35
CACAG
(2) INFORMATION FOR SEQ ID N0:357:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA {genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:357:
ID
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG 34
CACA
(2) INFORMATION FOR SEQ ID N0:358:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:358:
ID
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG 33
CAC
(2) INFORMATION FOR SEQ ID N0:359:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:359:
ID
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG 32
CA
(2) INFORMATION FOR SEQ ID N0:360:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:360:
ID
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG 31
C
(2) INFORMATION FOR SEQ ID N0:361:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: lin2ar
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 y PCT/US99/12775
{xi) SEQUENCE DESCRIPTION: SEQ N0:361:
ID
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG 30
(2) INFORMATION FOR SEQ ID N0:362:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:362:
ID
GAAAGCTGAG ATGGAGGGCG GCATGGCGG 29
(2) INFORMATION FOR SEQ ID N0:363:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:363:
ID
GAAAGCTGAG ATGGAGGGCG GCATGGCG 28
(2) INFORMATION FOR SEQ ID N0:364:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:364:
ID
GAAAGCTGAG ATGGAGGGCG GCATGGC 27
(2) INFORMATION FOR SEQ ID N0:365:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA.(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:365:
ID
GAAAGCTGAG ATGGAGGGCG GCATGG 26
(2) INFORMATION FOR SEQ ID N0:366:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:366:
ID
GAAAGCTGAG ATGGAGGGCG GCATG 25
(2) INFORMATION FOR SEQ ID N0:367:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~y PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:367:
ID
GAAAGCTGAG ATGGAGGGCG GCAT 24
(2) INFORMATION FOR SEQ ID N0:368:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:368:
ID
GAAAGCTGAG ATGGAGGGCG GCA 23
(2) INFORMATION FOR SEQ ID N0:369:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:369:
ID
GAAAGCTGAG ATGGAGGGCG GC 22
(2) INFORMATION FOR SEQ ID N0:370:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:370:
ID
GAAAGCTGAG ATGGAGGGCG G 21
(2) INFORMATION FOR SEQ ID N0:371:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:371:
ID
GAAAGCTGAG ATGGAGGGCG 20
{2) INFORMATION FOR SEQ ID N0:372:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:372:
ID
GAAAGCTGAG ATGGAGGGC lg
(2) INFORMATION FOR SEQ ID N0:373:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:373:
ID
GAAAGCTGAG ATGGAGGG 18
(2) INFORMATION FOR SEQ ID N0:374:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:374:
ID
GAAAGCTGAG ATGGAGG 17
(2) INFORMATION FOR SEQ ID N0:375:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:375:
ID
GAAAGCTGAG ATGGAG 16
(2) INFORMATION FOR SEQ ID N0:376:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA.(genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:376:
ID
GAAAGCTGAG ATGGA 15
(2) INFORMATION FOR SEQ ID N0:377:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:377:
ID
GAAAGCTGAG ATGG 14
(2) INFORMATION FOR SEQ ID N0:378:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:378:
ID
GAAAGCTGAG ATG 13
(2) INFORMATION FOR SEQ ID N0:379:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 bade pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:379:
GAAAGCTGAG AT 12
(2) INFORMATION FOR SEQ ID N0:380:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:380:
GAAAGCTGAG A ~ 11
(2) INFORMATION FOR SEQ ID N0:381:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:381:
GAAAGCTGAG 10
(2) INFORMATION FOR SEQ ID N0:382:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:382:
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAGGCTGGG 41
C
(2} INFORMATION FOR SEQ ID N0:383:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:383:
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAGGCTGGG 40
(2) INFORMATION FOR SEQ ID N0:384:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:384:
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAGGCTGG 39
(2) INFORMATION FOR SEQ ID N0:385:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:385:
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAGGCTG 38
(2) INFORMATION FOR SEQ ID N0:386:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:386:
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAGGCT 37
(2) INFORMATION FOR SEQ ID N0:387:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA'(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:387:
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAGGC 36
(2) INFORMATION FOR SEQ ID N0:388:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:388:
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAGG 35
(2) INFORMATION FOR SEQ ID N0:389:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:389:
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAG 34
(2} INFORMATION FOR SEQ ID N0:390:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:390:
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACA 33
(2) INFORMATION FOR SEQ ID N0:391:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:391:
ID
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC 32
AC
(2) INFORMATION FOR SEQ ID N0:392:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:392:
ID
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC 31
A
(2) INFORMATION FOR SEQ ID N0:393:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:393:
ID
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC 30
(2) INFORMATION FOR SEQ ID N0:394:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:394:
ID
AAAGCTGAGA TGGAGGGCGG CATGGCGGG 29
(2) INFORMATION FOR SEQ ID N0:395:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:395:
ID
AAAGCTGAGA TGGAGGGCGG CATGGCGG 2g
(2) INFORMATION FOR SEQ ID N0:396:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:396:
ID
AAAGCTGAGA TGGAGGGCGG CATGGCG 27
(2) INFORMATION FOR SEQ ID N0:397:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:397:
ID
AAAGCTGAGA TGGAGGGCGG CATGGC 26
(2) INFORMATION FOR SEQ ID N0:398:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
{C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:398:
ID
AAAGCTGAGA TGGAGGGCGG CATGG 25
(2) INFORMATION FOR SEQ ID N0:399:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
{C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:399:
ID
AAAGCTGAGA TGGAGGGCGG CATG 24
(2) INFORMATION FOR SEQ ID N0:900:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:400:
ID
AAAGCTGAGA TGGAGGGCGG CAT 23
(2) INFORMATION FOR SEQ ID N0:401:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:401:
ID
AAAGCTGAGA TGGAGGGCGG CA 22
(2) INFORMATION FOR SEQ ID N0:402:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:902:
ID
AAAGCTGAGA TGGAGGGCGG C 21
(2) INFORMATION FOR SEQ ID N0:403:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PC1'/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:403:
ID
AAAGCTGAGA TGGAGGGCGG 20
(2) INFORMATION FOR SEQ ID N0:404:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:404:
ID
AAAGCTGAGA TGGAGGGCG 19
(2) INFORMATION FOR SEQ ID N0:405:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:405:
ID
AAAGCTGAGA TGGAGGGC lg
(2) INFORMATION FOR SEQ ID N0:406:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:406:
ID
AAAGCTGAGA TGGAGGG 17
(2) INFORMATION FOR SEQ ID N0:407:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 16 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:907:
ID
AAAGCTGAGA TGGAGG 16
(2) INFORMATION FOR SEQ ID N0:408:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:908:
ID
AAAGCTGAGA TGGAG 15
(2) INFORMATION FOR SEQ ID N0:409:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:409:
ID
AAAGCTGAGA TGGA 14
(2) INFORMATION FOR SEQ ID N0:410:
_
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:410:
ID
AAAGCTGAGA TGG 13
(2) INFORMATION FOR SEQ ID N0:411:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:411:
ID
AAAGCTGAGA TG 12
(2) INFORMATION FOR SEQ ID N0:412:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:412:
ID
AAAGCTGAGA T 11
(2) INFORMATION FOR SEQ ID N0:413:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:413:
ID
AAAGCTGAGA 10
(2) INFORMATION FOR SEQ ID N0:414:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:414:
ID
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA 40
CAGGCTGGGC
(2) INFORMATION FOR SEQ ID N0:415:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:415:
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA CAGGCTGGG 3g
(2) INFORMATION FOR SEQ ID N0:416:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic. acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:416:
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA CAGGCTGG 3g
(2) INFORMATION FOR SEQ ID N0:417:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:417:
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA CAGGCTG 37
(2) INFORMATION FOR SEQ ID N0:418:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:418:
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA CAGGCT 36
(2) INFORMATION FOR SEQ ID N0:419:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:919:
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA CAGGC 35
(2} INFORMATION FOR SEQ ID N0:420:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:920:
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA CAGG 34
(2) INFORMATION FOR SEQ ID N0:421:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 . PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:421:
ID
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA 33
CAG
(2) INFORMATION FOR SEQ ID N0:922:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:422:
ID
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA 32
CA
(2) INFORMATION FOR SEQ ID N0:423:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:423:
ID
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA 31
C
(2) INFORMATION FOR SEQ ID N0:924:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:429:
ID
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA 30
(2) INFORMATION FOR SEQ ID N0:425:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA,(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:925:
ID
AAGCTGAGAT GGAGGGCGGC ATGGCGGGC 29
(2) INFORMATION FOR SEQ ID N0:426:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single.
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:426:
ID
AAGCTGAGAT GGAGGGCGGC ATGGCGGG 2g
(2) INFORMATION FOR SEQ ID N0:427:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
EPI-179
(xi) SEQUENCE DESCRIPTION: SEQ N0:427:
ID
AAGCTGAGAT GGAGGGCGGC ATGGCGG 27
(2) INFORMATION FOR SEQ ID N0:428:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:428:
ID
AAGCTGAGAT GGAGGGCGGC ATGGCG 26
(2} INFORMATION FOR SEQ ID N0:429:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:429:
ID
AAGCTGAGAT GGAGGGCGGC ATGGC. 25
(2) INFORMATION FOR SEQ ID N0:430:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:430:
ID
AAGCTGAGAT GGAGGGCGGC ATGG 24
(2) INFORMATION FOR SEQ ID N0:431:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:431:
ID
AAGCTGAGAT GGAGGGCGGC ATG 23
(2) INFORMATION FOR SEQ ID N0:432:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:'single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:432:
ID
AAGCTGAGAT GGAGGGCGGC AT 22
(2) INFORMATION FOR SEQ ID N0:433:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ; PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:433:
ID
AAGCTGAGAT GGAGGGCGGC A 21
(2) INFORMATION FOR SEQ ID N0:434:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:434:
ID
AAGCTGAGAT GGAGGGCGGC 20
(2) INFORMATION FOR SEQ ID N0:435:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:435:
ID
AAGCTGAGAT GGAGGGCGG lg
(2) INFORMATION FOR SEQ ID N0:936:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:936:
ID
AAGCTGAGAT GGAGGGCG lg
(2) INFORMATION FOR SEQ ID N0:437:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:437:
ID
AAGCTGAGAT GGAGGGC 17
(2) INFORMATION FOR SEQ ID N0:438:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:438:
ID
AAGCTGAGAT GGAGGG 16
(2) INFORMATION FOR SEQ ID N0:439:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PGT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:439:
ID
AAGCTGAGAT GGAGG 15
(2) INFORMATION FOR SEQ ID N0:440:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
{D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:940:
ID
AAGCTGAGAT GGAG 14
(2) INFORMATION FOR SEQ ID N0:441:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:941:
ID
AAGCTGAGAT GGA 13
(2) INFORMATION FOR SEQ ID N0:442:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:442:
ID
AAGCTGAGAT GG 12
(2} INFORMATION FOR SEQ ID N0:443:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic~acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:443:
ID
AAGCTGAGAT G 11
(2) INFORMATION FOR SEQ ID N0:444:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B} TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:494:
ID
AAGCTGAGAT 10
(2) INFORMATION FOR SEQ ID N0:445:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~~ PCTNS99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:445:
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC AGGCTGGGC 39
(2) INFORMATION FOR SEQ ID N0:946:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B} TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:446:
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC AGGCTGGG 38
(2) INFORMATION FOR SEQ ID N0:497:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:447:
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC AGGCTGG 37
(2) INFORMATION FOR SEQ ID N0:448:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:448:
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC AGGCTG 36
(2) INFORMATION FOR SEQ ID N0:449:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:499:
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC AGGCT 35
(2) INFORMATION FOR SEQ ID N0:950:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:450:
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC AGGC 3q
(2) INFORMATION FOR SEQ ID N0:451:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:451:
ID
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC 33
AGG
(2) INFORMATION FOR SEQ ID N0:952:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:452:
ID
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC 32
AG
(2) INFORMATION FOR SEQ ID N0:453:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:453:
ID
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC 31
A
(2) INFORMATION FOR SEQ ID N0:954:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic~acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:454:
ID
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC 30
(2) INFORMATION FOR SEQ ID N0:455:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:455:
ID
AGCTGAGATG GAGGGCGGCA TGGCGGGCA 2g
(2) INFORMATION FOR SEQ ID N0:956:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:456:
ID
AGCTGAGATG GAGGGCGGCA TGGCGGGC 28
(2) INFORMATION FOR SEQ ID N0:457:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:457:
ID
AGCTGAGATG GAGGGCGGCA TGGCGGG 27
(2) INFORMATION FOR SEQ ID N0:458:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:458:
ID
AGCTGAGATG GAGGGCGGCA TGGCGG 26
(2) INFORMATION FOR SEQ ID N0:459:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:459:
ID
AGCTGAGATG GAGGGCGGCA TGGCG 25
(2) INFORMATION FOR SEQ ID N0:460:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:460:
ID
AGCTGAGATG GAGGGCGGCA TGGC 24
{2) INFORMATION FOR SEQ ID N0:461:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA {genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:461:
ID
AGCTGAGATG GAGGGCGGCA TGG 23
(2) INFORMATION FOR SEQ ID N0:462:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:462:
ID
AGCTGAGATG GAGGGCGGCA TG 22
(2) INFORMATION FOR SEQ ID N0:463:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:463:
ID
AGCTGAGATG GAGGGCGGCA T 21
(2) INFORMATION FOR SEQ ID N0:964:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:464:
ID
AGCTGAGATG GAGGGCGGCA 20
(2) INFORMATION FOR SEQ ID N0:465:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:465:
ID
AGCTGAGATG GAGGGCGGC lg
(2) INFORMATION FOR SEQ ID N0:966:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:466:
ID
AGCTGAGATG GAGGGCGG lg
(2) INFORMATION FOR SEQ ID N0:467:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:467:
ID
AGCTGAGATG GAGGGCG ' 17
(2) INFORMATION FOR SEQ ID N0:468:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:468:
ID
AGCTGAGATG GAGGGC 16
(2) INFORMATION FOR SEQ ID N0:469:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 a PC'T/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:469:
ID
AGCTGAGATG GAGGG 15
(2) INFORMATION FOR SEQ ID N0:470:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(By TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(iiy MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:470:
ID
AGCTGAGATG GAGG 19
(2y INFORMATION FOR SEQ ID N0:471:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: l3 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:471:
ID
AGCTGAGATG GAG 13
(2) INFORMATION FOR SEQ ID N0:472:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(Dy TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:472:
ID
AGCTGAGATG GA 12
(2) INFORMATION FOR SEQ ID N0:473:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:973:
ID
AGCTGAGATG G 11
(2) INFORMATION FOR SEQ ID N0:974:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:474:
ID
AGCTGAGATG 10
(2) INFORMATION FOR SEQ ID N0:475:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(iiy MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:475:
GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCTGGGC 3g
(2) INFORMATION FOR SEQ ID N0:476:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:976:
GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCTGGG 37
(2) INFORMATION FOR SEQ ID N0:477:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ ID N0:477:
GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCTGG 36
(2) INFORMATION FOR SEQ ID N0:478:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:478:
GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCTG 35
(2) INFORMATION FOR SEQ ID N0:479:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:479:
GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCT 34
(2) INFORMATION FOR SEQ ID N0:480:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:480:
GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGC 33
(2) INFORMATION FOR SEQ ID N0:481:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
$L
(xi) SEQUENCE DESCRIPTION: SEQ N0:481:
ID
GCTGAGATGG AGGGCGGCAT GGCGGGCACA 32
GG
(2) INFORMATION FOR SEQ ID N0:482:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:482:
ID
GCTGAGATGG AGGGCGGCAT GGCGGGCACA 31
G
(2) INFORMATION FOR SEQ ID N0:483:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:483:
ID
GCTGAGATGG AGGGCGGCAT GGCGGGCACA 30
(2) INFORMATION FOR SEQ ID N0:484:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:484:
ID
GCTGAGATGG AGGGCGGCAT GGCGGGCAC 29
(2) INFORMATION FOR SEQ ID N0:985:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:485:
ID
GCTGAGATGG AGGGCGGCAT GGCGGGCA 2g
(2) INFORMATION FOR SEQ ID N0:486:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2? base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:486:
ID
GCTGAGATGG AGGGCGGCAT GGCGGGC 27
(2) INFORMATION FOR SEQ ID N0:487:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/tJS99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:487:
ID
GCTGAGATGG AGGGCGGCAT GGCGGG 26
(2) INFORMATION FOR SEQ ID N0:488:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:988:
ID
GCTGAGATGG AGGGCGGCAT GGCGG 25
(2) INFORMATION FOR SEQ ID N0:489:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA,(genomic)
{xi} SEQUENCE DESCRIPTION: SEQ N0:489:
ID
GCTGAGATGG AGGGCGGCAT GGCG 24
(2) INFORMATION FOR SEQ ID N0:490:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:490:
ID
GCTGAGATGG AGGGCGGCAT GGC 23
(2) INFORMATION FOR SEQ ID N0:491:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid.
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:491:
ID
GCTGAGATGG AGGGCGGCAT GG 22
(2) INFORMATION FOR SEQ ID N0:492:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:492:
ID
GCTGAGATGG AGGGCGGCAT G 21
(2) INFORMATION FOR SEQ ID N0:493:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:493:
GCTGAGATGG AGGGCGGCAT 20
(2) INFORMATION FOR SEQ ID N0:994:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:494:
GCTGAGATGG AGGGCGGCA lg
(2) INFORMATION FOR SEQ ID N0:495:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1B base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:495:
ID
GCTGAGATGG AGGGCGGC lg
(2) INFORMATION FOR SEQ ID N0:496:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:496:
ID
GCTGAGATGG AGGGCGG 17
(2} INFORMATION FOR SEQ ID N0:497:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:497:
ID
GCTGAGATGG AGGGCG 16
(2) INFORMATION FOR SEQ ID N0:498:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:498:
ID
GCTGAGATGG AGGGC ' 15
(2) INFORMATION FOR SEQ ID N0:499:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
CA 02316994 2000-06-30
WO 99/63938 PCTNS99/12775
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:499:
ID
GCTGAGATGG AGGG 14
(2) INFORMATION FOR SEQ ID N0:500:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:500:
ID
GCTGAGATGG AGG 13
(2) INFORMATION FOR SEQ ID N0:501:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:501:
ID
GCTGAGATGG AG 12
(2) INFORMATION FOR SEQ ID N0:502:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:502:
ID
GCTGAGATGG A 11
(2) INFORMATION FOR SEQ ID N0:503:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:503:
ID
GCTGAGATGG 10
(2) INFORMATION FOR SEQ ID N0:504:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:504:
ID
CTGAGATGGA GGGCGGCATG GCGGGCACAG 37
GCTGGGC
(2) INFORMATION FOR SEQ ID N0:505:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
CA 02316994 2000-06-30
WO 99/63938 ~~ PCT/US99/12775
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:505:
CTGAGATGGA GGGCGGCATG GCGGGCACAG GCTGGG 36
(2) INFORMATION FOR SEQ ID N0:506:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:506:
CTGAGATGGA GGGCGGCATG GCGGGCACAG GCTGG 35
(2) INFORMATION FOR SEQ ID N0:507:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:507:
CTGAGATGGA GGGCGGCATG GCGGGCACAG GCTG 34
(2) INFORMATION FOR SEQ ID N0:508:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:508:
CTGAGATGGA GGGCGGCATG GCGGGCACAG GCT 33
(2) INFORMATION FOR SEQ ID N0:509:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:509:
CTGAGATGGA GGGCGGCATG GCGGGCACAG GC 32
(2) INFORMATION FOR SEQ ID N0:510:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:510:
CTGAGATGGA GGGCGGCATG GCGGGCACAG G 31
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:511:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:511:
CTGAGATGGA GGGCGGCATG GCGGGCACAG 30
(2) INFORMATION FOR SEQ ID N0:512:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:512:
CTGAGATGGA GGGCGGCATG GCGGGCACA 29
(2) INFORMATION FOR SEQ ID N0:513:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:513:
CTGAGATGGA GGGCGGCATG GCGGGCAC 2g
(2) INFORMATION FOR SEQ ID N0:519:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:519:
CTGAGATGGA GGGCGGCATG GCGGGCA 27
(2) INFORMATION FOR SEQ ID N0:515:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:515:
CTGAGATGGA GGGCGGCATG GCGGGC 26
(2) INFORMATION FOR SEQ ID N0:516:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:516:
ID
CTGAGATGGA GGGCGGCATG GCGGG 25
(2) INFORMATION FOR SEQ ID N0:517:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic. acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:517:
ID
CTGAGATGGA GGGCGGCATG GCGG 24
(2) INFORMATION FOR SEQ ID N0:518:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:518:
ID
CTGAGATGGA GGGCGGCATG GCG 23
(2) INFORMATION FOR SEQ ID N0:519:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xiy SEQUENCE DESCRIPTION: SEQ N0:519:
ID
CTGAGATGGA GGGCGGCATG GC 22
(2) INFORMATION FOR SEQ ID N0:520:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:520:
ID
CTGAGATGGA GGGCGGCATG G 21
(2) INFORMATION FOR SEQ ID N0:521:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:521:
ID
CTGAGATGGA GGGCGGCATG 20
{2) INFORMATION FOR SEQ ID N0:522:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:,single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:522:
ID
CTGAGATGGA GGGCGGCAT 19
(2) INFORMATION FOR SEQ ID N0:523:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:523:
ID
CTGAGATGGA GGGCGGCA 18
(2) INFORMATION FOR SEQ ID N0:524:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:524:
ID
CTGAGATGGA GGGCGGC 17
(2) INFORMATION FOR SEQ ID N0:525:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:525:
ID
CTGAGATGGA GGGCGG 16
(2) INFORMATION FOR SEQ ID N0:526:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA,(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:526:
ID
CTGAGATGGA GGGCG 15
(2} INFORMATION FOR SEQ ID N0:527:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:527:
ID
CTGAGATGGA GGGC 14
(2) INFORMATION FOR SEQ ID N0:528:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/ITS99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:528:
ID
CTGAGATGGA GGG 13
(2) INFORMATION FOR SEQ ID N0:529:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:529:
ID
CTGAGATGGA GG 12
(2) INFORMATION FOR SEQ ID N0:530:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:530:
ID
CTGAGATGGA G . 11
(2) INFORMATION FOR SEQ ID N0:531:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:531:
ID
CTGAGATGGA 10
(2) INFORMATION FOR SEQ ID N0:532:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:532:
ID
TGAGATGGAG GGCGGCATGG CGGGCACAGG 36
CTGGGC
(2) INFORMATION FOR SEQ ID N0:533:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:533:
ID
TGAGATGGAG GGCGGCATGG CGGGCACAGG 35
CTGGG
(2) INFORMATION FOR SEQ ID N0:534:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ l PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:534:
ID
TGAGATGGAG GGCGGCATGG CGGGCACAGG 34
CTGG
(2) INFORMATION FOR SEQ ID N0:535:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:535:
ID
TGAGATGGAG GGCGGCATGG CGGGCACAGG 33
CTG
(2) INFORMATION FOR SEQ ID N0:536:
(ij SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:536:
ID
TGAGATGGAG GGCGGCATGG CGGGCACAGG 32
CT
{2) INFORMATION FOR SEQ ID N0:537:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA'(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:537:
ID
TGAGATGGAG GGCGGCATGG CGGGCACAGG 31
C
(2) INFORMATION FOR SEQ ID N0:538:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:538:
ID
TGAGATGGAG GGCGGCATGG CGGGCACAGG 30
(2) INFORMATION FOR SEQ ID N0:539:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:539:
ID
TGAGATGGAG GGCGGCATGG CGGGCACAG 2g
(2) INFORMATION FOR SEQ ID N0:540:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/I1S99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:590:
ID
TGAGATGGAG GGCGGCATGG CGGGCACA 2g
(2) INFORMATION FOR SEQ ID N0:541:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:541:
ID
TGAGATGGAG GGCGGCATGG CGGGCAC 27
(2) INFORMATION FOR SEQ ID N0:542:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:542:
ID
TGAGATGGAG GGCGGCATGG CGGGCA 26
(2) INFORMATION FOR SEQ ID N0:543:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:593:
ID
TGAGATGGAG GGCGGCATGG CGGGC 25
(2) INFORMATION FOR SEQ ID N0:544:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic~acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:599:
ID
TGAGATGGAG GGCGGCATGG CGGG 2q
(2) INFORMATION FOR SEQ ID N0:545:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:545:
ID
TGAGATGGAG GGCGGCATGG CGG 23
(2) INFORMATION FOR SEQ ID N0:596:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~~ PGT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:546:
ID
TGAGATGGAG GGCGGCATGG CG 22
(2) INFORMATION FOR SEQ ID N0:547:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:547:
ID
TGAGATGGAG GGCGGCATGG C 21
(2) INFORMATION FOR SEQ ID N0:548:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:548:
ID
TGAGATGGAG GGCGGCATGG 20
(2) INFORMATION FOR SEQ ID N0:549:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:549:
ID
TGAGATGGAG GGCGGCATG 19
(2) INFORMATION FOR SEQ ID N0:550:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:550:
ID
TGAGATGGAG GGCGGCAT 18
(2) INFORMATION FOR SEQ ID N0:551:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:551:
ID
TGAGATGGAG GGCGGCA 17
(2} INFORMATION FOR SEQ ID N0:552:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi} SEQUENCE DESCRIPTION: SEQ N0:552:
ID
TGAGATGGAG GGCGGC 16
(2) INFORMATION FOR SEQ ID N0:553:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:553:
ID
TGAGATGGAG GGCGG 15
(2) INFORMATION FOR SEQ ID N0:554:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:554:
ID
TGAGATGGAG GGCG 14
(2) INFORMATION FOR SEQ ID N0:555:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic'acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:555:
ID
TGAGATGGAG GGC 13
(2) INFORMATION FOR SEQ ID N0:556:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:556:
ID
TGAGATGGAG GG 12
(2) INFORMATION FOR SEQ ID N0:557:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:557:
ID
TGAGATGGAG G , 11
(2) INFORMATION FOR SEQ ID N0:558:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
~5~
(xi) SEQUENCE DESCRIPTION: SEQ N0:558:
ID
TGAGATGGAG 10
(2) INFORMATION FOR SEQ ID N0:559:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:559:
ID
GAGATGGAGG GCGGCATGGC GGGCACAGGC 35
TGGGC
(2) INFORMATION FOR SEQ ID N0:560:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:560:
ID
GAGATGGAGG GCGGCATGGC GGGCACAGGC 34
TGGG
(2) INFORMATION FOR SEQ ID N0:561:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:561:
ID
GAGATGGAGG GCGGCATGGC GGGCACAGGC 33
TGG
(2) INFORMATION FOR SEQ ID N0:562:.
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:562:
ID
GAGATGGAGG GCGGCATGGC GGGCACAGGC 32
TG
(2) INFORMATION FOR SEQ ID N0:563:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:563:
ID
GAGATGGAGG GCGGCATGGC GGGCACAGGC 31
T
(2) INFORMATION FOR SEQ ID N0:564:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
~ ~
(xi) SEQUENCE DESCRIPTION: SEQ N0:564:
ID
GAGATGGAGG GCGGCATGGC GGGCACAGGC 30
(2) INFORMATION FOR SEQ ID N0:565:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:565:
ID
GAGATGGAGG GCGGCATGGC GGGCACAGG 29
(2) INFORMATION FOR SEQ ID N0:566:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
.
(B) TYPE: nucleic
acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:566:
ID
GAGATGGAGG GCGGCATGGC GGGCACAG 28
(2) INFORMATION FOR SEQ ID N0:567:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 27 base pairs
(B} TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:567:
ID
GAGATGGAGG GCGGCATGGC GGGCACA 27
(2) INFORMATION FOR SEQ ID N0:568:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:568:
ID
GAGATGGAGG GCGGCATGGC GGGCAC 26
(2) INFORMATION FOR SEQ ID N0:569:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:569:
ID
GAGATGGAGG GCGGCATGGC GGGCA 25
(2) INFORMATION FOR SEQ ID N0:570:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:570:
ID
GAGATGGAGG GCGGCATGGC GGGC 24
(2) INFORMATION FOR SEQ ID N0:571:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:571:
ID
GAGATGGAGG GCGGCATGGC GGG 23
(2) INFORMATION FOR SEQ ID N0:572:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:572:
ID
GAGATGGAGG GCGGCATGGC GG 22
(2) INFORMATION FOR SEQ ID N0:573:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:573:
ID
GAGATGGAGG GCGGCATGGC G 21
(2) INFORMATION FOR SEQ ID N0:574:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
{B) TYPE: nucleic acid
{C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:574:
ID
GAGATGGAGG GCGGCATGGC 20
(2) INFORMATION FOR SEQ ID N0:575:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:575:
ID
GAGATGGAGG GCGGCATGG 19
(2) INFORMATION FOR SEQ ID N0:576:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCTNS99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:576:
ID
GAGATGGAGG GCGGCATG 18
(2) INFORMATION FOR SEQ ID N0:577:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
~
(B) TYPE: nucleic
acid
(C) STRANDEDNESS: single
{D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:577:
ID
GAGATGGAGG GCGGCAT 17
(2) INFORMATION FOR SEQ ID N0:578:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:578:
ID
GAGATGGAGG GCGGCA 16
(2) INFORMATION FOR SEQ ID N0:579:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
{C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:579:
ID
GAGATGGAGG GCGGC ~ 15
(2) INFORMATION FOR SEQ ID N0:580:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:580:
ID
GAGATGGAGG GCGG 14
(2) INFORMATION FOR SEQ ID N0:581:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:581:
ID
GAGATGGAGG GCG 13
(2) INFORMATION FOR SEQ ID N0:582:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:582:
ID
GAGATGGAGG GC 12
(2) INFORMATION FOR SEQ ID N0:583:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:583:
ID
GAGATGGAGG G 11
(2) INFORMATION FOR SEQ ID N0:589:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:584:
ID
GAGATGGAGG 10
(2) INFORMATION FOR SEQ ID N0:585:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:585:
ID
AGATGGAGGG CGGCATGGCG GGCACAGGCT 34
GGGC
(2) INFORMATION FOR SEQ ID N0:586:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:586:
ID
AGATGGAGGG CGGCATGGCG GGCACAGGCT 33
GGG
(2) INFORMATION FOR SEQ ID N0:587:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:587:
ID
AGATGGAGGG CGGCATGGCG GGCACAGGCT 32
GG
(2) INFORMATION FOR SEQ ID N0:588:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:588:
ID
AGATGGAGGG CGGCATGGCG GGCACAGGCT 31
G
(2) INFORMATION FOR SEQ ID N0:589:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:589:
ID
AGATGGAGGG CGGCATGGCG GGCACAGGCT 30
(2) INFORMATION FOR SEQ ID N0:590:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:590:
ID
AGATGGAGGG CGGCATGGCG GGCACAGGC 29
(2) INFORMATION FOR SEQ ID N0:591:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:591:
ID
AGATGGAGGG CGGCATGGCG GGCACAGG 28
(2) INFORMATION FOR SEQ ID N0:592:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:592:
ID
AGATGGAGGG CGGCATGGCG GGCACAG 27
(2) INFORMATION FOR SEQ ID N0:593:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:593:
ID
AGATGGAGGG CGGCATGGCG GGCACA 26
(2} INFORMATION FOR SEQ ID N0:594:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B} TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:594:
ID
AGATGGAGGG CGGCATGGCG GGCAC 25
(2) INFORMATION FOR SEQ ID N0:595:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:595:
ID
AGATGGAGGG CGGCATGGCG GGCA 24
{2) INFORMATION FOR SEQ ID N0:596:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:596:
ID
AGATGGAGGG CGGCATGGCG GGC 23
(2) INFORMATION FOR SEQ ID N0:597:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
{C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:597:
ID
AGATGGAGGG CGGCATGGCG GG 22
(2) INFORMATION FOR SEQ ID N0:598:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:598:
ID
AGATGGAGGG CGGCATGGCG G 21
(2) INFORMATION FOR SEQ ID N0:599c
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:599:
ID
AGATGGAGGG CGGCATGGCG 20
(2) INFORMATION FOR SEQ ID N0:600:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~~Z PGT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:600:
ID
AGATGGAGGG CGGCATGGC 19
(2) INFORMATION FOR SEQ ID N0:601:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:601:
ID
AGATGGAGGG CGGCATGG lg
(2) INFORMATION FOR SEQ ID N0:602:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:602:
ID
AGATGGAGGG CGGCATG 17
(2) INFORMATION FOR SEQ ID N0:603:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:603:
ID
AGATGGAGGG CGGCAT 16
(2) INFORMATION FOR SEQ ID N0:609:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:609:
ID
AGATGGAGGG CGGCA 15
(2) INFORMATION FOR SEQ ID N0:605:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:605:
ID
AGATGGAGGG CGGC 19
(2) INFORMATION FOR SEQ ID N0:606:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~~~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:606:
ID
AGATGGAGGG CGG 13
(2) INFORMATION FOR SEQ ID N0:607:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:607:
ID
AGATGGAGGG CG 12
(2) INFORMATION FOR SEQ ID N0:608:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA,(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:608:
ID
AGATGGAGGG C 11
(2) INFORMATION FOR SEQ ID N0:609:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:609:
ID
AGATGGAGGG 10
(2) INFORMATION FOR SEQ ID N0:610:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:610:
ID
GATGGAGGGC GGCATGGCGG GCACAGGCTG 33
GGC
(2) INFORMATION FOR SEQ ID N0:611:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:611:
ID
GATGGAGGGC GGCATGGCGG GCACAGGCTG 32
GG
(2) INFORMATION FOR SEQ ID N0:612:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:612:
ID
GATGGAGGGC GGCATGGCGG GCACAGGCTG 31
G
(2) INFORMATION FOR SEQ ID N0:613:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:613:
ID
GATGGAGGGC GGCATGGCGG GCACAGGCTG 30
(2) INFORMATION FOR SEQ ID N0:614:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:614:
ID
GATGGAGGGC GGCATGGCGG GCACAGGCT 29
(2) INFORMATION FOR SEQ ID N0:615:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:615:
ID
GATGGAGGGC GGCATGGCGG GCACAGGC 28
(2) INFORMATION FOR SEQ ID N0:616:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:616:
ID
GATGGAGGGC GGCATGGCGG GCACAGG 27
(2} INFORMATION FOR SEQ ID N0:617:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:617:
ID
GATGGAGGGC GGCATGGCGG GCACAG 26
(2) INFORMATION FOR SEQ ID N0:618:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ,u~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:618:
ID
GATGGAGGGC GGCATGGCGG GCACA 25
(2) INFORMATION FOR SEQ ID N0:619:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:619:
ID
GATGGAGGGC GGCATGGCGG GCAC 24
(2) INFORMATION FOR SEQ ID N0:620:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:620:
ID
GATGGAGGGC GGCATGGCGG GCA 23
(2) INFORMATION FOR SEQ ID N0:621:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:621:
ID
GATGGAGGGC GGCATGGCGG GC 22
(2) INFORMATION FOR SEQ ID N0:622:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:622:
ID
GATGGAGGGC GGCATGGCGG G 21
(2) INFORMATION FOR SEQ ID N0:623:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:623:
ID
GATGGAGGGC GGCATGGCGG 20
(2) INFORMATION FOR SEQ ID N0:629:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:624:
ID
GATGGAGGGC GGCATGGCG lg
(2) INFORMATION FOR SEQ ID N0:625:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:625:
ID
GATGGAGGGC GGCATGGC lg
(2) INFORMATION FOR SEQ ID N0:626:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 17 base pairs
(B} TYPE: nucleic~acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:626:
ID
GATGGAGGGC GGCATGG 17
(2) INFORMATION FOR SEQ ID N0:627:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:627:
ID
GATGGAGGGC GGCATG 16
(2) INFORMATION FOR SEQ ID N0:628:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:628:
ID
GATGGAGGGC GGCAT . 15
(2) INFORMATION FOR SEQ ID N0:629:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:629:
ID
GATGGAGGGC GGCA 14
(2) INFORMATION FOR SEQ ID N0:630:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:630:
ID
GATGGAGGGC GGC 13
(2) INFORMATION FOR SEQ ID N0:631:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:631:
ID
GATGGAGGGC GG 12
(2) INFORMATION FOR SEQ ID N0:632:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:632:
ID
GATGGAGGGC G 11
(2) INFORMATION FOR SEQ ID N0:633:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:633:
ID
GATGGAGGGC 10
(2) INFORMATION FOR SEQ ID N0:634:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:634:
ID
ATGGAGGGCG GCATGGCGGG CACAGGCTGG 32
GC
(2) INFORMATION FOR SEQ ID N0:635:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA'(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:635:
ID
ATGGAGGGCG GCATGGCGGG CACAGGCTGG 31
G
(2) INFORMATION FOR SEQ ID N0:636:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
l)
(xi) SEQUENCE DESCRIPTION: SEQ N0:636:
ID
ATGGAGGGCG GCATGGCGGG CACAGGCTGG 30
(2) INFORMATION FOR SEQ ID N0:637:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:637:
ID
ATGGAGGGCG GCATGGCGGG CACAGGCTG 29
(2) INFORMATION FOR SEQ ID N0:638:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:638:
ID
ATGGAGGGCG GCATGGCGGG CACAGGCT 2g
(2) INFORMATION FOR SEQ ID N0:639:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:639:
ID
ATGGAGGGCG GCATGGCGGG CACAGGC 27
(2) INFORMATION FOR SEQ ID N0:640:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:640:
ID
ATGGAGGGCG GCATGGCGGG CACAGG 26
(2) INFORMATION FOR SEQ ID N0:641:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:691:
ID
ATGGAGGGCG GCATGGCGGG CACAG 25
(2) INFORMATION FOR SEQ ID N0:692:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
~
(C) STRANDEDNESS:
single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
1r~3
(xi) SEQUENCE DESCRIPTION: SEQ N0:642:
ID
ATGGAGGGCG GCATGGCGGG CACA 24
(2) INFORMATION FOR SEQ ID N0:643:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:693:
ID
ATGGAGGGCG GCATGGCGGG CAC 23
(2) INFORMATION FOR SEQ ID N0:644:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:644:
ID
ATGGAGGGCG GCATGGCGGG CA 22
(2) INFORMATION FOR SEQ ID N0:645:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:645:
ID
ATGGAGGGCG GCATGGCGGG C 21
(2) INFORMATION FOR SEQ ID N0:646:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: Iin~ar
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:646:
ID
ATGGAGGGCG GCATGGCGGG 20
(2) INFORMATION FOR SEQ ID N0:697:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:647:
ID
ATGGAGGGCG GCATGGCGG 19
(2) INFORMATION FOR SEQ ID N0:648:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/I1S99/12775
~U
(xi) SEQUENCE DESCRIPTION: SEQ N0:648:
ID
ATGGAGGGCG GCATGGCG 18
(2) INFORMATION FOR SEQ ID N0:649:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:649:
ID
ATGGAGGGCG GCATGGC 17
(2) INFORMATION FOR SEQ ID N0:650:
(i) SEQUENCE CHARACTERISTICS:
(Ay LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:650:
ID
ATGGAGGGCG GCATGG 16
(2) INFORMATION FOR SEQ ID N0:651:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:651:
ID
ATGGAGGGCG GCATG 15
(2) INFORMATION FOR SEQ ID N0:652:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:652:
ID
ATGGAGGGCG GCAT 19
(2) INFORMATION FOR SEQ ID N0:653:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic'acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:653: -
ID
ATGGAGGGCG GCA 13
(2) INFORMATION FOR SEQ ID N0:659:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 (' ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:654:
ID
ATGGAGGGCG GC 12
{2) INFORMATION FOR SEQ ID N0:655:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:655:
ID
ATGGAGGGCG G 11
(2) INFORMATION FOR SEQ ID N0:656:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:656:
ID
ATGGAGGGCG 10
(2) INFORMATION FOR SEQ ID N0:657:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS:,single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:657:
ID
TGGAGGGCGG CATGGCGGGC ACAGGCTGGG 31
C
(2) INFORMATION FOR SEQ ID N0:658:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:658:
ID
TGGAGGGCGG CATGGCGGGC ACAGGCTGGG 30
(2) INFORMATION FOR SEQ ID N0:659:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
{D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:659:
ID
TGGAGGGCGG CATGGCGGGC ACAGGCTGG 2g
(2) INFORMATION FOR SEQ ID N0:660:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ') 2 PCT/US99/I2775
(xi) SEQUENCE DESCRIPTION: SEQ N0:660:
ID
TGGAGGGCGG CATGGCGGGC ACAGGCTG 2g
(2) INFORMATION FOR SEQ ID N0:661:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:661:
ID
TGGAGGGCGG CATGGCGGGC ACAGGCT 27
(2) INFORMATION FOR SEQ ID N0:662:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:662:
ID
TGGAGGGCGG CATGGCGGGC ACAGGC 26
(2) INFORMATION FOR SEQ ID N0:663:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:663:
ID
TGGAGGGCGG CATGGCGGGC ACAGG 25
(2) INFORMATION FOR SEQ ID N0:664:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:664:
ID
TGGAGGGCGG CATGGCGGGC ACAG 24
(2) INFORMATION FOR SEQ ID N0:665:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:665:
ID
TGGAGGGCGG CATGGCGGGC ACA 23
(2) INFORMATION FOR SEQ ID N0:666:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
i4~
(xi) SEQUENCE DESCRIPTION: SEQ N0:666:
ID
TGGAGGGCGG CATGGCGGGC AC 22
(2) INFORMATION FOR SEQ ID N0:667:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:667:
ID
TGGAGGGCGG CATGGCGGGC A 21
(2) INFORMATION FOR SEQ ID N0:668:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic, acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:66B:
ID
TGGAGGGCGG CATGGCGGGC 20
(2) INFORMATION FOR SEQ ID N0:669:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:669:
ID
TGGAGGGCGG CATGGCGGG lg
(2) INFORMATION FOR SEQ ID N0:6?0:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:670:
ID
TGGAGGGCGG CATGGCGG lg
(2) INFORMATION FOR SEQ ID N0:671:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:671:
ID
TGGAGGGCGG CATGGCG 17
(2) INFORMATION FOR SEQ ID N0:672:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:672:
ID
TGGAGGGCGG CATGGC 16
(2) INFORMATION FOR SEQ ID N0:673:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:673:
ID
TGGAGGGCGG CATGG 15
(2) INFORMATION FOR SEQ ID N0:674:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:679:
ID
TGGAGGGCGG CATG lq
(2) INFORMATION FOR SEQ ID N0:675:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:675:
ID
TGGAGGGCGG CAT 13
(2) INFORMATION FOR SEQ ID N0:676:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:676:
ID
TGGAGGGCGG CA 12
(2) INFORMATION FOR SEQ ID N0:677:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:677:
ID
TGGAGGGCGG C 11
(2) INFORMATION FOR SEQ ID N0:678:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:678:
ID
TGGAGGGCGG 10
(2) INFORMATION FOR SEQ ID N0:679:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic~acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:679:
ID
GGAGGGCGGC ATGGCGGGCA CAGGCTGGGC 30
(2) INFORMATION FOR SEQ ID N0:680:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:680:
ID
GGAGGGCGGC ATGGCGGGCA CAGGCTGGG 29
(2) INFORMATION FOR SEQ ID N0:681:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:681:
ID
GGAGGGCGGC ATGGCGGGCA CAGGCTGG 28
(2) INFORMATION FOR SEQ ID N0:682:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:682:
ID
GGAGGGCGGC ATGGCGGGCA CAGGCTG 27
(2) INFORMATION FOR SEQ ID N0:683:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B} TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:683:
ID
GGAGGGCGGC ATGGCGGGCA CAGGCT 26
(2) INFORMATION FOR SEQ ID N0:684:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PeT /US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:689:
ID
GGAGGGCGGC ATGGCGGGCA CAGGC 25
(2) INFORMATION FOR SEQ ID N0:685:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:685:
ID
GGAGGGCGGC ATGGCGGGCA CAGG 24
(2) INFORMATION FOR SEQ ID N0:686:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:686:
ID
GGAGGGCGGC ATGGCGGGCA CAG 23
(2) INFORMATION FOR SEQ ID N0:687:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:687:
ID
GGAGGGCGGC ATGGCGGGCA CA 22
(2) INFORMATION FOR SEQ ID N0:688:
(i) SEQUENCE CHARACTERISTICS:
(Ay LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(iiy MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:688:
ID
GGAGGGCGGC ATGGCGGGCA C 21
(2) INFORMATION FOR SEQ ID N0:689:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:689:
ID
GGAGGGCGGC ATGGCGGGCA 20
(2) INFORMATION FOR SEQ ID N0:690:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
,
(xi) SEQUENCE DESCRIPTION: SEQ N
ID 0:690:
GGAGGGCGGC ATGGCGGGC lg
(2) INFORMATION FOR SEQ ID N0:691:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:691:
ID
GGAGGGCGGC ATGGCGGG lg
(2) INFORMATION FOR SEQ ID N0:692:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:692:
ID
GGAGGGCGGC ATGGCGG ~ 17
(2) INFORMATION FOR SEQ ID N0:693:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:693:
ID
GGAGGGCGGC ATGGCG 16
(2) INFORMATION FOR SEQ ID N0:699:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:699:
ID
GGAGGGCGGC ATGGC 15
(2) INFORMATION FOR SEQ ID N0:695:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic. acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:695:
ID
GGAGGGCGGC ATGG lq
(2) INFORMATION FOR SEQ ID N0:696:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 t ' PGT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:696:
ID
GGAGGGCGGC ATG 13
(2) INFORMATION FOR SEQ ID N0:697:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:697:
ID
GGAGGGCGGC AT 12
(2) INFORMATION FOR SEQ ID N0:698:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:69B:
ID
GGAGGGCGGC A 11
(2) INFORMATION FOR SEQ ID N0:699.:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:,single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:699:
ID
GGAGGGCGGC 10
(2) INFORMATION FOR SEQ ID N0:700:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:700:
ID
GAGGGCGGCA TGGCGGGCAC AGGCTGGGC 2g
(2) INFORMATION FOR SEQ ID N0:701:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:701:
ID
GAGGGCGGCA TGGCGGGCAC AGGCTGGG 2g
(2) INFORMATION FOR SEQ ID N0:702:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
~ ~9
(xi) SEQUENCE DESCRIPTION: SEQ N0:702:
ID
GAGGGCGGCA TGGCGGGCAC AGGCTGG 27
(2) INFORMATION FOR SEQ ID N0:703:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA,(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:703:
ID
GAGGGCGGCA TGGCGGGCAC AGGCTG 26
(2) INFORMATION FOR SEQ ID N0:709:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
{D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:704:
ID
GAGGGCGGCA TGGCGGGCAC AGGCT 25
(2) INFORMATION FOR SEQ ID N0:705:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:705:
ID
GAGGGCGGCA TGGCGGGCAC AGGC 24
(2) INFORMATION FOR SEQ ID N0:706:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:706:
ID
GAGGGCGGCA TGGCGGGCAC AGG 23
(2) INFORMATION FOR SEQ ID N0:707:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
{C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:707:
ID
GAGGGCGGCA TGGCGGGCAC AG 22
(2) INFORMATION FOR SEQ ID N0:708:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:708:
ID
GAGGGCGGCA TGGCGGGCAC A 21
(2) INFORMATION FOR SEQ ID N0:709:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:709:
ID
GAGGGCGGCA TGGCGGGCAC 20
(2) INFORMATION FOR SEQ ID N0:710:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:710:
ID
GAGGGCGGCA TGGCGGGCA 1g
(2) INFORMATION FOR SEQ ID N0:711:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:711:
ID
GAGGGCGGCA TGGCGGGC lg
(2) INFORMATION FOR SEQ ID N0:712:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:712:
ID
GAGGGCGGCA TGGCGGG 17
(2) INFORMATION FOR SEQ ID D10:713:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:713:
ID
GAGGGCGGCA TGGCGG 16
{2) INFORMATION FOR SEQ ID N0:719:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCTNS99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:714:
ID
GAGGGCGGCA TGGCG 15
(2) INFORMATION FOR SEQ ID N0:715:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:715:
ID
GAGGGCGGCA TGGC 14
(2) INFORMATION FOR SEQ ID N0:716:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:716:
ID
GAGGGCGGCA TGG 13
(2) INFORMATION FOR SEQ ID N0:717:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:717:
ID
GAGGGCGGCA TG 12
(2) INFORMATION FOR SEQ ID N0:718:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:718:
ID
GAGGGCGGCA T 11
(2} INFORMATION FOR SEQ ID N0:719:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTIQN: SEQ N0:719:
ID
GAGGGCGGCA 10
(2) INFORMATION FOR SEQ ID N0:720:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
'2Z
(xi) SEQUENCE DESCRIPTION: SEQ N0:720:
ID
AGGGCGGCAT GGCGGGCACA GGCTGGGC 2g
(2) INFORMATION FOR SEQ ID N0:721:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:'single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:721:
ID
AGGGCGGCAT GGCGGGCACA GGCTGGG 27
(2) INFORMATION FOR SEQ ID N0:722:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:722:
ID
AGGGCGGCAT GGCGGGCACA GGCTGG 26
(2) INFORMATION FOR SEQ ID N0:723:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:723:
ID
AGGGCGGCAT GGCGGGCACA GGCTG 25
(2) INFORMATION FOR SEQ ID N0:729:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:729:
ID
AGGGCGGCAT GGCGGGCACA GGCT 24
(2) INFORMATION FOR SEQ ID N0:725:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:725:
ID
AGGGCGGCAT GGCGGGCACA GGC 23
(2) INFORMATION FOR SEQ ID N0:726:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
123
(xi) SEQUENCE DESCRIPTION: SEQ N0:726:
ID
AGGGCGGCAT GGCGGGCACA GG 22
(2) INFORMATION FOR SEQ ID N0:727:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:727:
ID
AGGGCGGCAT GGCGGGCACA G 21
(2) INFORMATION FOR SEQ ID N0:728:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:728:
ID
AGGGCGGCAT GGCGGGCACA 20
(2) INFORMATION FOR SEQ ID N0:729:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:729:
ID
AGGGCGGCAT GGCGGGCAC 1g
(2) INFORMATION FOR SEQ ID N0:730:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:730:
ID
AGGGCGGCAT GGCGGGCA lg
(2) INFORMATION FOR SEQ ID N0:731:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:731:
ID
AGGGCGGCAT GGCGGGC 17
(2) INFORMATION FOR SEQ ID N0:732:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:732:
ID
AGGGCGGCAT GGCGGG 16
(2) INFORMATION FOR SEQ ID N0:733:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
{xi) SEQUENCE DESCRIPTION: SEQ N0:733:
ID
AGGGCGGCAT GGCGG 15
(2) INFORMATION FOR SEQ ID N0:739:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:734:
ID
AGGGCGGCAT GGCG 14
(2) INFORMATION FOR SEQ ID N0:735:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:735:
ID
AGGGCGGCAT GGC 13
(2) INFORMATION FOR SEQ ID N0:736:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:736:
ID
AGGGCGGCAT GG 12
(2) INFORMATION FOR SEQ ID N0:737:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:737:
ID
AGGGCGGCAT G 11
(2) INFORMATION FOR SEQ ID N0:738:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:738:
ID
AGGGCGGCAT 10
(2) INFORMATION FOR SEQ ID N0:739:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:739:
ID
GGGCGGCATG GCGGGCACAG GCTGGGC 27
(2) INFORMATION FOR SEQ ID N0:740:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SE N0:740:
ID
GGGCGGCATG GCGGGCACAG GCTGGG 26
(2) INFORMATION FOR SEQ ID N0:741:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA.(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:741:
ID
GGGCGGCATG GCGGGCACAG GCTGG 25
(2) INFORMATION FOR SEQ ID N0:792:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:742:
ID
GGGCGGCATG GCGGGCACAG GCTG 24
(2} INFORMATION FOR SEQ ID N0:743:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:743:
ID
GGGCGGCATG GCGGGCACAG GCT 23
(2) INFORMATION FOR SEQ ID N0:744:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/ITS99/1Z775
(xi) SEQUENCE DESCRIPTION: SEQ N0:744:
ID
GGGCGGCATG GCGGGCACAG GC 22
(2) INFORMATION FOR SEQ ID N0:745:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:745:
ID
GGGCGGCATG GCGGGCACAG G , 21
(2) INFORMATION FOR SEQ ID N0:746:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:746:
ID
GGGCGGCATG GCGGGCACAG 20
(2) INFORMATION FOR SEQ ID N0:797:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(iiy MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:797:
ID
GGGCGGCATG GCGGGCACA lg
(2) INFORMATION FOR SEQ ID N0:748:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:748:
ID
GGGCGGCATG GCGGGCAC lg
(2) INFORMATION FOR SEQ ID N0:749:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:749:
ID
GGGCGGCATG GCGGGCA 17
(2) INFORMATION FOR SEQ ID N0:750:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCTNS99/12775
12~
(xi) SEQUENCE DESCRIPTION: SEQ N0:750:
ID
GGGCGGCATG GCGGGC 16
(2) INFORMATION FOR SEQ ID N0:751:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
{ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:751:
ID
GGGCGGCATG GCGGG 15
(2) INFORMATION FOR SEQ ID N0:752:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:752:
ID
GGGCGGCATG GCGG 14
(2) INFORMATION FOR SEQ ID N0:753:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
{D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:753:
ID
GGGCGGCATG GCG 13
(2) INFORMATION FOR SEQ ID N0:754:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:759:
ID
GGGCGGCATG GC 12
(2) INFORMATION FOR SEQ ID N0:755:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA {genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:755:
ID
GGGCGGCATG G 11
(2) INFORMATION FOR SEQ ID N0:756:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 '~~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:756:
ID
GGGCGGCATG ' 10
(2) INFORMATION FOR SEQ ID N0:757:
(i) SEQUENCE CHARACTERISTICS:'
(A} LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:757:
ID
GGCGGCATGG CGGGCACAGG CTGGGC 26
(2) INFORMATION FOR SEQ ID N0:758:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:758:
ID
GGCGGCATGG CGGGCACAGG CTGGG 25
(2) INFORMATION FOR SEQ ID N0:759:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic, acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:759:
ID
GGCGGCATGG CGGGCACAGG CTGG 24
(2) INFORMATION FOR SEQ ID N0:760:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:760:
ID
GGCGGCATGG CGGGCACAGG CTG 23
(2) INFORMATION FOR SEQ ID N0:761:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:761:
ID
GGCGGCATGG CGGGCACAGG CT 22
(2) INFORMATION FOR SEQ ID N0:762:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99163938 PCT/US99/12775
i
(xi) SEQUENCE DESCRIPTION: SEQ N0:762:
ID
GGCGGCATGG CGGGCACAGG C 21
(2) INFORMATION FOR SEQ ID N0:763:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:763:
ID
GGCGGCATGG CGGGCACAGG 20
(2) INFORMATION FOR SEQ ID N0:764:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:769:
ID
GGCGGCATGG CGGGCACAG 19
(2) INFORMATION FOR SEQ ID N0:765:
(i) SEQUENCE CHARACTERISTICS:
(Ay LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:765:
ID
GGCGGCATGG CGGGCACA lg
(2) INFORMATION FOR SEQ ID N0:766:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:766:
ID
GGCGGCATGG CGGGCAC 17
(2) INFORMATION FOR SEQ ID N0:767:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B} TYPE: nucleic acid
(Cy STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:767:
ID
GGCGGCATGG CGGGCA 16
(2) INFORMATION FOR SEQ ID N0:768:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA.(genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
1 ~~
(xi) SEQUENCE DESCRIPTION: SEQ N0:768:
ID
GGCGGCATGG CGGGC 15
(2) INFORMATION FOR SEQ ID N0:769:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:769:
ID
GGCGGCATGG CGGG 14
(2) INFORMATION FOR SEQ ID N0:770:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic'acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:770:
ID
GGCGGCATGG CGG 13
(2) INFORMATION FOR SEQ ID N0:771:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:771:
ID
GGCGGCATGG CG 12
(2) INFORMATION FOR SEQ ID N0:772:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:772:
ID
GGCGGCATGG C , 11
(2) INFORMATION FOR SEQ ID N0:773:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:773:
ID
GGCGGCATGG 10
(2) INFORMATION FOR SEQ ID N0:779:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PC'T/US99/12775
~3 i
(xi) SEQUENCE DESCRIPTION: SEQ N0:779:
ID
GCGGCATGGC GGGCACAGGC TGGGC 25
(2) INFORMATION FOR SEQ ID N0:775:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:775:
ID
GCGGCATGGC GGGCACAGGC TGGG 29
(2) INFORMATION FOR SEQ ID N0:776:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:776:
ID
GCGGCATGGC GGGCACAGGC TGG 23
(2) INFORMATION FOR SEQ ID N0:777:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:777:
ID
GCGGCATGGC GGGCACAGGC TG 22
(2) INFORMATION FOR SEQ ID N0:778:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:778:
ID
GCGGCATGGC GGGCACAGGC T 21
(2) INFORMATION FOR SEQ ID N0:779:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:779:
ID
GCGGCATGGC GGGCACAGGC 20
(2) INFORMATION FOR SEQ ID N0:780:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/IJS99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:780:
ID
GCGGCATGGC GGGCACAGG 1g
(2) INFORMATION FOR SEQ ID N0:781:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:781:
ID
GCGGCATGGC GGGCACAG lg
(2) INFORMATION FOR SEQ ID N0:782:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:782:
ID
GCGGCATGGC GGGCACA 17
(2) INFORMATION FOR SEQ ID N0:783:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:783:
ID
GCGGCATGGC GGGCAC ~ 16
(2) INFORMATION FOR SEQ ID N0:784:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:784:
ID
GCGGCATGGC GGGCA 15
(2) INFORMATION FOR SEQ ID N0:785:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:785:
ID
GCGGCATGGC GGGC 14
(2) INFORMATION FOR SEQ ID N0:786:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic_acid.
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:786:
ID
GCGGCATGGC GGG 13
{2) INFORMATION FOR SEQ ID N0:787:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:787:
ID
GCGGCATGGC GG 12
(2) INFORMATION FOR SEQ ID N0:788:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:788:
ID
GCGGCATGGC G 11
(2) INFORMATION FOR SEQ ID N0:789:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:789:
ID
GCGGCATGGC 10
(2) INFORMATION FOR SEQ ID N0:790:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:790:
ID
CGGCATGGCG GGCACAGGCT GGGC 24
(2) INFORMATION FOR SEQ ID N0:791:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:791:
ID
CGGCATGGCG GGCACAGGCT GGG 23
(2) INFORMATION FOR SEQ ID N0:792:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
~
(xi) SEQUENCE DESCRIPTION: SEQ N0:792:
ID
CGGCATGGCG GGCACAGGCT GG 22
(2) INFORMATION FOR SEQ ID N0:793:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:793:
ID
CGGCATGGCG GGCACAGGCT G 21
(2) INFORMATION FOR SEQ ID N0:799:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:794:
ID
CGGCATGGCG GGCACAGGCT 20
(2) INFORMATION FOR SEQ ID N0:795:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:795:
ID
CGGCATGGCG GGCACAGGC 19
(2) INFORMATION FOR SEQ ID N0:796:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:796:
ID
CGGCATGGCG GGCACAGG 18
(2) INFORMATION FOR SEQ ID N0:797:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:797:
ID
CGGCATGGCG GGCACAG 17
(2) INFORMATION FOR SEQ ID N0:798:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PGT/US99/12775
~ ~
(xi) SEQUENCE DESCRIPTION: SEQ N0:798:
ID
CGGCATGGCG GGCACA 16
(2) INFORMATION FOR SEQ ID N0:799:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:799:
ID
CGGCATGGCG GGCAC 15
(2) INFORMATION FOR SEQ ID N0:800:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(iiy MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:800:
ID
CGGCATGGCG GGCA 14
(2) INFORMATION FOR SEQ ID N0:801:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:801:
ID
CGGCATGGCG GGC 13
(2) INFORMATION FOR SEQ ID N0:802:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:802:
ID
CGGCATGGCG GG 12
(2) INFORMATION FOR SEQ ID N0:803:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:803:
ID
CGGCATGGCG G 11
(2) INFORMATION FOR SEQ ID N0:809:
(iy SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 1.2 PCT/US99/12775
,
1
(xi) SEQUENCE DESCRIPTION: SEQ N
ID :804:
0
CGGCATGGCG 10
(2) INFORMATION FOR SEQ ID N0:805:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:805:
ID
GGCATGGCGG GCACAGGCTG GGC 23
(2) INFORMATION FOR SEQ ID N0:806:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:806:
ID
GGCATGGCGG GCACAGGCTG GG 22
(2) INFORMATION FOR SEQ ID N0:807:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:807:
ID
GGCATGGCGG GCACAGGCTG G 21
(2) INFORMATION FOR SEQ ID N0:808:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:808:
ID
GGCATGGCGG GCACAGGCTG 20
(2} INFORMATION FOR SEQ ID N0:809:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:809:
ID
GGCATGGCGG GCACAGGCT lg
(2) INFORMATION FOR SEQ ID N0:810:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
W O 99/63938 i ~3 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:810:
ID
GGCATGGCGG GCACAGGC lg
(2) INFORMATION FOR SEQ ID N0:811:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:811:
ID
GGCATGGCGG GCACAGG 17
(2) INFORMATION FOR SEQ ID N0:812:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic, acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:812:
ID
GGCATGGCGG GCACAG 16
(2) INFORMATION FOR SEQ ID N0:813:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:813:
ID
GGCATGGCGG GCACA 15
(2) INFORMATION FOR SEQ ID N0:819:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ NO:B14:
TD
GGCATGGCGG GCAC 14
(2) INFORMATION FOR SEQ ID N0:815:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:815:
ID
GGCATGGCGG GCA 13
(2) INFORMATION FOR SEQ ID N0:816:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:816:
ID
GGCATGGCGG GC 12
(2) INFORMATION FOR SEQ ID N0:817:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:817:
ID
GGCATGGCGG G 11
(2) INFORMATION FOR SEQ ID N0:818:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:818:
ID
GGCATGGCGG 10
(2) INFORMATION FOR SEQ ID N0:819:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:819:
ID
GCATGGCGGG CACAGGCTGG GC 22
(2) INFORMATION FOR SEQ ID N0:820:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ NO:B20:
ID
GCATGGCGGG CACAGGCTGG G 21
(2) INFORMATION FOR SEQ ID N0:821:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:821:
ID
GCATGGCGGG CACAGGCTGG 20
(2) INFORMATION FOR SEQ ID N0:822:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
~3~
(xi) SEQUENCE DESCRIPTION: SEQ N0:822:
ID
GCATGGCGGG CACAGGCTG 19
(2) INFORMATION FOR SEQ ID N0:823:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic~acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:823:
ID
GCATGGCGGG CACAGGCT lg
(2) INFORMATION FOR SEQ ID N0:829:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:824:
ID
GCATGGCGGG CACAGGC 17
(2) INFORMATION FOR SEQ ID N0:825:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:825:
ID
GCATGGCGGG CACAGG 16
(2) INFORMATION FOR SEQ ID N0:826:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:826:
ID
GCATGGCGGG CACAG 15
(2) INFORMATION FOR SEQ ID N0:827:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:827:
ID
GCATGGCGGG CACA 14
(2) INFORMATION FOR SEQ ID N0:828:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D} TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:828:
ID
GCATGGCGGG CAC 13
(2) INFORMATION FOR SEQ ID N0:829:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:829:
ID
GCATGGCGGG CA 12
(2) INFORMATION FOR SEQ ID N0:830:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:830:
ID
GCATGGCGGG C 11
(2) INFORMATION FOR SEQ ID N0:831:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:831:
ID
GCATGGCGGG 10
(2) INFORMATION FOR SEQ ID N0:832:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA.(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:832:
ID
CATGGCGGGC ACAGGCTGGG C 21
(2) INFORMATION FOR SEQ ID N0:833:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:833:
ID
CATGGCGGGC ACAGGCTGGG 20
(2) INFORMATION FOR SEQ ID N0:834:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ( ~ 1 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:834:
ID
CATGGCGGGC ACAGGCTGG lg
(2) INFORMATION FOR SEQ ID N0:835:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:835:
ID
CATGGCGGGC ACAGGCTG 18
(2) INFORMATION FOR SEQ ID N0:836:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:836:
ID
CATGGCGGGC ACAGGCT . 17
(2) INFORMATION FOR SEQ ID N0:837:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:837:
ID
CATGGCGGGC ACAGGC 16
(2) INFORMATION FOR SEQ ID N0:838:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:838:
ID
CATGGCGGGC ACAGG 15
(2) INFORMATION FOR SEQ ID N0:839:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:839:
ID
CATGGCGGGC ACAG 19
(2) INFORMATION FOR SEQ ID N0:840:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/I2775
~
(xi) SEQUENCE DESCRIPTION: SEQ N0:890:
ID
CATGGCGGGC ACA 13
(2) INFORMATION FOR SEQ ID N0:841:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:841:
ID
CATGGCGGGC AC 12
(2) INFORMATION FOR SEQ ID N0:842:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:842:
ID
CATGGCGGGC A 11
(2) INFORMATION FOR SEQ ID N0:843:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:843:
ID
CATGGCGGGC 10
(2) INFORMATION FOR SEQ ID N0:899:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:844:
ID
ATGGCGGGCA CAGGCTGGGC 20
(2) INFORMATION FOR SEQ ID N0:845:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:845:
ID
ATGGCGGGCA CAGGCTGGG 19
(2) INFORMATION FOR SEQ ID N0:846:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(Cy STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PC'T/US99/12775
~ ~~
(xi) SEQUENCE DESCRIPTION: SEQ N0:846:
ID
ATGGCGGGCA CAGGCTGG 18
(2) INFORMATION FOR SEQ ID N0:847:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:847:
ID
ATGGCGGGCA CAGGCTG 17
(2) INFORMATION FOR SEQ ID N0:848:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: ,single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:898:
ID
ATGGCGGGCA CAGGCT 16
(2) INFORMATION FOR SEQ ID N0:849:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:849:
ID
ATGGCGGGCA CAGGC 15
(2) INFORMATION FOR SEQ ID N0:850:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic~acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi} SEQUENCE DESCRIPTION: SEQ N0:850:
ID
ATGGCGGGCA CAGG 14
(2) INFORMATION FOR SEQ ID N0:851:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:851:
ID
ATGGCGGGCA CAG 13
(2) INFORMATION FOR SEQ ID N0:852:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ( PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:852:
ID
ATGGCGGGCA CA 12
(2) INFORMATION FOR SEQ ID N0:853:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 11 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:853:
ID
ATGGCGGGCA C 11
(2) INFORMATION FOR SEQ ID N0:854:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:854:
ID
ATGGCGGGCA 10
(2) INFORMATION FOR SEQ ID N0:855:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:855:
ID
TGGCGGGCAC AGGCTGGGC 19
(2) INFORMATION FOR SEQ ID N0:856:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:856:
ID
TGGCGGGCAC AGGCTGGG 18
(2) INFORMATION FOR SEQ ID X10:857:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:857:
ID
TGGCGGGCAC AGGCTGG 17
(2) INFORMATION FOR SEQ ID N0:858:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ 5~ PCT/C1S99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:858:
ID
TGGCGGGCAC AGGCTG 16
(2) INFORMATION FOR SEQ ID N0:859:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:859:
ID
TGGCGGGCAC AGGCT 15
(2) INFORMATION FOR SEQ ID N0:860:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:860:
ID
TGGCGGGCAC AGGC 19
(2) INFORMATION FOR SEQ ID N0:861:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:861:
ID
TGGCGGGCAC AGG 13
(2) INFORMATION FOR SEQ ID N0:862:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:862:
ID
TGGCGGGCAC AG 12
(2) INFORMATION FOR SEQ ID N0:863:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:863:
ID
TGGCGGGCAC A ~ 11
(2) INFORMATION FOR SEQ ID N0:864:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 '~~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:864:
ID
TGGCGGGCAC 10
(2) INFORMATION FOR SEQ ID N0:865:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 18 base pairs
{B) TYPE: nucleic acid
{C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:865:
ID
GGCGGGCACA GGCTGGGC 18
(2) INFORMATION FOR SEQ ID N0:866:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:866:
ID
GGCGGGCACA GGCTGGG 17
(2) INFORMATION FOR SEQ ID N0:867:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:867:
ID
GGCGGGCACA GGCTGG 16
(2) INFORMATION FOR SEQ ID N0:868:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:868:
ID
GGCGGGCACA GGCTG 15
(2) INFORMATION FOR SEQ ID N0:869:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:869:
ID
GGCGGGCACA GGCT 14
(2) INFORMATION FOR SEQ ID N0:870:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
{D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99163938 ~ PCTNS99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:870:
ID
GGCGGGCACA GGC 13
(2) INFORMATION FOR SEQ ID N0:871:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:871:
ID
GGCGGGCACA GG 12
(2) INFORMATION FOR SEQ ID N0:872:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:872:
ID
GGCGGGCACA G 11
(2) INFORMATION FOR SEQ ID N0:873:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:873:
ID
GGCGGGCACA 10
(2) INFORMATION FOR SEQ ID N0:874:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:874:
ID
GCGGGCACAG GCTGGGC 17
(2) INFORMATION FOR SEQ ID N0:875:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:875:
ID
GCGGGCACAG GCTGGG 16
(2) INFORMATION FOR SEQ ID N0:876:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 ' ~ PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:876:
ID
GCGGGCACAG GCTGG 15
(2) INFORMATION FOR SEQ ID N0:877:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:877:
ID
GCGGGCACAG GCTG 14
(2) INFORMATION FOR SEQ ID N0:878:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:878:
ID
GCGGGCACAG GCT 13
(2) INFORMATION FOR SEQ ID N0:879:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:879:
ID
GCGGGCACAG GC 12
(2) INFORMATION FOR SEQ ID N0:880:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:880:
ID
GCGGGCACAG G 11
(2) INFORMATION FOR SEQ ID N0:881:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:881:
ID
GCGGGCACAG 10
(2) INFORMATION FOR SEQ ID N0:882:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/b3938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:882:
ID
CGGGCACAGG CTGGGC 16
(2) INFORMATION FOR SEQ ID N0:883:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:883:
ID
CGGGCACAGG CTGGG 15
(2) INFORMATION FOR SEQ ID N0:889:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:889:
ID
CGGGCACAGG CTGG 14
(2) INFORMATION FOR SEQ ID N0:885:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:885:
ID
CGGGCACAGG CTG 13
(2) INFORMATION FOR SEQ ID N0:886:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:886:
ID
CGGGCACAGG CT 12
(2) INFORMATION FOR SEQ ID N0:887:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:887:
ID
CGGGCACAGG C 11
(2) INFORMATION FOR SEQ ID N0:888:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic~acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:888:
ID
CGGGCACAGG 10
(2) INFORMATION FOR SEQ ID N0:889:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:889:
ID
GGGCACAGGC TGGGC 15
(2) INFORMATION FOR SEQ ID N0:890:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:890:
ID
GGGCACAGGC TGGG 14
(2) INFORMATION FOR SEQ ID N0:891:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:891:
ID
GGGCACAGGC TGG 13
(2) INFORMATION FOR SEQ ID N0:892:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:892:
ID
GGGCACAGGC TG 12
(2) INFORMATION FOR SEQ ID N0:893:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:893:
ID
GGGCACAGGC T 11
(2) INFORMATION FOR SEQ ID N0:894:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(xi) SEQUENCE DESCRIPTION: SEQ N0:899:
ID
GGGCACAGGC 10
(2) INFORMATION FOR SEQ ID N0:895:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:895:
ID
GGCACAGGCT GGGC 14
(2) INFORMATION FOR SEQ ID N0:896:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA.(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:896:
ID
GGCACAGGCT GGG 13
(2) INFORMATION FOR SEQ ID N0:897:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:897:
ID
GGCACAGGCT GG 12
(2) INFORMATION FOR SEQ ID N0:898:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:898:
ID
GGCACAGGCT G 11
(2) INFORMATION FOR SEQ ID N0:899:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:899:
ID
GGCACAGGCT 10
(2) INFORMATION FOR SEQ ID N0:900:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PC'T/US99/12775
IS2
(xi) SEQUENCE DESCRIPTION: SEQ N0:900:
ID
GCACAGGCTG GGC 13
(2) INFORMATION FOR SEQ ID N0:901:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:901:
ID
GCACAGGCTG GG 12
(2) INFORMATION FOR SEQ ID N0:902:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:902:
ID
GCACAGGCTG G 11
(2) INFORMATION FOR SEQ ID N0:903:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:'single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:903:
ID
GCACAGGCTG 10
(2) INFORMATION FOR SEQ ID N0:904:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:904:
ID
CACAGGCTGG GC 12
(2) INFORMATION FOR SEQ ID N0:905:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:905:
ID
CACAGGCTGG G 11
(2) INFORMATION FOR SEQ ID N0:906:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
~S3
(xi) SEQUENCE DESCRIPTION: SEQ N0:906:
ID
CACAGGCTGG 10
(2) INFORMATION FOR SEQ ID N0:907:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA'(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:907:
ID
ACAGGCTGGG C 11
(2) INFORMATION FOR SEQ ID N0:908:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:908:
ID
ACAGGCTGGG 10
(2) INFORMATION FOR SEQ ID N0:909:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:909:
ID
CAGGCTGGGC 10
(2} INFORMATION FOR SEQ ID N0:910:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 51 base pairs
(B} TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:910:
ID
GGCGGCCTGG AAAGCTGAGA TGGAGGGCGG 51
CATGGCGGGC ACAGGCTGGG C
(2) INFORMATION FOR SEQ ID N0:911:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:911:
ID
GCGGCCTGGA AAGCTGAGAT GGAGGGCGGC 50
ATGGCGGGCA CAGGCTGGGC
(2) INFORMATION FOR SEQ ID N0:912:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:912:
ID
CA 02316994 2000-06-30
WO 99!63938 PCT/US99/12775
IS'~
CGGCCTGGAA AGCTGAGATG GAGGGCGGCA TGGCGGGCAC AGGCTGGGC49
(2) INFORMATION FOR SEQ ID N0:913:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 98 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:913:
GGCCTGGAAA GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCTGGGC48
(2) INFORMATION FOR SEQ ID N0:914:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 97 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:,single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:914:
GCCTGGAAAG CTGAGATGGA GGGCGGCATG GCGGGCACAG GCTGGGC47
(2) INFORMATION FOR SEQ ID N0:915:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:915:
CCTGGAAAGC TGAGATGGAG GGCGGCATGG CGGGCACAGG CTGGGC96
(2) INFORMATION FOR SEQ ID N0:916:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:916:
CTGGAAAGCT GAGATGGAGG GCGGCATGGC GGGCACAGGC TGGGC45
(2) INFORMATION FOR SEQ ID N0:917:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 94 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:917:
TGGAAAGCTG AGATGGAGGG CGGCATGGCG GGCACAGGCT GGGC44
(2) INFORMATION FOR SEQ ID N0:918:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:918:
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
~~s
GGAAAGCTGA GATGGAGGGC GGCATGGCGG GCACAGGCTG GGC 43
(2) INFORMATION FOR SEQ ID N0:919:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:919:
GAAAGCTGAG ATGGAGGGCG GCATGGCGGG CACAGGCTGG GC 42
(2) INFORMATION FOR SEQ ID N0:920:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:920:
AAAGCTGAGA TGGAGGGCGG CATGGCGGGC ACAGGCTGGG C 41
(2) INFORMATION FOR SEQ ID N0:921:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:921:
AAGCTGAGAT GGAGGGCGGC ATGGCGGGCA CAGGCTGGGC 40
(2) INFORMATION FOR SEQ ID N0:922:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:922:
AGCTGAGATG GAGGGCGGCA TGGCGGGCAC AGGCTGGGC 39
(2) INFORMATION FOR SEQ ID N0:923:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:923:
GCTGAGATGG AGGGCGGCAT GGCGGGCACA GGCTGGGC 38
(2) INFORMATION FOR SEQ ID N0:924:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 37 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:924:
CTGAGATGGA GGGCGGCATG GCGGGCACAG GCTGGGC 37
CA 02316994 2000-06-30
WO 99/63938 1 ~ PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:925:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:925:
ID
TGAGATGGAG GGCGGCATGG CGGGCACAGGC 36
CTGGG
(2} INFORMATION FOR SEQ ID N0:926:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:926:
ID
GAGATGGAGG GCGGCATGGC GGGCACAGGC 35
TGGGC
(2) INFORMATION FOR SEQ ID N0:927:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:927:
ID
AGATGGAGGG CGGCATGGCG GGCACAGGCT 34
GGGC
(2) INFORMATION FOR SEQ ID N0:928:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:928:
ID
GATGGAGGGC GGCATGGCGG GCACAGGCTG 33
GGC
(2) INFORMATION FOR SEQ ID N0:929:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:929:
ID
ATGGAGGGCG GCATGGCGGG CACAGGCTGG 32
GC
(2) INFORMATION FOR SEQ ID N0:930:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:930:
ID
TGGAGGGCGG CATGGCGGGC ACAGGCTGGG 31
C
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
~ S'~
(2) INFORMATION FOR SEQ ID N0:931:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:931:
ID
GGAGGGCGGC ATGGCGGGCA CAGGCTGGGC 30
(2) INFORMATION FOR SEQ ID N0:932:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:932:
ID
GAGGGCGGCA TGGCGGGCAC AGGCTGGGC 29
(2) INFORMATION FOR SEQ ID N0:933:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:933:
ID
AGGGCGGCAT GGCGGGCACA GGCTGGGC 28
(2) INFORMATION FOR SEQ ID N0:934:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:934:
ID
GGGCGGCATG GCGGGCACAG GCTGGGC 27
(2) INFORMATION FOR SEQ ID N0:935:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:935:
ID
GGCGGCATGG CGGGCACAGG CTGGGC 26
(2) INFORMATION FOR SEQ ID N0:936:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:936:
ID
GCGGCATGGC GGGCACAGGC TGGGC 25
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
tS$
(2) INFORMATION FOR SEQ ID N0:937:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:937:
ID
CGGCATGGCG GGCACAGGCT GGGC 29
(2) INFORMATION FOR SEQ ID N0:938:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:938:
ID
GGCATGGCGG GCACAGGCTG GGC 23
(2) INFORMATION FOR SEQ ID N0:939:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:939:
ID
GCATGGCGGG CACAGGCTGG GC 22
(2) INFORMATION FOR SEQ ID N0:940:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:940:
ID
CATGGCGGGC ACAGGCTGGG C 21
(2) INFORMATION FOR SEQ ID N0:941:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: lingar
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:941:
ID
ATGGCGGGCA CAGGCTGGGC 20
(2) INFORMATION FOR SEQ ID N0:992:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:942:
ID
TGGCGGGCAC AGGCTGGGC 19
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
iS~
(2) INFORMATION FOR SEQ ID N0:943:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:993:
ID
GGCGGGCACA GGCTGGGC 18
(2) INFORMATION FOR SEQ ID N0:944:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:944:
ID
GCGGGCACAG GCTGGGC 17
(2} INFORMATION FOR SEQ ID N0:945:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:945:
ID
CGGGCACAGG CTGGGC 16
(2) INFORMATION FOR SEQ ID N0:946:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ N0:946:
ID
GGGCACAGGC TGGGC 15
(2) INFORMATION FOR SEQ ID N0:947:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:947:
ID
GGCACAGGCT GGGC 14
(2) INFORMATION FOR SEQ ID N0:948:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 base pairs
(B) TYPE: nucleic. acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ N0:948:
ID
GCACAGGCTG GGC 13
CA 02316994 2000-06-30
WO 99/63938 PCT/ITS99/12775
n
(2) INFORMATION FOR SEQ ID N0:949:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:949:
CACAGGCTGG GC 12
(2) INFORMATION FOR SEQ ID N0:950:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:950:
ACAGGCTGGG C 11
(2) INFORMATION FOR SEQ ID N0:951:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:951:
CAGGCTGGGC 10
(2) INFORMATION FOR SEQ ID N0:952:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic}
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:952:
AGGCTGGGC
(2) INFORMATION FOR SEQ ID N0:953:
9
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:953:
TTT TCC TTC CTT TGT CTC TCT TC 23
(2) INFORMATION FOR SEQ ID N0:954:
(i} SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:954:
GCT CCC GGC TGC CTG 15
CA 02316994 2000-06-30
WO 99/63938 PC"T/US99/12775
~6r
(2) INFORMATION FOR SEQ ID N0:955:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:955:
SEQ ID
CTCGGC CGT GCG GCT CTG TCG CTC 29
CCG GT
(2)INFORMATION FOR SEQ ID N0:956:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:956:
SEQ ID
CCGCCG CCC TCC GGG GGG TC 20
(2)INFORMATION FOR SEQ ID N0:957:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:957:
SEQ ID
TGCTGC CGT TGG CTG CCC 18
(2)INFORMATION
FOR
SEQ
ID
N0:958:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:958:
SEQ ID
CTTCTG CGG GTC GCC GG 17
(2)INFORMATION
FOR
SEQ
ID
N0:959:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic~acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:959:
SEQ ID
TGCTGG GCT TGT GGC 15
(2)INFORMATION
FOR
SEQ
ID
N0:960:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:960:
SEQ ID
GGCCTC TCT TCT GGG 15
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(2) INFORMATION FOR SEQ ID N0:961:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: N0:961:
SEQ ID
CCTGGT CCC TCC GT 19
(2)INFORMATION FOR SEQ ID N0:962:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: N0:962:
SEQ ID
GGTGGC TCC TCT GC 19
(2)INFORMATION FOR SEQ ID N0:963:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:.single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: N0:963:
SEQ ID
GCTTGG TCC TGG GGC TGC 18
(2)INFORMATION FOR SEQ ID N0:969:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: N0:964:
SEQ ID
TGCTCT CCT CTC CTT 15
(2)INFORMATION FOR SEQ ID N0:965:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: _ base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: N0:965:
SEQ ID
TGCTTT TCT TTT CTG GGC CTC 21
(2) INFORMATION FOR SEQ ID N0:966:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:966:
CA 02316994 2000-06-30
WO 99/63938 PCTlUS99/I2775
X63
TGT GGT CTG TTT TTT TCT G 19
(2) INFORMATION FOR SEQ ID N0:967:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(iij MOLECULE TYPE: DNA (genomic)
(xij SEQUENCE DESCRIPTION: SEQ ID N0:967:
GCC CTG CTG GGG CGC TCT CC 20
(2) INFORMATION FOR SEQ ID N0:968:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:968:
GCC GCC CGC CTG GCT CCC-3= 18
(2) INFORMATION FOR SEQ ID N0:969:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D} TOPOLOGY: linear
(ii} MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:969:
GGB GCC CBT GBT GGG CBT GCC 21
(2) INFORMATION FOR SEQ ID N0:970:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY:~linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:970:
GTG GTT CTT GCC CTC CTT TGG CTG 24
(2) INFORMATION FOR SEQ ID N0:971:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:971:
CCG TGC CCG CTC CCC GGC 18
(2) INFORMATION FOR SEQ ID N0:972:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B} TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA~(genomic)
CA 02316994 2000-06-30
WO 99/63938 ~ PCT/US99/I277S
(xi)SEQUENCE DESCRIPTION: N0:972:
SEQ ID
CTCCTG GCG GGT GGC CGT TG 20
(2)INFORMATION
FOR
SEQ
ID
N0:973:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:973:
SEQ ID
GGCCCG TGT TCC CCT GGG 18
(2)INFORMATION
FOR
SEQ
ID
N0:979:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:974:
SEQ ID
GCCTGG GGC TCC CTT CTC TC 20
(2)INFORMATION
FOR
SEQ
ID
N0:975:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:975:
SEQ ID
GCCCTT CTT GCT GGG CCT C 19
(2)INFORMATION
FOR
SEQ
ID
N0:976:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:976:
SEQ ID
TGCTGC TGC TGG TGC TGT GGC CCC 25
C
(2)INFORMATION
FOR
SEQ
ID
N0:977:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:978:
SEQ ID
GTACACCGAGGAGCCCATGATGGGCATGCCACAGACGACAGGC
93
(2) INFORMATION FOR SEQ ID N0:978:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
CA 02316994 2000-06-30
WO PCT/US99/12775
99/63938
,6s
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: SEQ ID N0:978:
GTBCBCCGBGGBGCCCBTGBTGGGCBTGCCBCBGBCGBCBGGC
43
{2)INFORMATION FOR SEQ ID N0:979:
{i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: SEQ ID N0:979:
GGCGCC GTG CCG CGT CTT GGT GGC GGC GG 29
(2)INFORMATION FOR SEQ ID N0:980:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: SEQ ID N0:980:
GTTCGC GCC CGC GCG GGG CCC,CTC CGG TCC 30
(2)INFORMATION
FOR
SEQ
ID
N0:981:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: SEQ ID N0:981:
TTGGCC CGC GCG CCC GCC CGT CTC GGG CTG GGC 35
GG
{2)INFORMATION
FOR
SEQ
ID
N0:982:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: SEQ ID N0:982:
CGGGTC GGG GCC CCC CGC GGC C 22
(2)INFORMATION
FOR
SEQ
ID
N0:983:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS:~single
(D) TOPOLOGY: linear
(ii}MOLECULE TYPE: DNA (genomic)
(xi}SEQUENCE DESCRIPTION: SEQ ID N0:983:
GCCTCG GGG CTG GGG CGC TGG TGG CCG GG 29
(2)INFORMATION
FOR
SEQ
ID
N0:989:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:984:
SEQ ID
CCGCGCCTC CGC CTG CCG CTT CTG 24
(2)INFORMATION
FOR
SEQ
ID
N0:985:
(i)SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:985:
SEQ ID
GCTGGGCCC CGG GCG CCC CCT 21
(2)INFORMATION
FOR
SEQ
ID
N0:986:
(i)SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:986:
SEQ ID
CCCCTCTTG CTC GGG TCC CCG TG 23
(2)INFORMATION
FOR
SEQ
ID
N0:987:
(i)SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:987:
SEQ ID
ACAGCGCGTCCTGTGTCTCCAGCAGCATGGCCGGGCCAGCTGGGCCCC
48
(2) INFORMATION FOR SEQ ID N0:988:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:988:
BCBGCGCGTCCTGTGTCTCCBGCBGCBTGGCCGGGCCBGCTGGGCCCC 48
(2) INFORMATION FOR SEQ ID N0:989:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: _ base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:989:
ACA GAG CAT GCT GTT GTT GGG CAT CTT GCC TTC CCA GGG 39
(2) INFORMATION FOR SEQ ID N0:990:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
CA 02316994 2000-06-30
WO 99/63938 ~ ~~ PCT/US99/12775
(C} STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:990:
SEQ ID
BCBGBG CB TGC TGT TGT TGG GCB CTT CCC BGG G 39
TCT TGC
(2)INFORMATION
FOR
SEQ
ID
N0:991:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA'(genomic)
(xi)SEQUENCE DESCRIPTION: N0:991:
SEQ ID
CCCTTT TCT GGT GGG GTG 18
(2)INFORMATION
FOR
SEQ
ID
N0:992:
(i) SEQUENCE CHARACTERISTICS:
(A} 'LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:992:
SEQ ID
GTGCTG TTG TTG GGC 15
(2)INFORMATION
FOR
SEQ
ID
N0:993:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii}MOLECULE TYPE: DNA (genomic)
(xi)SEQUENCE DESCRIPTION: N0:993:
SEQ ID
TTTCTT CTG TTC CC 14
(2)INFORMATION
FOR
SEQ
ID
N0:994:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii)MOLECULE TYPE: DNA (genomic}
(xi)SEQUENCE DESCRIPTION: N0:994:
SEQ ID
CCCTTT TCT GGT GGG GTG 18
(2) INFORMATION FOR SEQ ID N0:995:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:995:
GTG CTG TTG TTG GGC 15
(2) INFORMATION FOR SEQ ID N0:996:
(i) SEQUENCE CHARACTERISTICS:
(A} LENGTH: 14 base pairs
CA 02316994 2000-06-30
WO 99/63938 ,~~ PCT/US99/12775
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: N0:996:
SEQ ID
TTTCTT CTG TTC CC 14
{2)INFORMATION FOR SEQ ID N0:997:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: N0:997:
SEQ ID
CTCGTC GCC GTC GCC GGC GGG 21
(2)INFORMATION FOR SEQ ID N0:998:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: N0:998:
SEQ ID
GGGTGG TGC TAT TGT CGG GC 20
(2)INFORMATION FOR SEQ ID N0:999:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: N0:999:
SEQ ID
GGCCCA GGG CCA GCC 15
(2)INFORMATION FOR SEQ ID N0:1000:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: NO:1000:
SEQ ID
GGCCGG GCC AGC CGG GCC CGG 21
(2)INFORMATION FOR SEQ ID N0:1001:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: NO:1001:
SEQ ID
GATGGA GGG CGG CAT GGC GGG 21
(2)INFORMATION FOR SEQ ID N0:1002:
(i) SEQUENCE CHARACTERISTICS:
CA 02316994 2000-06-30
WO 99/63938 PCT/US99/12775
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic. acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:1002:
GTA GGT GGC GGG CAA GGC GGG 21
(2) INFORMATION FOR SEQ ID N0:1003:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:1003:
GAT GGA GGC GGG CAT GGC GGG 21
(2) INFORMATION FOR SEQ ID N0:1004:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:1004:
GAT GGA GGG CGG CAT GGC GGG 21
